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8Abstract
Randomised Controlled Trials (RCTs) are regarded as a ‘gold standard’ 
technique to evaluate and compare clinical interventions. Strict ethical 
criteria dictate the participation of  humans in clinical research, based on 
informed consent, voluntary decision making and putting patients’ interests 
first. 
Demand for RCTs in Trauma and Orthopaedics is high, but patient 
recruitment continues to pose a significant challenge, especially when 
the treatments being compared are obviously different. Lack of  blinding, 
treatment preference and negative perception of  random allocation to 
interventions are among the obstacles which need to be considered.
Based on review and analysis of  current knowledge, an attempt is made to 
develop a new recruitment process that incorporates high ethical standards 
and provision of  the best possible clinical care for an individual patient. 
By integrating the principle of  clinical equipoise, modern technology and 
statistical concepts, such as subjective probability, the Patient Eligibility 
Assessment through Clinical Equipoise (PEACE) framework has been 
introduced. This provides an alternative that could be used in trials where 
the fixed eligibility criteria approach is likely to fail. It was tested involving 
77 real clinical cases from a national multi-centre trauma RCT, which 
compared contrasting treatments. 
A new trial recruitment approach aiming to avoid direct contact between a 
patient and a treating clinician was rolled out in the same trial. The feedback 
was collected from both the clinicians and the patients involved. Thematic 
analysis of  23 semi-structured interviews improved understanding of  
the various factors influencing patients’ decision about trial participation. 
Further typological analysis provided a valuable insight into the different 
attitudes that patients adopted when faced with the dilemma. In particular, 
that many are positive towards research involvement, but not comfortable 
with randomisation based on fixed eligibility criteria. 
According to these results, a new model for patient recruitment is 
suggested, which could be researched and tested in future trials.
9Abbreviations and glossary
Attitude – a psychological tendency that is expressed by evaluating a 
particular entity with some degree of  favor or disfavor.
Attribute – a factor that affects a decision or choice.
Cochrane Collaboration – the internationally recognised independent 
non-profit organisation formed to present healthcare research evidence in 
systematic way. Freely accessible online systematic reviews are published 
through Cochrane Library.
Cue – a stimulus or an attribute expressed by a subject, that prompts and/
or influences a decision formation.
CUP [Collective Uncertainty Project] – an independent research project 
set up within the UK Heel Fracture Trial in order to develop and test a 
methodological framework that can assess and compare level of  uncertainty 
in expert opinions about a clinical case in real time.
Equipoise – in clinical research: genuine uncertainty whether one 
intervention (treatment, procedure etc.) is beneficial when compared to 
other intervention(s). Can be described as:
 Clinical or collective – shared between clinicians in the expert   
 medical community 
 Individual – related to one person (clinician, patient etc.)
 Theoretical – in description of  individual, because some degree of  
   preference is highly likely
10
 Effective – same as individual, but in addition to direct intervention  
 effects, takes into account all attributes that influence a decision,  
 such as personal values, social responsibility etc.
Expert belief – expected likelihood or forecast of  a certain outcome from 
an expert.
Grounded theory – open-minded approach to qualitative data without pre-
formulated hypothesis. 
Implicit assumption - an assumption that includes the underlying 
agreements or statements made in the development of  a logical 
argument, course of  action, decision, or judgment that are not explicitly 
voiced nor necessarily understood by the decision maker. Often, these 
assumptions are made based on personal life experiences, and are 
not consciously apparent in the decision making environment. These 
assumptions can be the source of  apparent paradoxes, misunderstandings 
and resistance to change in human behaviour or decision making.
Paradigm shift – change of  core assumptions and views shared by 
scientific communities. Introduced in 1962 in the landmark book about the 
history of  science ‘The Structure of  Scientific Revolutions’ by Thomas S. 
Kuhn.
PEACE [Patient Eligibility Assessment through Clinical Equipoise] 
– the new concept and methodological framework for patient eligibility 
assessment in an RCT. Developed during the CUP (see above).
PTIV [Patient Trial Information Video] – as part of  the new approach 
to patient recruitment to RCTs.
Randomisation – in clinical research: allocating patients via random 
assignment to an investigated intervention or control.
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RCT [Randomised Controlled Trial] – type of  clinical research to 
compare interventions.
Strong expert vote – an opinion (outcome prognosis) expressed by an 
expert in one or two categories only for a clinical case assessment within 
the PEACE concept.
Statistical inference – a procedure used to draw conclusions from datasets 
arising from experiments.
Utility –value of  a choice attribute to a decision maker, depending on its 
probability.
Verstehen – the concept of  understanding a phenomenon in its context.
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Chapter 1 Review of theory and practice  
   of patient recruitment in    
   challenging surgical trials
Understanding the patient recruitment process in challenging surgical 
trials is the subject of  this study. A trial is considered challenging when 
substantially different procedures are being compared (such as open versus 
minimally invasive, or operative versus non-operative interventions, for 
example physiotherapy) (Ergina, Cook et al. 2009). My aim is to explore 
existing and novel strategies to modify the process of  patient involvement 
as trial subjects. These changes need to take into account the ethical and 
methodological concerns of  all involved parties (patients, clinicians and 
researchers), in order to improve the integrity of  the trial. 
This chapter starts with an overview of  the methodological fundamentals 
of  clinical trials (1.1) and attempts to review the theoretical and ethical 
basis of  patient involvement in clinical trials (1.2). It then looks at issues 
surrounding random treatment allocation and patient recruitment specific 
to surgical trials (1.3). Finally, the effects of  clinical research on patients as 
subjects to both research and clinical care are uncovered (1.4-5). 
A systematic approach was adopted for the literature search across several 
relevant platforms (PubMed, MEDLINE, PsycINFO, EMBASE, CINAHL 
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etc., see Appendix L for a Search Strategy example), but no formal 
systematic review was completed. This allowed some freedom in paper 
selection and inclusion according to the research question and subject 
relevance. 
The chapter is summarised (1.6) to formulate a list of  research questions 
that are grouped together for ease of  future reference.
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1.1 Methodological fundamentals of a clinical trial
Medical research aims to increase knowledge in order to advance medical 
practice. Research methods differ depending on the problem to be 
investigated and the research discipline involved. In order to evaluate the 
effectiveness and safety of  an intervention in clinical practice, such as a 
drug, an investigation or a surgical procedure, an experimental study needs 
to be performed. This can be contrasted with an observational study, where 
the investigator observes, describes, analyses and interprets an existing 
or pre-existing setting but does nothing to influence events. Both such 
experimental and observational types of  studies come under the umbrella 
of  clinical research; this generally involves humans, who may often be ill 
or in distress, as research subjects. This calls for high ethical standards and 
scrutiny, which have to be considered and enforced, when any such research 
is designed and undertaken. In the UK, Ethics Committees represent an 
internationally established and regulated system (World Medical Association 
2008) that oversee all research involving humans. They monitor the safety, 
rights and welfare of  participants.
The aim of  an experimental study is to assess differences in observed 
outcomes that are a direct consequence of  the relative efficacy of   the 
interventions being compared, rather than being affected by a multitude of  
other (confounding) factors, such as the age, gender or the physiological 
and clinical background of  the subjects. It follows that patient allocation 
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to the tested interventions needs to be controlled, in order to achieve 
comparable groups of  individuals who should ideally reflect the study 
population. Such controlled experimental studies of  clinical practice are 
usually called ‘clinical trials’. This term is now used much more commonly 
than an alternative term ‘experimental trial’ to reflect high ethical standards 
and commitment to the best possible patient care (Gauch 2008).
A number of  factors need to be controlled in a clinical trial to ensure a 
fair comparison of  interventions. First of  all, criteria for selecting subjects 
for a study have to be defined. These are called ‘eligibility criteria’. They 
define the characteristics a subject must have in order to be eligible for trial 
participation. Apart from demographics, these might include definition of  a 
disease/condition and various other elements, such as background health or 
mental status.
Delivery of  the experimental intervention itself  also needs to be specified. 
The test intervention is often compared to a control (standard or placebo) 
intervention using a chosen measure, preferably a validated score, which 
is specific to the researched condition. Use of  a control group is one of  
the signature characteristics of  a clinical trial. Without a rational direct 
comparison, an experimental study is extremely vulnerable to error. The 
patients’ responses may be influenced by a researcher’s enthusiasm and 
(even unconscious) reassurance, the placebo effect and other psychological 
factors. Historical controls are usually unreliable, due to environmental and 
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welfare changes, general care advances, stage of  diagnosis and multiple other 
factors that evolve or change over time.
Bias is another major concern when assessing or interpreting the findings 
of  a clinical trial. ‘Bias is a systematic distortion of  a result due to a factor 
not allowed for in the design of  the study’ (Smith and Smith 2003, p. 33). 
Randomisation and blinding are the classical techniques used to alleviate bias. 
Random allocation gives all eligible patients the same chance of  receiving 
either of  the compared interventions. It is independent of  a patient’s 
characteristics, preference or of  the clinician’s opinion. The Cochrane 
methodology review confirms that, when trials are non-randomised, it is 
impossible to predict the magnitude or direction of  possible selection biases 
(Odgaard-Jensen, Vist et al. 2011). This leads to the distortion of  treatment 
effects, often presenting them as more significant or sometimes even as a 
reversal of  the ‘true’ direction of  the effect (e.g. from harmful to beneficial or 
vice versa).  
The goal of  blinding is to keep trial participants and researchers ignorant, 
and therefore not susceptible to conscious or unconscious bias or influence, 
by concealing the type of  intervention allocated to each participant. Trials can 
be single-blind when only the patient is unaware of  an allocated intervention, 
double-blind when the investigator does not know either, or triple-blind 
when even the data monitoring body or study statistician are not allowed to 
know. Trials where interventions are not concealed are known as open trials.
17
The very features of  Randomised Control Trials (RCTs) described above 
(placebo control, randomisation and blinding),  are seen as essential  by 
the research community, but can be viewed as foreign to the principles of  
clinical care if  they are not justified by medical benefits to patients (Miller 
and Brody 2003). This gives rise to inherent and on-going conflicts for 
clinicians between therapeutic obligations to provide the best possible care 
for current patients and clinical research responsibilities to improve care 
continuously for the benefit of  future patients. This issue is reviewed in the 
next part of  this chapter.
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1.2 Ethical basis of patient recruitment to an RCT
Randomised Controlled Trials (RCTs) became a gold standard technique 
for evaluating new drugs and treatment regimes in clinical medicine 
following publication of  the landmark RCT of  streptomycin for pulmonary 
tuberculosis in 1948 (Medical Research Council).  In a RCT patients are 
assigned on a random basis to the various treatments being compared; 
this causes prognostic variables to be randomly distributed across the 
trial intervention groups, so that no treatment is biased through patient 
selection.  This brings reliability and scientific integrity to research findings 
and makes these trials very attractive to clinical scientists. However, this 
very principle of  randomisation took the dilemma of  the clinician’s ethical 
obligations to a new level.  On the one hand there is an obligation to 
provide the best possible care for an individual patient and on the other 
hand there is a responsibility to society and future patients to continuously 
improve the quality of  care. This was described by Adams (1989, pp. 449-
50) as a distinction between ‘action-aims’ and ‘outcome-aims’ as follows:
“We can say that I was doing the best for my patients as an action-aim 
insofar as I am disposed to do (now) what I think is best for my (present) 
patients. I have it as an outcome-aim insofar as I am disposed to try (now) 
to bring it about that I do (in the rest of  my career) the best for my (present 
and future) patients”.
These ethical considerations led to the development of  the equipoise 
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principle.  This states that genuine uncertainty about the relative merits 
of  different treatments to be compared must be present before a patient 
is offered the opportunity to take part in clinical research (Fried 1974). 
The equipoise principle puts the individual patient first. It does not 
allow clinicians to compromise their patients’ interests even for the sake 
of  greater potential benefits to other patients. This principle was later 
reinforced in the Declaration of  Helsinki (Association 2008). 
Individual equipoise, however, proved to be an “overwhelmingly fragile” 
concept and was referred to by Freedman as theoretical equipoise (1987). 
Even though it may not be known which treatment is better, most 
individual patients tend to have preferences, which may be more or less 
rational. In comparing potential arms of  a RCT, each person will make 
comparisons which are unique depending on personal values, such as risks 
versus benefits, attitude to risk taking and innovations. This comparison 
between options will lead to equipoise at different points for different 
people even when they have the same knowledge of  the case or subject 
(Veatch 2006).
 In addition, individual equipoise is subject to change for a number of  
reasons. These reasons may include peer pressure, results of  imperfect 
studies and the influence of  advertising. So Freedman proposed that 
clinical equipoise (also known as collective equipoise) should be used as a 
justification for inviting patients to participate in RCTs. He defined clinical 
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equipoise as “honest, professional disagreement among expert clinicians 
about the preferred treatment” p.144, (Freedman 1987, p. 144). He argued 
that collective equipoise should override the individual clinician’s lack of  
individual equipoise to allow him/her to enter patients in the trial even 
when clinicians hold their own preferences.
It has to be noted here that there has been little discussion of  what counts 
as knowledge when applied to uncertainty (Ashcroft 1999). Many feel 
that uncertainty needs clearer definition if  a concept of  clinical equipoise 
is to be applied to the ethical judgement of  research (Paradis 2006). Yet 
Freedman’s argument remains very strong and at present it is still accepted 
by society that collective equipoise is required before a clinical trial can be 
approved (Chard and Lilford 1998).
Currently, in order to recruit patients into human trials ethically, reasonable 
and/or substantial uncertainty (Peto and Baigent 1998) between expert 
clinicians about compared treatments (i.e. clinical equipoise) needs to be 
established. Once established, a case needs to be presented to an Ethics 
Committee. Sometimes it is presented as informal information (e.g. 
opinions of  local clinicians), sometimes as semi-formal information (e.g. 
evidence of  diversity in practice across institutions/clinicians or different 
opinions in the literature), at other times as formal information by specific 
measurement of  expert belief, although this is very rare (Freedman and 
Spiegelhalter 1992; Lilford 1994). Ethics Committees represent society with 
21
a diverse mix of  clinicians, scientists, people trained in ethics and law, lay 
members etc. In particular, they judge whether trial participants could be 
disadvantaged, if  allocated to one or another intervention being compared 
in a trial. If  a proposed trial is ethically approved, this uncertainty about 
a treatment or procedure choice needs to be explained to a potential trial 
participant. In addition, a patient has to be informed about the nature, 
significance, implications and risks of  the suggested interventions, so that 
an informed choice can be made about proposed trial participation. When 
all necessary research and clinical information is given and sufficiently 
understood, patients themselves need to reach effective equipoise (Chard 
and Lilford 1998). This is the point in the decision process where the 
expected utilities of  both treatment options are the same in patients’ minds. 
In other words, this is the point where the pros and cons of  different 
intervention options, from a patient perspective, are too close to hold an 
obvious preference towards one or another option. At this point their trial 
consent is regarded as freely obtained. 
In spite of  all that has been stated in the previous paragraph, the principle 
of  clinical equipoise does not remain unchallenged. This is mainly due to 
difficulties with the practical application of  this principle in clinical trials 
(Weijer and Miller 2003). Traditionally, physicians tend to express disregard 
or denial of  uncertainty when faced with the treatment of  an individual 
patient, even when there is no evidence to prove any difference between 
two treatments (Katz 1984). This remains the case even when clinical 
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equipoise has been demonstrated and accepted by clinicians at the start of  
a trial. There are possibly a number of  explanations for this phenomenon. 
These explanations may include apparent emotional ties which clinicians 
develop with a standard treatment, especially if  they have had some good 
results and this treatment has been presented as the best choice by them. It 
is difficult to disagree with Paradis when he states that “often in medicine, 
we do not know what it is that we do not know. We have a tendency to 
equate reason, observation, and past experience with knowledge and with 
certainty.” (Paradis 2006, p. 62).
Some authors are suspicious of  the very fact that the principle of  equipoise 
requirement includes commitment to the traditional account of  physicians’ 
therapeutic obligations. They believe that this makes it erroneous in theory 
and practice. They argue that “clinical research, by virtue of  being aimed at 
producing generalizable knowledge, adopting methods foreign to medical 
care (e.g., randomization, masked treatment assignment, and the use of  
placebo controls), and including procedures that carry risks to research 
participants that are not justified by medical benefits to them, should be 
understood as governed by ethical norms distinctive from those that apply 
to clinical medicine.”(Miller 2006, p. 59). According to them “clinical 
research, including treatment trials, would be impossible if  it were held to 
the ethical standard of  promoting the medical best interests of  patients 
that governs therapeutic medicine,” (Miller 2003, p. 165). They propose a 
‘difference position’ which views  the clinician’s activity as being divided 
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into three activities distinct in their nature and goals, namely therapeutic 
care, clinical research and public health (Brody 2006). They argue these 
three activities require different ethical approaches.  
This view is criticised by other opponents of  clinical equipoise on the basis 
that it denies clinical trial participants the privileges and protections of  the 
traditional therapeutic relationship (Chiong 2006). Although the “difference 
position” comes with a proposition of  a safeguard framework aimed to 
prevent patient exploitation (Miller and Brody 2003; Buchanan and Miller 
2005), it appears that a principle of  non-exploitation can be interpreted in 
different ways to support different views. Chiong argues that both clinical 
research and therapeutic medicine should follow the same therapeutic 
ethical framework of  the “similarity position”. It follows that clinical 
research should continuously search for alternative and improved study 
designs to minimise ethical research compromises, such as blinding, extra 
investigations and placebo procedures. These all carry attendant risks to 
patients even when these risks are minor. 
The “similarity position” fits perfectly with the clinical equipoise principle. 
However, the equipoise application is criticised by Chiong also for rigidly 
disallowing clinicians from facing the question of  compromises in patient 
care justified by the potential benefits to third parties. However his proposal 
that “the therapeutic obligation can be discharged by providing good 
enough treatment” (p. 37), reflects one of  the clinical equipoise followers’ 
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interpretations that the clinician’s obligation “does not require the provision 
of  the best possible care, rather it requires the provision of  competent 
care” (Miller and Weijer 2003, p.115). Both statements expose a degree 
of  compromise to clinical care provision that is felt necessary with the 
currently available RCT methodology.
The theoretical premise for this study is the contention that “equipoise 
exists if  well-designed studies have yet to answer the question as to which 
of  two interventions are to be preferred for a particular population of  
patients” (Halpern 2006, p. 2). The principle of  clinical equipoise reflects 
the high ethical standards of  clinical research expected by society and has 
been accepted widely as a trigger for setting up a trial and benchmark for 
ethical approval. However, it fails to be transferred into the practice of  
clinical trials.  This is because individual equipoise is a fragile and unreliable 
concept that is usually not present when a patient is recruited to a trial by a 
clinician. The offer of  a random allocation to a treatment is usually based 
on clinical equipoise demonstrated when a trial is suggested and set up. 
This randomisation issue and other methodological difficulties related to 
challenging surgical RCTs are discussed in the following sections.
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1.3 RCTs for surgical interventions
It is generally accepted that there is a place for RCTs in modern surgical 
practice. As evidence for this assertion, it would probably be sufficient 
to recall examples of  surgical practice where less rigorously evaluated 
procedures have been found to be ineffective: gastric freezing for a bleeding 
peptic ulcer, carotid body denervation for bronchial asthma, prophylactic 
portacaval shunt to prevent oesophageal variceal bleeding, nephropexy for 
visceroptosis, removal of  a chronically inflamed appendix and periarterial 
sympathectomy or internal mammary arterial ligation to improve angina 
symptoms (Cobb, Thomas et al. 1959; Baum 1981; Salzman 1985). 
Moreover, there is a shocking list of  surgical procedures that became parts 
of  standard practice before being proven ineffective: routine tonsillectomy, 
routine circumcision, repeated cesarean delivery, internal-thoracic-artery 
ligation, jejunoilial bypass for morbid obesity, laparotomy for tuberculous 
peritonitis or pelvic inflammatory disease, adrenalectomy for essential 
hypertension, and extracranial or intracranial bypass for carotid-artery 
occlusion (Freeman, Vawter et al. 1999) 
However, there are at least two more arguments exposing an increasing 
need for high quality evaluation of  differences between treatments. 
First, with improvements in various aspects of  healthcare, the risk of  
biased estimation of  treatment effects between particular procedures in 
observational studies is higher than ever (Boutron, Ravaud et al. 2007). 
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Surgery is a part of  a complex intervention where the wider context of  the 
surgical team and pre-operative and post-operative care are important. A 
multitude of  confounding factors, such as the availability of  appropriate 
equipment, treatment delays, staffing issues, physiotherapy regime and so 
on, all play their part and can affect the eventual outcome. 
 In a recent example concerning trauma surgery, only a meta-analysis of  
RCTs, comparing the use of  intramedullary nails with extramedullary 
implants for extracapsular hip fractures, showed significantly more peri- and 
post-operative complications associated with intramedullary devices (Parker 
and Handoll 2008).
Secondly, the tremendous diversity in practice patterns at the present time 
across institutions, coupled with the continuously increasing range of  
available interventions, suggests a rather low level of  agreement between 
clinicians about the value of  those interventions (Halpern 2006). Patient 
demands, pathology itself  and treatment indications change with time. 
Surgical treatments are usually less standardised: one surgeon may carry out 
a procedure differently from another and have a different level of  skill and 
experience, even when the intervention has the same ‘label’.
Randomised Controlled Trials (RCTs) are recognised as representing the 
highest level of  published evidence, either on their own or as part of  
systematic reviews, and are used to inform decisions regarding all areas of  
clinical care (Centre for Evidence-Based Medicine, University of  Oxford, 
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www.cebm.net). In the UK, the National Institute for Health Research 
(NIHR) is the main public funder of  clinical trials (www.netscc.ac.uk). 
RCTs are regarded as the gold standard methodology in clinical trials. In 
particular the pragmatic randomised control trial design (discussed later), is 
the mainstream for studies supported by its Health Technology Assessment 
Programme. Clinical Trials Units (CTU) are seen as central to the overall 
vision of  expanding the number and volume of  clinical trials in the UK, 
so in 2008 the CTU Support Funding was introduced. Major independent 
research organisations, some of  them charitable, such as Arthritis Research 
UK, fund clinical research with the expectation that an RCT will be the 
appropriate methodology to answer important research questions regarding 
efficacy and effectiveness for a test intervention.  These factors to a large 
extent explain the recent surge of  the RCT as the most favoured clinical 
trial design in surgery.
However, it is important to understand that rigid application of  available 
RCT methodology is certainly not a panacea that will provide answers 
to all the clinical research questions that need answering (Senn 2013). 
Particularly in surgical applications, RCT efficiency in proving definitive 
answers to many research questions is more debatable. There is ongoing 
argument about the reliability and the limits of  RCTs in surgical practice 
(Abel and Koch 1999), and even their scientific value. In particular, this 
critique concerns the applicability of  group probabilities derived from large 
trials to subgroups with different disease and background characteristics 
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or to individual patients (Sleigh 1997; Herman 1998). It is not uncommon 
that a particular research question remains unanswered even after a careful 
methodological review of  the results of  several RCTs dealing with the same 
question. For example, in the case of  very common distal radius fractures, 
117 patient management questions were identified by expert evidence 
reviewers. Evidence from 114 related RCTs covered 31 of  these research 
questions to some extent, but only five provided sufficient evidence to 
judge effectiveness and to compare particular interventions (Handoll and 
Madhok 2003). 
Available evidence from the Cochrane Library indicates that currently 
surgical RCTs systematically fail to produce meaningful advice about 
procedure choices. The Cochrane Collaboration is the internationally 
recognised independent non-profit organisation formed to present 
healthcare research evidence in a systematic way. Treatment reviews 
usually include randomised and quasi-randomised trials. For example, in 
a wide-ranging review of  internal fixation implants for intracapsular hip 
fractures in adults, 30 studies involving 6334 participants (6339 fractures) 
were analysed but no clear conclusions could be reached on the choice of  
implant from the available evidence within randomised trials (Parker and 
Stockton 2001).
In order to improve the chances of  detecting a difference between 
interventions, natural variability between research subjects needs to be 
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deliberately decreased. This can be achieved by introduction of  extensive 
and restrictive controls of  trial eligibility and intervention delivery. This 
principle is used in exploratory or explanatory trials of  new interventions 
that aim to answer the question ‘can this work?’, not ‘will it work?’ (Lilford, 
Braunholtz et al. 2004). An exploratory trial gives freedom to refine a new 
procedure in the early development stages and to assess the impact and 
safety of  the procedure. Such a trial seeks to assess whether an intervention 
can work under favourable conditions, i.e. treatment efficacy. Those patients 
who are expected to be most suited to the treatment are enrolled and 
usually treated by surgeons with considerable related expertise. However, 
generalisability of  results for a target population in wider clinical practice 
suffers. 
To answer the ‘will it work?’ question a pragmatic trial design is used. It 
seeks to inform clinical decision making by evaluating an intervention in a 
realistic clinical setting. Pragmatic RCTs follow the principle of  larger and 
simpler trial design with the widest possible entry criteria to allow more 
clinicians and patients with different prior beliefs and values to participate 
(Lilford, Braunholtz et al. 2004). Usually these are large multi-centre trials, 
so that legitimate variations in clinical practice and expertise levels, which 
are representative of  the clinical community in which the intervention is 
used, can be incorporated into the evaluation. It follows that the pragmatic 
trial design is beneficial when a technique is to be introduced in common 
practice or a more established surgical intervention is being researched, due 
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to the complex nature of  such an intervention. 
In real life, however, many surgical trials display some characteristics 
that reflect more than one type or are poorly reported, defying easy 
categorisation (Cook 2009). Paradoxically, it often happens that the search 
for consensus between many experts prior to a larger trial leads to complex 
eligibility criteria. The known prognostic factors, which influence pre-
set eligibility criteria at the start of  a trial, are not necessarily the most 
important ones or the ones that a clinician regards as important in a specific 
case (Abel and Koch 1999). More complex eligibility criteria are more open 
to interpretation by a clinician, who makes an individual decision about a 
patient’s trial eligibility. This is one of  the common criticisms of  RCTs, that 
they themselves introduce a selection bias.  
In addition, patient recruitment in modern randomised trials of  invasive 
treatments remains low, in the order of  30% of  eligible patients or lower 
even in well-designed trials (Buchbinder, Osborne et al. 2008; Weinstein, 
Lurie et al. 2008). This is the case in spite of  numerous methodological 
advances in recent years and results in an even smaller proportion out of  an 
already small number of  eligible patients being randomised; so applicability 
of  the results to the more general patient population may be problematic.
The challenge to recruit the targeted number of  patients even in excellent 
surgical RCTs can be demonstrated by the example of  the MRC spine 
stabilisation trial. It was calculated that a sample size of  133 subjects 
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would be required in each of  three treatment groups that were compared: 
spinal fusion, flexible stabilisation and intensive rehabilitation programme 
(Fairbank, Frost et al. 2005). This seemed a realistic target considering 
that the trial was set up in 15 UK hospitals and that about 1000 lumbar 
fusions were performed in England per year at the time. Both surgeon 
and patient had to be in individual equipoise for a patient to be eligible 
for the trial. This appears to ignore Freedman’s principle of  ‘theoretical 
equipoise’, which is shown to be inherently fragile, difficult to attain and 
impossible to maintain (Freedman 1987), but it redefines a challenge of  
the practical application of  ‘clinical equipoise’. After 6.5 years (June 1996 
to February 2002) 349 patients were randomised in two groups:  two 
surgical options became a single spinal stabilisation surgery group. It looks 
as if  some lessons have been learned. The recent Spine Patient Outcome 
Research Trial (SPORT) employed an innovative design. It recruited in 
both randomised (501 participants) and observational (743 participants) 
cohorts from 13 spine clinics in 11 US states (Weinstein, Lurie et al. 2008). 
Even with these flexible arrangements, 747 patients declined to participate 
in the study. This represents 25% recruitment to the randomised cohort, 
a percentage which is similar to recruitment levels in other challenging 
surgical RCTs.  
The complexity and specific issues of  surgical trials are not a new 
phenomenon and have been discussed over the years (Love 1975; Stirrat, 
Farrow et al. 1992; McCulloch, Taylor et al. 2002; Boutron, Tubach et al. 
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2003; Ergina, Cook et al. 2009).  Blinding is usually impossible for a number 
of  reasons. Scars are difficult to conceal, especially when procedures are 
obviously different. Lack of  blinding makes a patient’s individual preference 
especially high (Paramasivan, Huddart et al. 2011) and the surgeon’s 
preference has to be disclosed, if  present, to a patient on request. A patient 
has to consent to surgery, so having a good enough reason to perform 
a procedure and trust in one’s ability to improve or sort out a problem 
is of  paramount importance. It is a surgeon who is going to perform an 
invasive procedure, in contrast to a drug prescription, and a surgeon’s skill 
and experience can differ even with regard to individual procedures in 
the same subspecialty. The ‘learning curve’ effect, i.e. gaining experience 
in performing a new procedure, needs to be accounted for, as necessary. 
On the other hand, surgical innovations do not require formal approval 
through clinical trials, in contrast with the stringent procedures of  a new 
drug approval. With the continual evolution of  technology and marketing 
forces, they often become established, common practice and even popular 
and in demand before being compared properly to alternative procedures, 
so patient recruitment becomes even more challenging (Ergina, Cook et al. 
2009). A complex of  procedures for a structured evaluation of  every new 
surgical intervention or modification is still at the recommendation stage 
(McCulloch, Altman et al. 2009).
A number of  solutions to improve surgical trial design have been suggested 
over the last fifteen years.  A paper entitled ‘Framework for Design and 
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Evaluation of  Complex Interventions to Improve Health’ (Campbell, 
Fitzpatrick et al. 2000) proposed sequential phases of  developing such 
RCTs, that included modelling, an exploratory trial and integration of  
quantitative and qualitative methods. Two significant books have been 
published recently on Bayesian methods in Clinical Trials (Spiegelhalter, 
Abrams et al. 2004; Berry 2011). Yet the proposed solutions struggle to 
find a way into mainstream surgical research and structured methodological 
advice specific to surgical trials is not easily available.  The National Health 
Service (NHS) Research and Development Methodology Programme 
has introduced some interesting methodological developments during 
the past decade which could provide opportunities for imaginative trial 
design solutions. Unfortunately, however, these have now simply been 
archived (http://webarchive.nationalarchives.gov.uk/20040308042406/
publichealth.bham.ac.uk/nccrm/).  The MRC ConDuCT (Medical 
Research Council Collaboration and innovation for Difficult or Complex 
randomised controlled Trials) Hub was created in Bristol in April 2009, but 
the financial support and available resources were limited initially. This has 
now developed into ConDuCT II, as part of  MRC’s Network of  Hubs for 
Trials Methodology Research, with a particular focus on the needs of  RCTs 
in surgery. This move created an extensive nationwide resource aimed at 
research and educational support for clinical investigators.
Hopefully there will be more support and research into methodological 
options available to investigators in explaining and offering a random 
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allocation to a treatment. The offer is triggered by pre-set eligibility criteria, 
which are based on clinical equipoise demonstrated prior to the start of  
a trial, but may not correlate with individual equipoise, when the actual 
patient is recruited. Jenkins and colleagues report that, during discussions 
with patients about randomisation into a trial, clinical oncologists expressed 
uncertainty about treatment decisions in virtually all of  the consultations. 
That was in spite of  the fact that only in 14.6% of  consultations was the 
uncertainty expressed as personal; more commonly, only general uncertainty 
was expressed (Jenkins, Fallowfield et al. 1999). We are not aware of  such 
studies in surgical RCTs, but it has been suggested that surgeons are even 
less inclined to uncertainty (McCulloch, Taylor et al. 2002). It is part of  
the surgeons’ ethos to believe in themselves and their surgical skills: some 
believe that uncertainty is antithetical to surgical training (Rudicel and 
Esdaile 1985). Surgeons are trained to make decisions in the presence of  
limited evidence: they seem to be less tolerant of  uncertainty than in other 
medical specialties (McCulloch, Kaul et al. 2005). At the same time, it is a 
common practice to discuss difficult cases when the treatment choice is not 
obvious. Even though surgeons may (and probably will) have a treatment 
preference for a given patient, they will have different levels of  confidence 
about efficacy and may not be certain that their preference is correct 
(Weijer, Shapiro et al. 2000). Having discussed the ‘surgeon factor’ in a 
RCT, patients’ involvement is examined next. 
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1.4 Patients in surgical RCTs
Randomised controlled trials rely on hundreds or thousands of  patients 
giving their consent to participate. Consent or refusal to participate in 
such trials is adequately informed only if  patients understand two key 
elements in addition to the description of  what will happen to them in their 
particular trial. These two key elements are, first, that participants will be 
allocated randomly to treatment arms, and second, that at the start of  the 
trial there are no convincing grounds for supposing that any patient would 
be advantaged or disadvantaged by being allocated to one treatment arm 
rather than another.
 Examination of  assumptions held by members of  the public when 
invited to participate in a hypothetical RCT exposed a large mismatch with 
the assumptions underlying the trial design. Most participants found it 
unacceptable to suggest allocating treatments at random; furthermore, the 
scientific benefits of  randomisations were not recognised. Around half  the 
participants had difficulty in accepting that a clinician could be completely 
uncertain about which of  the treatments was better. This extensive in-
depth work from the NHS Research and Development Health Technology 
Assessment (R&D HTA) Programme “suggests that many potential trial 
participants may have difficulty understanding and remembering trial 
information that conforms to current best practice in its descriptions of  
randomisation and equipoise” (Robinson, Kerr et al. 2005, p. iv). Several 
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authors have found that those who refuse to take part in RCTs know less 
overall about the subject of  a trial than those who consent to participate 
(Leach, Hilton et al. 1999; Lovegrove, Rumsey et al. 2000; Fleissig, Jenkins 
et al. 2001). In research into participants’ understanding of  equipoise, it 
is awareness of  this uncertainty that is assessed most often, rather than 
understanding of  the term equipoise itself. 
Some authors hold the view that the central ethical problem in clinical 
research designs is the process of  informed consent, rather than the tension 
between individual and collective ethics (Pullman and Wang 2001). It is 
therefore important for a good quality clinical trial not only that current 
evidence is presented as fairly and as clearly as possible, but also that 
patients understand that judgement about possible treatment outcomes 
in an individual case can vary between investigators (Lilford 2003). The 
possible effects of  individual preferences  on the patient recruitment 
process can be limited by having consent and randomisation moderated 
by a third party (Lilford, Braunholtz et al. 2004) or by pre-randomisation 
(Adamson, Cockayne et al. 2006).
Pre-randomisation implies that the consenting process is primarily about 
a proposed intervention, rather than a proposed research that is viewed 
as associated and secondary to the intervention. To allow this, a patient is 
randomised at the point of  eligibility assessment. When suggested originally 
to improve patient recruitment in challenging RCTs (Zelen 1979), the 
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full research consent was only obtained from participants who were pre-
allocated the experimental intervention. Control treatment was regarded as 
the best standard care, so availability of  the experimental intervention was 
not mentioned. Permission for research follow up and data collection could 
be asked separately. This was called the single consent method. The double 
consent method was introduced later (Zelen 1990), where retrospective 
consent was sought from participants pre-allocated to any intervention 
group, which allowed all participants an option to refuse and ‘crossover’ 
to an alternative procedure. Both pre-randomisation techniques were used 
successfully over the years across different medical specialties and scenarios 
with acceptable crossover rates (Adamson, Cockayne et al. 2006). The most 
well known in Trauma and Orthopaedics is the RCT of  arthroscopy for 
osteoarthritis of  the knee (Chang, Falconer et al. 1990). It claimed a six-fold 
increase in patient recruitment and had a high impact on clinical practice 
resulting in dramatic reduction of  arthroscopic procedures, which were 
demonstrated to be ineffective. However, the issue of  retrospective consent 
remains controversial both ethically and legally. Some argue that this makes 
pre-randomisation completely unacceptable (Marquis 1986), but mostly 
a cautious approach is adopted at the discretion of  the Research Ethics 
Committees (Schellings, Kessels et al. 2009).
The most effective available way of  improving understanding in the 
informed consent process for prospective research participants appears 
to be having a study team member or a neutral educator spend more time 
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talking one-on-one with them (Flory and Emanuel 2004). At the same time, 
some studies demonstrate that  the use of  visual aids improves the ability 
to remember facts and risks associated with treatments, beyond a verbal 
presentation alone: this is particularly true of  surgical treatments (Moseley, 
Wiggins et al. 2006). However, these studies disagree on the question of  
whether video groups were more willing to participate in a trial (Fureman, 
Meyers et al. 1997; Weston, Hannah et al. 1997). 
The latest Cochrane review of  the audio-visual presentation of  information 
for informed consent for participation in clinical trials (Ryan, Prictor et al. 
2008) demonstrated weak evidence that the intervention may have limited 
positive effects on the quality of  information disclosed, and may increase 
patients’ willingness to participate in the short-term.  The authors of  the 
review encourage investigators to continue to explore innovative methods 
of  providing information to potential trial participants. 
Qualitative techniques are increasingly included in medical and health 
research to help in the interpretation of  quantitative results or the 
understanding of  trials (Snowdon, Garcia et al. 1997; Featherstone and 
Donovan 1998). In the controversial ProtecT (prostate testing for cancer 
and treatment) trial comparing surgery, radiotherapy and monitoring, 
changes to the content and delivery of  study information according to 
the results of  the parallel qualitative study of  the process of  recruitment 
increased recruitment rates from 40% to 70% (Donovan, Mills et al. 
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2002). However, the decision making process about trial participation is 
more complex than a rational assessment of  available information. This is 
discussed in the next section.
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1.5 Patient decision making process about trial    
 participation
Decision making is the process of  selecting one of  multiple options based 
on their true or perceived utility. In other words, decision makers must 
weigh up the probability and compare possible outcomes at different points 
in time. Economists and psychologists have long studied how people make 
choices that can lead to rewards or punishments of  different amounts 
at different times with different  probabilities (Kenji and Shalden 2012). 
This leads to the development of  economic and psychological models 
of  the decision making process. Economic models such as ‘Rational 
Choice Theory’ imply a tendency to maximise benefits and minimise the 
costs. This theory uses utilities that represent a patient’s subjective value 
for choice attributes, such as a health state or a treatment characteristic 
(Schacter, Gilbert et al. 2011). Psychological models take into account the 
more emotional aspects of  decision-making, assessing people’s attitudes in 
different circumstances. Attitudes are defined as a psychological tendency 
that is expressed by evaluating a particular entity with some degree 
of  favour or disfavour. Modern neurophysiological data accord with 
psychological models of  decision-making (Eagly and Chaiken 1993).
It appears that decision making is a combination of  reasoning and 
emotional processes which can be rational or irrational, and often 
influenced by implicit assumptions. The value of  different attributes 
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changes depending on circumstances and personal attitudes. Therefore 
modern decision making models tend to be tailored to an area of  interest 
and take into account both economic and psychological factors.
Investigations of  views about clinical trials have suggested that both lay 
people and clinicians may hold views about trial treatments even without 
being given any substantive information about them: the default assumption 
seems not to be one of  equipoise (Appelbaum, Roth et al. 1987). It is 
suggested (Robinson, Kerr et al. 2005) that patients’ prior knowledge and 
expectations about the normal sequence of  events in a consultation may 
make it hard for them to process an unexpected invitation to enter a trial. 
Once they have made the necessary switch, they are likely to attempt to 
make sense of  why the trial is being conducted in a particular way, for 
example why treatments are allocated at random. However readable and 
clear the trial information, if  it merely describes what will happen without 
offering explanations that connect with patients’ existing knowledge and 
beliefs, patients may come up with their own, incorrect, interpretations 
(Featherstone and Donovan 1998; Featherstone and Donovan 2002). Their 
consent or refusal to participate in the trial may thus not be genuinely 
informed.
Greater disclosure about treatment options and the clinical trial itself  
seems to prompt people to either select one of  the treatments or refuse 
randomisation (Edwards, Lilford et al. 1998; Wragg, Robinson et al. 2000). 
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Surveys found that people were often unwilling to participate in randomised 
trials even when they held a positive attitude towards research in general 
(Fallowfield, Jenkins et al. 1998; Purdy, Finkelstein et al. 2000; Fleissig, 
Jenkins et al. 2001). The patient’s level of  uncertainty is not defined simply 
by probabilities of  outcomes, but also by how they value those outcomes 
(Dudley 1986). In other words, where a treatment has well-known side 
effects, the point of  equipoise is not ‘no effect’ but an effect big enough to 
compensate for its perceived disadvantage. This point is defined by decision 
analysis as that where the expected utilities of  both treatment options 
are the same (Lilford and Thornton 1992). It was later called ‘effective 
equipoise’ (Chard and Lilford 1998). 
It has been argued that it is the  equipoise of  the subjects, and not that of  
clinicians or researchers, that is morally significant because they are the ones 
who are subjected  to the effects of  a clinical trial (Veatch 2002). Whoever 
we choose to refer to in a clinical trial, equipoise at present is understood as 
“inherently a subjective concept based on idiosyncratic evaluative judgments 
about the projected benefits and harms of  alternatives, as well as personal 
value orientations toward risk-taking and optimism about innovation” 
(Veatch 2006, p. 56). There are so many variables to consider for each 
individual which are normally well beyond the expertise or knowledge of  
a clinician or investigator: cultural background, economic, legal, religious, 
familial and aesthetic interests are just some of  them. If  researchers do not 
know how the patient will assess the expected benefits and harms of  the 
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treatments, how can they know when the patient would be more or less 
equally poised between treatments and thus more inclined to volunteer? 
Furthermore, not only might some subjects choose to enter trials when they 
have a preference for one treatment arm, they may have that preference at a 
point of  their decision process that is quite different from that of  clinicians 
and investigators. 
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1.6 Summary and research questions 
This final part of  this introduction chapter aims to summarise the evidence 
presented, leading to formulation of  research questions. The questions are 
grouped together for ease of  reference.
Despite increasing numbers of  surgical RCTs, and financial investment in 
them, their efficiency in answering research questions and their ability to 
influence surgical practice remains low. This could be explained by a lack 
of  methodological rigour and poor patient recruitment. Poor recruitment 
reduces trial power and the applicability of  results to the general patient 
population, especially at a subgroup level. Obstacles for efficient patient 
recruitment may well include the following: an individual surgeon’s lack of  
equipoise, the ethical obligation to provide the best possible treatment, and 
the requirement to admit in front of  a patient insufficient knowledge to 
determine the best choice of  intervention. This is coupled with a patient’s 
understandable reluctance to accept random allocation to a treatment when 
substantially different procedures are being compared (such as open versus 
minimally invasive, or operative versus non-operative interventions, for 
example physiotherapy). The reluctance is likely to be even greater when 
surgical innovations are involved, especially when they are already available 
outside the trial (Ergina, Cook et al. 2009). For both parties, detachment 
from decision making about a choice of  treatment seems to be rather 
uncomfortable and damaging for the surgeon-patient relationship  (Fung 
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and Lore 2002). This ‘surgeon’ issue cannot be ignored in the same way as 
clinicians are in drug trials simply because surgeons are integral to surgical 
interventions.  
Strict and complex pre-set eligibility criteria are often necessary with 
current trial set ups; but this is at odds with pragmatic trial principles by 
further reducing the numbers of  trial participants. The distinction from 
the explanatory trial becomes blurred, further reducing the applicability of  
results to standard surgical practice or policies. The application of  pre-set 
fixed trial eligibility criteria often fails to transfer the principle of  clinical 
equipoise to the process of  patient recruitment into a trial. This creates 
inherent conflict between a clinician’s therapeutic obligation to provide 
the best possible care for an individual patient and their clinical research 
responsibility to society to maximise trial participation for the benefit of  
many future patients. This is because often either a patient or a recruiting 
clinician, or neither, are in individual equipoise about a treatment choice, 
especially when compared interventions are obviously different and the 
involved parties feel unable to express their opinion and/or preference. The 
dilemma leads to the first research question of  this study:
1) Is it possible to develop a methodology that integrates/transfers the   
 principle of Clinical Equipoise into a clinical trial recruitment  process? 
Legally enforced ethical regulations dictate that trial participation should be 
voluntary and based on informed consent. Some factors affecting a patient’s 
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effective equipoise, such as treatment preference and poor understanding 
of  the principles behind random treatment allocation, are known to prevent 
patients from enrolling.
The process of  informed consent is central to the ethical and legal 
acceptability of  any research that involves humans. When trial information 
is presented by a clinician, patients hold certain assumptions and 
expectations about a consultation, which may lead to difficulties in 
providing unbiased explanation about treatment options. Trial introduction 
by a third party and pre-randomisation have been used previously to limit 
the exposure of  an individual clinician’s opinion and/or preference. In 
addition, the use of  patient information videos has been shown to enhance 
understanding and to provide reassurance for patients invited to take part in 
clinical trials. 
As mentioned already, it can be difficult for a treating clinician to provide 
impartial advice about treatment options in the context of  a clinical trial. A 
patient has the right to know a surgeon’s personal opinion and judgement. 
Also, consenting to clinical research can be a rather time-consuming 
process, yet it is crucial to informed decision making by a patient about trial 
participation. This motivates the next research question:
2) How to achieve clear, impartial and consistent delivery of trial information  
 to patients in the context of a challenging surgical trial, when the   
 compared interventions are obviously different? 
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When innovations are introduced, it is a good research practice to 
understand the experience of  recipients/users. “Researchers should assess 
systematically the effects of  different intervention components and delivery 
characteristics, and should involve consumers in intervention development” 
(Ryan, Prictor et al. 2008, online CD003717).
Usually, patients do not expect a clinical trial to be a part of  their clinical 
care. Factors leading to ‘effective equipoise’ sufficient for their agreement 
to participate are poorly understood. There is limited systematic analysis 
of  patient experience data available directly from surgical trials (Mills, 
Donovan et al. 2003; Paramasivan, Huddart et al. 2011; Leighton, Lonsdale 
et al. 2012) and none to my knowledge from trauma and orthopaedic trials. 
More specific knowledge about patients’ response within different types 
of  clinical studies may help individual researchers and  trial design teams 
to choose an approach that promotes better-informed and more rational 
decisions about taking part. This leads to the final research question to be 
answered: 
3) What is the patient perspective on the recruitment process in a challenging  
 surgical trial, when the best current advice as well as innovative approaches  
 to the principles of patient participation are integrated? 
It is my intention in the remainder of  this thesis to provide answers to the 
proposed research questions and to suggest further work and development 
on the basis of  the research which I have carried out. A challenging trauma 
48
trial is described in Chapter 2 as an appropriate setting to test and explore 
some of  the ideas and solutions proposed elsewhere in this study. The study 
design is complex, multi-faceted and uses both qualitative and quantitative 
methods. An overview of  the research methods used throughout this 
study is given in Chapter 3, including a more detailed description of  the 
qualitative methodology and the study population. The research process 
is explained and results are described over the course of  three chapters 
(Chapters 4, 5 and 6), before combining all the relevant outcomes from 
the different studies into some conclusions in Chapter 7.
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Chapter 2 The UK Heel Fracture Trial (UK  
   HeFT)
The research questions posed in the previous chapter assume development 
and introduction of  a new trial recruitment methodology based not only 
on a solid theoretical background, but also through better understanding 
of  a surgical trial population. This chapter describes a trauma trial that 
provided a test setting for the methodology that was going to be developed 
during the course of  this study. This is in line with modern principles of  
translational research that theoretical and methodological developments 
are tested for practical application whenever possible and at the earliest 
opportunity. In addition, this approach allows direct user feedback both 
from clinicians and patients.
The UK Heel Fracture Trial (UK HeFT), in which I was closely involved, 
provided both the opportunity and the stimulus for my research project into 
patient recruitment. Its aim was to compare operative and non-operative 
treatment of  displaced intra-articular calcaneal (heel bone) fractures. 
The intervention arm involved a modern surgical procedure performed 
within three weeks of  the injury, by surgeons trained and experienced in 
the technique. The control arm was treated with analgesia and elevation 
to control pain and swelling. This was followed by early mobilisation and 
standardised physiotherapy regime, the same for both treatment arms. It 
was not clear from earlier evidence whether the possibility of  improved 
50
results after surgery (Sanders 2000) justified the risk of  frequent and serious 
complications, reported by other studies (Folk, Starr et al. 1999; Howard, 
Buckley et al. 2003). Such contrasting trial interventions presented a 
challenge to patient recruitment, as discussed in the previous chapter.
At the time it started in 2007, the UK HeFT was the largest national trauma 
trial designed according to current methodological advice. It was compliant 
with modern regulations and recommendations on the best clinical 
research practice. The study was set up as a multi-centre, two-arm, parallel 
group, assessor-blind randomised controlled trial (ISRCTN 37188541). It 
was designed as a pragmatic trial and all the participating surgeons were 
recognised as foot and ankle or trauma specialists. The Chief  Investigator 
had overall responsibility for the conduct of  the trial and had fiscal control 
over grant funds. He also headed the central trial office. The central trial 
office team included a trial co-ordinator, statisticians and co-investigators. 
Each trial centre had an expert surgeon designated as a Principal 
Investigator, with responsibility for local trial conduct and leadership. 
They were supported by Research Assistants, who facilitated patient 
recruitment and paperwork processing. The primary outcome was based 
on the injury-specific patient-reported outcome score at two years after 
injury. The Kerr-Atkins was a validated, reliable, patient-derived outcome 
instrument for pain and function following calcaneal fracture, accepted 
by surgeons working in the area (Kerr, Prothero et al. 1996). However, 
since participants were inevitably aware of  the trial arm to which they were 
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allocated, the possibility of  ‘preference’ bias or a surgical placebo effect 
had to be accounted for in patients’ reports. Secondary outcomes included 
risk of  complications, potential differences in quality of  life, stiffness and 
deformity of  the hindfoot, gait and foot pressure patterns.
All patients in participating trial centres diagnosed with calcaneal fractures 
during the trial recruitment period were assessed for trial eligibility 
according to pre-set fixed eligibility criteria. Patients were eligible if  
they were at least 18 years old and able to give informed consent with a 
recent (less than 3 weeks) closed, intra-articular, displaced (sub-talar joint 
posterior facet displacement of  at least 2 mm) calcaneal fracture. They 
were excluded if  they had very severe deformity of  the hindfoot (described 
in subjective terms as ‘fibula impingement’), other serious lower limb 
injuries (which the local investigator judged would be likely to influence 
outcome of  the calcaneal fracture at two years), would be unfit for surgery 
(e.g. due to severe cardiac impairment), suffered from peripheral vascular 
disease, or would be unable to adhere to trial procedures or to complete 
questionnaires. 
A novel recruitment process was introduced that confined the clinician’s 
role to assessing eligibility and grading fracture severity before seeing a 
patient. Specially trained research associates (nurses or physiotherapists) 
then approached eligible patients about the possibility of  participation in 
the trial. A patient trial information video was used to ensure a complete, 
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standardised and balanced explanation of  the trial. Patients had the option 
of  watching the video in the presence of  a research associate, who would 
be able to clarify any immediate queries or concerns. A compact DVD 
player was then left with  patients for at least a 24 hour period to enable 
them watch it again as necessary on their own or with friends or relatives. 
A research assistant then returned to assist with any further questions and 
enquires about the patient’s decision whether to accept an invitation to 
enter the trial. This process was researched as part of  my study and it is 
described in more detail in Chapter 5.  
Participants were recruited from patients presenting to 22 collaborating 
hospitals in the UK (Appendix A) during the period January 2007 to 
December 2009 to achieve a recruitment target of  150 participants. The 
patient screening process was audited continuously at every centre. A 
Principal Investigators and Research Assistants network was co-ordinated 
by the Trial Central Office. Regular educational and networking events 
were organised to stimulate peer review and exchange experience about the 
patient recruitment process, in addition to trial site monitoring. 
 Patients who consented to take part in the trial were randomised on a 
1:1 basis to receive operative or non-operative care. Mixed clinical and 
questionnaire follow up was arranged at six weeks, then 6, 12, 18 and 
24 months. At the final two year follow up appointments, participants 
were assessed by a single independent physiotherapist, who was unaware 
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of  treatment allocation. Heel width and hindfoot ranges of  movement 
(dorsiflexion, plantarflexion, inversions and eversion) were measured in 
comparison with the other side and gait was assessed. During examination, 
participants were asked to wear thin socks to obscure surgical scars and not 
to disclose the treatment they had received.
A trial flow diagram (Fig. 2.1) demonstrates the trial profile and stages of  
the trial recruitment process researched in the context of  this study. These 
stages include  identifying eligible patients, presenting trial information 
according to the informed consent principle and then managing patient 
decision making about trial participation. Of  502 eligible patients identified 
in this trial according to pre-set fixed eligibility criteria, only 151 (30%) 
agreed to take part. The most common reason for declining, by a significant 
margin, was a preference towards either operative or non-operative care, 
which was evenly balanced (144:146). 
Statistical analysis of  patient demographic data for the trial (Appendix 
B) showed that the injury tended to occur in younger men and in older 
rather than younger women. Even when they were eligible, younger men 
and middle-aged women were more likely to refuse to enter the trial.  This 
caused some concern that women and younger men might be under-
represented in the trial, although this was considered when interpreting 
the trial results. Overall there were four times more men presenting with 
the injury considered eligible for the trial, which was expected.  The 
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1494 patients not eligable
 under 18 years of age 46
 open fracture 45
 undisplaced fracture 477
 extra-articular fracture 395
 fracture more than three weeks old 27
 bilateral (before change in criteria 25
	 fibula	impingement	 57
 previous abnormality 4
 other serious injuries 177
 peripheral vascular disease 10
 contra-indication to surgury 50
 unable to adhere to trial procedures 99
 unable to give informed consent 8
 patient self-discharged 29
	 trial	staff	not	available	 24
 military 1
 admitting surgeon not in trial 20
2006 patients with calcaneal fractures
3 potentially eligible patients missed from 
recruitment
7 patients for whom data is incomplete or 
missing
502
eligible patients
351 patients declined to participate
 preferred non-operative care 146
 preferred operative care 144
 wanted to be treated close to home 11
 self-discharged 9
 wanted private care 1
 did not want to participate in research 22
 did not want follow-up assessments 9
 no reason given 9
151
patients randomised
78 allocated to non-operative care
3 received operative care
 all changed their minds after   
 randomisation: one was   
	 influenced	by	referring	hospital		 	
 and one by his wife who was a   
 district nurse
Follow-up at two years
78 (95%) primary outcome assessed
4 not followed up
 2 died
 1 withdrew
 1 lost to follow-up
73 allocated to operative care
5 received non-operative care
 2 changed their minds after   
 randomisation
 1 declined surgury during wait for   
 operation
 2 declined surgery after later   
 discussion with surgeons
Follow-up at two years
69 (95%) primary outcome assessed
4 not followed up
 1 died
 1 withdrew
 2 lost to follow-up
ITT analysis of 151 patients
Light green area – trial eligibility assessment stage researched in the context of the PEACE 
methodological framework (Chapter  4). Brown coloured box – patient groups adding up to 
263 patients, many of whom would have been assessed for trial eligibility on an individual basis 
if the PEACE framework was used, rather than excluded according to pre-set criteria (Chapter 
4.4).
Violet area – trial recruitment stage researched in the context of the PTIV recruitment approach 
(Chapter 5). Yellow coloured box – two groups adding up to 290 patients who were mostly 
positive	towards	research,	but	not	able	to	accept	the	randomisation	offer	in	its	current	form	
(Chapter 6).
Figure 2.1. The UK HeFT patient throughput.
55
proportion refusing to enter the trial was similar: 72% for women and 68% 
for men. This is in line with recent high-quality challenging interventional 
trials (Buchbinder, Osborne et al. 2008; Weinstein, Lurie et al. 2008), 
when treatment arms are significantly different. Taking into account the 
limitations outlined above, after two years no beneficial symptomatic or 
functional advantage of  operative treatment was identified, compared 
to non-operative care in patients with typical displaced intra-articular 
fractures of  the calcaneus. At the same time, the risk of  complications was 
confirmed to be higher after surgery.
Having outlined the context of  my research and the particular trial it was 
tested in, I am now in a position to describe the study design in the next 
chapter.
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Chapter 3 Study design and methodology
The patient recruitment process into surgical RCTs, which is the subject 
of  this study, can be divided into three consecutive phases: identification 
of  eligible patients, invitation to take part in a trial based on the principle 
of  informed consent and the decision process by a subject about trial 
participation. The three research questions posed in chapter 1.6 reflect 
these three phases. The approach taken to research the three distinctive 
issues inevitably had to involve mixed methods. This presented a significant 
challenge, because I had to find a way to acquire new knowledge and 
balance between different subjects (methodological development and 
qualitative reflection) with different theoretical backgrounds (experimental 
and observational). In addition, I had to find a way to develop 
collaborations that did not exist in my institution. However, it was felt 
important to adopt the mixed methods approach not only because the 
research issues to be addressed were linked as parts of  the same process, 
but also because the feedback and reflection from stakeholders, in particular 
subjects, of  proposed innovations could enrich and strengthen an argument 
to transfer these innovations in future practice. This attempt to design a 
transferable methodological research project is explained next, starting with 
the first research question:
1) Is it possible to develop a methodology that integrates/transfers the principle  
 of Clinical Equipoise into a clinical trial recruitment process? 
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The principle of  Clinical Equipoise is used to justify the proposal of  
a clinical trial, but is substituted by the application of  trial eligibility 
criteria when a patient’s eligibility is assessed. It has been demonstrated 
in chapter 1.2 & 1.3 that although pre-set eligibility criteria reflect the 
clinical equipoise present at the start of  a trial in relation to the relevant 
patient population, it often falls short of  being affirmed in relation to 
an individual patient assessment. This may lead to lower confidence that 
the patient in question would not be disadvantaged through random 
allocation to interventions compared in the trial. Currently however, there 
is no methodological alternative available to assess patient eligibility for 
a RCT, other than an application of  the pre-set fixed eligibility criteria. 
Once the eligibility criteria are met, the patient has to be offered trial 
participation, which assumes random allocation to the intervention arms 
even when a patient and/or a treating clinician are not equipoised about 
the choice. It follows that to answer the first research question of  this 
study about the randomisation offer, it is necessary to suggest and develop 
a methodological framework that incorporates expression of  clinical 
equipoise at the stage of  identification of  eligible patients for a RCT. 
Research into novel methodologies is often complex and typically requires 
a multi-disciplinary approach. This work is no exception. At different 
stages it involved collaborating with, amongst others, an IT specialist and 
a statistician. Methods used to develop a new framework for patient trial 
eligibility assessment through quantifying and demonstrating levels of  
clinical equipoise in real time for an individual patient are described later in 
this chapter (3.1). 
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The second research question concerns trial information delivery to 
patients, based on the principle of  informed consent:
2) How to achieve clear, impartial and consistent delivery of trial information  
 to patients in the context of a challenging surgical trial, when the compared  
 interventions are obviously different? 
The methodological improvement in order to provide consistent and clear 
presentation of  research and clinical information to eligible patients is 
outlined(3.2). 
Both new methodological developments were tested during the challenging 
trauma trial which was described in chapter 2. The aim was to assess the 
potential benefits, practicalities and relevance to similar trials that may 
be undertaken in different fields in the future. When innovations are 
introduced, it is good research practice to understand the experience of  
recipients/users. “Researchers should assess systematically the effects of  
different intervention components and delivery characteristics, and should 
involve consumers in intervention development” (Ryan, Prictor et al. 2008, 
online CD003717). This principle links to the final research question:
3) What is the patient perspective on the recruitment process in a challenging  
 surgical trial, when the best current advice as well as innovative approaches  
 to the principles of patient participation are integrated? 
This research question, that seeks an understanding and meaning of  
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patients’ experiences of  the trial recruitment process, merits the application 
of  qualitative methods. There was a rather limited expertise of  qualitative 
research available in our department, so I had to look for help and 
assistance from experienced qualitative researchers pro-actively. This 
eventually led to effective collaboration and supervision arrangements, as 
described in the final part of  the chapter (3.3). The choice of  the qualitative 
approach allowed me to study the wider influences which shaped patients’ 
decision making about participation in a trial comparing invasive and non-
invasive treatment. After all, it is a patient’s voluntary participation that is 
at the centre of  a trial’s success or failure. Better understanding of  patient 
motivations towards clinical research participation may help to shape both 
current and future methodological modifications.
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3.1 A new methodological framework development 
I aim to describe consecutive the steps taken, in order to develop a new 
methodological framework for trial eligibility assessment. The framework 
is designed to be easily understood by clinicians and implemented in real 
time during the course of  a trial. This process brought together a number 
of  research methods across different disciplines. Their complementary 
and complex relationship is illustrated in Figure 3.1, accompanied by an 
explanation in the text.
Figure 3.1. Methods used to develop a new methodological framework.
61
The literature review in chapter 1.2 indicates that Clinical Equipoise as 
the basis for setting up a clinical trial is usually demonstrated by a failure 
of  consensus between experts about the effectiveness of  an experimental 
intervention compared to a control. This is usually caused by the lack of  
knowledge that enables experts to forecast the outcome of  a proposed 
intervention. A “measure of  a state of  knowledge” (Jaynes and Bretthorst 
2003) can be demonstrated using the concept of  Bayesian subjective 
probability. Bayesian methods allow one to quantify the level of  an 
expert’s individual uncertainty or confidence about the effectiveness of  an 
intervention. When experts’ opinions are combined, or pooled, it is safe to 
assume that for most patients in a trial population, the experts should fail to 
reach an agreement in presence of  clinical equipoise, which is necessary for 
a patient to be recruited ethically. This concept provides a platform from 
which to develop ideas in the challenging trial setting.
An expert treatment prognosis can be viewed as a Bayesian prior which 
is assigned to a specific hypothesis; it is personal and varies with an 
individual’s knowledge and expertise. However, turning informally 
expressed ideas into a mathematical prior distribution is perhaps one of  
the most difficult aspects of  Bayesian analysis (Spiegelhalter, Abrams et al. 
2004). There are five widely used approaches: (i) elicitation of  subjective 
opinion, (ii) summarising past evidence, (iii) default priors, (iv) ‘robust’ 
priors and (v) estimation of  priors using hierarchical models. There is no 
such thing as a correct prior or method of  determination, but option (i) 
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is the most suitable to elicit and quantify the collective subjective opinion 
from a panel of  experts in real time. It has the advantage of  being dynamic 
and flexible, because knowledge and preferences can change during 
the course of  a trial. This may happen, for example, on the publication 
of  related research, or as individual and collective clinical experience 
accumulates amongst experts.
Development of  an online tool for opinion elicitation has been the first 
step to bring the Clinical Equipoise assessment in real time. Previously, 
elicitation of  subjective opinion in surgical settings has been achieved by 
collecting opinions through a questionnaire survey (Young, Harrison et al. 
2004) or by a series of  scenario-based specialist interviews (Lilford 1994).  
Both methods are time and labour intensive and could only be used to 
support a justification to start clinical research. An alternative technique, 
which involves the collection of  subjective judgements in relation to clinical 
decision making, allows participants to distribute 100 points between bins 
that reflect their ‘weight of  belief ’ in a range of  available outcome options 
(Parmar, Spiegelhalter et al. 1994; Parmar, Griffiths et al. 2001). This 
technique was used to develop a novel web-based tool for the collection 
and measurement of  specialist beliefs about a specific clinical case (Chapter 
4.1). The technical implementation was achieved in collaboration with Mr S 
Brydges, eLab, the University of  Warwick. Freely available software (Adobe 
Flash Player, MSDN Microsoft Data tables) and the University of  Warwick 
web-based platforms (Warwick Forums, SiteBuilder) were used. The 
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tool was then tested in a pilot study. A questionnaire, as well as informal 
feedback, was used to assess expert perception and usability of  the tool. I 
was interested in technical issues, format, clinical information sufficiency 
and ultimately whether I had the experts’ support to take the study further. 
Accordingly, a combination of  closed (choice of  categories) and open 
questions was used to guide responses (Appendix K). The questionnaire 
was designed in an easy to read one page format with spaces for comments 
(Boynton and Greenhalgh 2004). It was posted to surgeons’ secretaries 
upon completion of  the pilot study.   
Once the voting data for a case are obtained, two potential approaches 
to pooling the opinions are available, (i) a parametric model based on 
a Beta distribution and (ii) a nonparametric model based on estimated 
means and standard deviations. Statistical models of  expert opinions 
were developed in collaboration with Dr N Parsons, Medical Research 
Statistician, Statistics and Epidemiology, Warwick Medical School. An 
Opinion Elicitation Course was attended (CRiSM: Centre for Research 
in Statistical Methodology, 13/04/2011, University of  Warwick). 
Subjective logic principles (Jøsang 1997) were used to develop a statistical 
model that allowed us to measure and visually present a level of  clinical 
equipoise for an individual clinical case. The formal statistical methods 
necessary to implement the model, which are outside the scope of  this 
thesis, are described in detail elsewhere (Parsons, Kulikov et al. 2011) (see 
Appendix I). The focus here is on the underlying conceptual framework 
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and interpretation of  clinical equipoise levels (Chapter 4.2). In particular, 
decisions about trial eligibility depend on the application of  decision rules. 
There is little research available on this subject, other than a stand-alone 
ground-breaking paper where collective equipoise levels sufficient for 
initiating a clinical trial were estimated (Johnson, Lilford et al. 1991). This 
ethometric study with the general public investigated how much collective 
equipoise can be disturbed before potential trial subjects deem it to be 
unethical. Their findings suggested that “trials are perceived as unethical 
when equipoise is disturbed beyond 70:30. In other words, when 70 per 
cent of  experts favour treatment A, then 50 per cent of  subjects would 
prefer that treatment A be administered rather than subjected to critical 
assessment.”  When 80% of  experts favour one treatment, less than 3% 
of  the lay public would consider human trials morally justifiable. Based 
on these estimates, decision rules were suggested and this complemented 
the development of  the Patient Eligibility Assessment through Clinical 
Equipoise (PEACE) methodological framework.
To test the new methodology, the PEACE framework was introduced as an 
independent research project called ‘Collective Uncertainty Project’ within 
the UK HeFT (Chapter 4.3). The aim was for real clinical cases to be 
assessed in real time by an expert panel consisting of  principal investigators 
in the context of  a challenging trauma trial, but without interfering with 
the clinical management or the trial course itself. This was achieved by 
asking eligible patients to consent to the use of  their clinical data at least 6 
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weeks after the injury, when a decision about trial participation was made 
and a treatment course was initiated. The use of  ethical approval was 
kept separate from the main trial (Appendix  C). This had the additional 
advantage of  approaching both patients who agreed to take part in the 
UK HeFT and those who did not. Surgeons who were involved in case 
assessments as part of  the expert panel were asked for their feedback 
informally and via questionnaires (4.3.1). On this occasion the questionnaire 
design was more complex (Appendix G). Although anonymous, some 
background information was requested from experts to reflect levels of  
specialist surgical and research experience. Data examples were given and 
the choice of  categories included an open element to stimulate reflection of  
the study involvement experience.
Finally, patient understanding and views about the possible introduction 
of  the new framework in future trials were researched, as part of  the 
qualitative study (using semi-structured interviews), which is described later 
in this chapter (3.3).
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3.2 Methodological improvement to patient recruitment  
 approach
To answer the second research question, concerning trial information 
delivery to patients , the new trial recruitment approach is suggested that 
aims to avoid direct contact between a patient and a treating clinician until 
a decision about trial participation is made (Chapter 5). This is to prevent 
possible disclosure of  likely treatment preference by a surgeon, so that a set 
of  standardised unbiased trial information is presented to every potential 
participant. The sequence of  steps undertaken to introduce and test such 
methodological development is illustrated in Figure 3.2.
Figure 3.2. New patient recruitment approach development.
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The approach was based on developing and recording an audio-visual 
presentation of  trial information, supplemented by one-to-one personal 
support from a research team. The video was to become the main 
source of  research and clinical information for an eligible patient. This 
methodological improvement is effectively a combination of  two methods 
that have been shown previously to improve understanding and reduce bias 
during the consent process for a clinical trial (chapter 1.4). On this basis, it 
was approved both by the Ethics and the Trial Steering Committees to be 
introduced in the challenging surgical trial described in the chapter 2.
The format of  the Patient Trial Information Video (PTIV) was discussed 
with the UK HeFT set-up team.  It was decided that it should be in the 
form of  an expert explaining the injury and the trial using appropriate 
illustrations. The Chief  Investigator of  the UK HeFT (Damian Griffin, 
Professor of  Trauma and Orthopaedic Surgery) drafted a script based on 
recommendations by the National Research Ethics Service on informed 
consent and essential information that needed to be provided to patients 
invited to take part in clinical research. The video was filmed, processed 
and edited by the Warwick Medical School Audio-Visual Team. The 
video was distributed to the Trial Steering Committee (including non-
medical members), collaborating Principal Investigators (surgeons) and 
physiotherapists involved in trial planning. Comments were collected, 
the script re-drafted and the video filmed again accordingly. After a 
repeat circulation, new editing touches were applied. Finally, the video 
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was introduced and discussed with the first three patients eligible for the 
UK HeFT by the Chief  Investigator himself  and the Trial Co-ordinator. 
Patients’ comments were analysed by the trial set-up team and final editing 
touches were applied. A CD with the final version of  the PTIV is attached.
Research Assistants involved in every trial centre were trained by the UK 
HeFT Head Office based at Warwick Medical School to approach and 
introduce eligible patients to the video and then assist with all patient 
queries.
Clinicians’ reaction was uniformly positive in every trial centre from the 
outset and remained so for the duration of  the trial. Therefore, the formal 
exploration of  their views and feedback was not felt necessary. On the 
other hand, patients’ views as subjects of  the trial recruitment process were 
researched (Chapter 5.2), as part of  the qualitative study described next. 
These data proved crucial in illuminating strengths and weaknesses of  the 
proposed approach (Chapter 5.3).
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3.3 Patient experience of recruitment to a trauma trial 
‘Qualitative investigations can thus be used to elucidate challenges to 
recruitment in trials with very different treatment arms, but require 
sufficient time to be undertaken successfully.’ (Paramasivan, Huddart et al. 
2011, p.1)
As mentioned already in this chapter, it is of  vital importance to learn about 
the impact of  the suggested new trial interventions on patients, as subjects 
of  those interventions. The Patient Trial Information Video (PTIV) based 
recruitment approach was introduced directly in the challenging surgical 
RCT (Chapter 5.1), while the new framework for trial eligibility assessment 
was researched as an independent project integrated within the same trial 
(Chapter 4.3). In this way, both interventions became a part of  patient’s 
experience in the surgical RCT with very different treatment arms (Chapter 
2). 
There are rather limited data available directly from such trials about factors 
that influence patient decisions about participation, as highlighted by the 
literature review in Chapter 1.5. This led to the third research question 
concerning gaining further insight into the patient perspective of  the trial 
recruitment process.
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The research question dictated the choice of  theory and methods applied 
to answer it, as illustrated in Figure 3.3. The aim was to understand the 
experience of  being approached about participation in the clinical trial 
from the perspective of  the patients who had been through this situation 
in the UK Heel Fracture Trial. This is in line with the Verstehen approach 
(Holloway and Wheeler 2010), which assumes a reflective reconstruction 
of  particular situations that these patients found themselves in and 
Figure 3.3. Patient decision making process about trial participation
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interpretation of  the decision-making process about research participation, 
with attention to factors which affected or which could modify this process. 
With this approach it is crucial to interpret a phenomenon from the 
perspective of  the people affected by it, as it is constructed by those people. 
Phenomenological methods could not be used, however, because it was 
important to uncover a multitude of  factors that led to either a positive or 
a negative decision for different patients, even though they were in a similar 
context. Phenomenology suggests a holistic perspective to life experiences, 
so that the researched phenomenon is explored by means of  extracting 
common themes (essential structures or essences) that go beyond individual 
cases, rather than focusing on the narratives of  each participant (Holloway 
and Wheeler 2010).
Grounded Theory, on the other hand, starts with a careful search for any 
emerging themes and topics from every individual account, which are coded 
and analysed right from the start and which guide ongoing data collection. 
Through data comparison, initial concepts or even hypotheses are formed, 
which inform and guide the further research process. The systematic 
generation of  a new theory is guided purely by emerging data, rather than 
by testing a pre-conceived hypothesis. (Glaser and Strauss 1967; Green and 
Thorogood 2009).
Thematic analysis of  content (Adams and Preiss 1960) combines the open-
minded approach of  grounded theory with the phenomenological principle 
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of  identifying common themes. This method emphasises organisation of  
the narrative data through a structured process. Although it starts with 
minimally organised rich data interpretation and coding, the end aim 
is to identify common patterns (themes) within data through constant 
comparison and re-evaluation (Braun and Clarke 2006). The researcher 
is pro-active in data interpretation and analysis, which is in line with my 
efforts to understand patient trial experience, specifically in response to 
current and proposed recruitment interventions, as this may affect their 
future use and development. The phases of  thematic analysis followed in 
this study are described later. 
Ethical approval was sought and obtained for this study (Appendix E).
Subjects were recruited in a single centre, which was one of  the largest 
UK HeFT centres - the University Hospital of  Coventry and Warwickshire 
(UHCW). All 47 patients who agreed to provide their data for the Collective 
Uncertainty Project, introduced earlier (3.1) were invited to interviews. 
Patient information sheets presented as an invitation letter with separate 
reply slips (Appendix F) and pre-paid return envelopes were posted. 
After two weeks, telephone calls and email reminders followed. Options 
to be interviewed either at one of  two local hospital sites or at home were 
offered.
Individual stories of  a decision making process about the trial participation 
were of  prime interest. For this reason it was felt that group patient 
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interviews, where shared experiences are explored, would not be 
appropriate.  A semi-structured interview format made it possible to set an 
agenda for personalised data extraction, while allowing sufficient flexibility 
for patients’ responses to determine the information which was provided 
and themes which were discussed. Structured interviews would not have 
allowed patients to develop their own narrative of  the events, while 
unstructured interviews on the other hand may not have covered certain 
topics of  interest, such as more specific feedback about introduced and 
proposed new methodologies from this study.  In addition, unstructured 
interviews do not allow direct comparison of  data between patients. 
This would have prevented a typological analysis that developed into an 
important part of  this study as described later.
My experience as a clinician in the same specialty provided the background 
in the development of  theoretical sensitivity in order to categorise 
significant and less important topics to be covered in the interviews. On 
the other hand, there was a risk that interviewees could view me as another 
member of  a clinical team, rather than an independent researcher, and 
modify their responses accordingly.
Analysing Qualitative Interviews Training Course was attended 
(26-27/02/2008, Health Experience Research Group, the University of  
Oxford). The interview schedule was developed in collaboration with 
the course providers, when common research interests were uncovered 
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(Appendix D). The schedule had three distinct parts. The initial narrative 
component was prompted at the start of  interviews. Patients were 
asked how their injury occurred and what happened to them until the 
moment a treatment decision was made. Topics of  special interest for an 
interviewer included the way they were approached about taking part in a 
clinical trial and what influenced their decision about participation and/
or treatment. They were left free to develop their stories, only occasionally 
being interrupted for clarification or more in-depth explanation of  a 
new, interesting or important theme. This aimed to reveal the issues and 
topics that mattered most to patients when making a decision about trial 
participation. The intention was also to allow interviewees to express 
themselves, to relax and find their comfort zone during the interview, thus 
enabling them to bring back memories of  the event that had happened up 
to two years previously. 
This retrospective recollection of  events that happened a considerable 
time prior to an interview relied on the patient’s memory and their verbal 
report of  those memories. This can be viewed as a potential weakness of  
the selected approach. However, this time lapse may have clarified truly 
important issues that really mattered for many of  the interviewees. 
The initial narrative part was followed by showing and discussing the 
PTIV. For some patients this refreshed not only memories of  the video 
itself, but also of  the trial recruitment process in general. Patients were 
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free to interrupt the video to make comments and raise queries, or to leave 
these until after the viewing was complete. Some important topics, such as 
‘clarity of  information’ in the video, were prompted if  not commented on 
spontaneously. Being a trainee orthopaedic surgeon and part of  the trial 
set-up team helped me to appreciate the difference between the intended 
impact of  the provided trial information and patients’ interpretation.
Finally, the PEACE results for a patient’s own calcaneal fracture were 
shown. This was a completely new experience, so time was taken to explain 
result diagrams and to answer queries. The interviewees were then asked 
to imagine that these results were available at an earlier stage and used as 
a basis for inviting them to take part in the trial. Their reaction, and in 
particular the way that this would influence their decision, was recorded.
As a first step, two interviews were conducted with an experienced 
interviewer-researcher from the Health Experience Research Group, 
University of  Oxford. This allowed practical interviewing experience to 
be gained and adjustments to the interview schedule to be made. Other 
interviews were conducted independently by myself, seven of  them in 
patients’ homes. The shortest interview was 25 minutes in duration and the 
longest took over an hour.
Interviews were recorded with an Olympus digital voice recorder VN-
5500PC. Hand written notes of  thoughts and ideas occurring during 
interviews were also taken. Two interviews were transcribed by the Health 
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Experience Research Group, one by myself  and the other by a transcriber 
registered with the University of  Warwick.
Thematic analysis (Guest, MacQueen et al. 2012) starts with getting familiar 
with the data and generating initial codes. I was familiar with the data, 
because I interviewed all participants and recorded my initial impressions, 
for example the emotional context, in research notebooks. Coding is 
the primary process for developing themes from the raw data prior to 
interpretation. It recognises important and meaningful parts of  a narrative 
from the subject’s point of  view. This is often reflected in labelling codes 
with the terminology used by participants. To generate codes, I listened to 
interview audio recordings while reading through transcripts and I used 
notes taken during interviews. I used QSR NVivo 8 software that facilitated 
the interview data management and the coding of  emerging topics.  
As the coding progressed simultaneously with the data collection 
(interviews), codes were grouped into common themes. They were revised 
and re-grouped as further data emerged, evolving as a cyclical process 
of  constant data comparison. Eventually, a number of  themes formed 
an outcome of  coding for analytic reflection. At this stage the themes 
related to the research question were reviewed and refined, looking for 
connections and formation of  coherent patterns. These patterns are 
described and explained in the relevant chapters 4.3.2, 5.2 and 6.1. The 
qualitative research supervisor (Dr Ann Adams, Warwick Medical School) 
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continuously monitored and cross-checked the data analysis at all stages.
When analysing interviews it became apparent that some patients had 
broadly similar responses and attitudes towards the invitation to take part 
in the RCT. After discussion with the supervisor, the typological analysis 
(Holloway and Wheeler 2010)  was applied in view of  this emerging picture. 
Understanding and anticipating certain response patterns from potential 
trial participants may help to improve the trial recruitment process, 
especially with a view to developing a new methodology application. A 
psychological model of  clinical decision-making as a classification process 
(Fig. 3.4) was adapted from work by Adams et al. (2008) to facilitate a 
structured approach to the analysis of  interview data that relates to a 
patient’s decision-making process. 
Figure 3.4.	A	psychological	model	of	clinical	decision	making	as	a	classification	process.	
(Adams et al., 2008)
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Buckingham and Adams (2000) analysed a multitude of  clinical decision-
making theories that were confined to different discipline contexts. The 
underlying similarities were identified and allowed the development of  
a  unifying framework for interpreting decisions across different clinical 
domains. In particular, nursing and medical clinical decision processes 
could be analysed and compared directly. My interview data suggested that 
the UK HeFT patients were put in a similar position to clinicians making 
decisions when invited to take part in the trial and given a lot of  clinical 
information about the choice of  two very different treatments for their 
injury. 
The components of  the Buckingham & Adams framework were transferred 
into a master table (Table 3.1) to adapt it for analysis of  the patient 
decision making process. The table was populated from every interview 
according to patients’ responses (Appendix H). The first column called 
‘Patient and context attributes’ listed the interviewee characteristics with 
identifier. The next two columns (‘Cue selection’ and ‘Relevant cues’) 
presented factors that influenced their decision process, from a selection 
of  key factors to those more broadly supporting the decision. Next came 
the emotional context in the ‘Psychological representation of  cues’ column 
as described by patients and how they weighed or conceptualised the 
relevant factors. Different sources of  information and knowledge, such 
as prior experience, media and online resources, other people’s opinions, 
including family and friends, were listed in the ‘Cue integration’ column. 
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The ‘Potential outcomes’ column identified patient expectations and 
concerns about the possible effects of  either the experimental or control 
interventions. The next column ‘Certainties’ described background beliefs 
upon which a decision was based. Finally, the actual decision about whether 
to join the trial was stated in ‘Outcomes’ column together with the patient’s 
reflection about it, after having experienced a chosen treatment. 
This structured approach allowed direct comparison between interviews, 
and in particular, identification of  recurrent themes. This is different 
however from the thematic analysis described earlier, aiming to identify the 
important decision making components that influence a patient’s decision 
(concerns etc reflected in the themes). The use of  the model organises 
these themes to clarify the decision making process. In turn, this leads to 
better understanding of  the mechanisms for patients’ decision making, 
such as factors and potential outcomes that are most influential in shaping 
the decisions they make. This should help to recognise the type of  patient 
response in future similar trials in order to anticipate and target better their 
information needs and how best to approach them about the issue of  trial 
participation, with the aim of  improving recruitment.
Responses were compared and those showing similar patterns were 
grouped together to form a separate table for each emerging type 
of  patient stance. This material was cross checked by, and discussed 
with, the qualitative research supervisor. One example of  tabularised 
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interview material for patient types presented by more than one patient is 
demonstrated in Appendix H. All patient types with quotes are described 
in detail in Chapter 6.2.
Having outlined in this chapter the methods used to approach the research 
questions posed in chapter 1, it is now possible to describe how these 
methods were used to attempt to answer these questions. The next chapter 
explains in some detail how deconstructing the ethical and theoretical 
basis of  clinical research helps to build a novel methodological framework 
for patient recruitment that may become a valuable alternative to current 
standard approaches in the difficult environment of  challenging surgical 
trials.
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Chapter 4 Study A: Development of the   
   PEACE methodological    
   framework
This chapter describes the development of  a new methodological 
framework for patient eligibility assessment in a challenging surgical trial to 
address the first research question from Chapter 1.6:
Is it possible to develop a methodology that integrates/transfers the principle of 
Clinical Equipoise into a clinical trial recruitment process?
The framework is based on elements of  standard clinical care, where for 
instance a clinician considers treatment options for a case and undertakes 
risk assessment about the suitability of  one or another treatment. If  a 
case is difficult and there is no clear evidence in favour of  one or another 
treatment, it is good clinical practice to discuss and listen to one’s peers 
before making a final decision, or indeed agree a collective treatment 
decision with colleagues. The proposition of  this study is that every 
potentially eligible case for a challenging surgical trial should be treated in 
this way. This proposition is adopted firstly because the main reason for 
instigating a clinical trial is the lack of  definitive evidence in favour of  one 
or another treatment, and secondly because fixed pre-set eligibility criteria 
are an inadequate basis for complex clinical decision making. The challenge 
is then to develop a feasible system to assess clinical cases in real time 
during the course of  a trial. 
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The clinical decision making system described in the following sections 
combines statistical methods, in order to elicit and assess opinions, and 
modern on-line technology to allow immediate transfer of  assessment data 
to the trial management team. The formal statistical methods necessary to 
implement the clinical decision making system were developed collaboratively 
with Dr Nick Parsons (Statistics and Epidemiology, Warwick Medical 
School) and are outside the scope of  this thesis. The focus here is on the 
underlying conceptual framework and interpretation, rather than details of  
the implementation which are described in detail elsewhere (Parsons, Kulikov 
et al. 2011).
Three stages of  the methodological framework development formed the 
Collective Uncertainty Project and were outlined in Chapter 3: (i) online tool, 
(ii) statistical model and (iii) proof  of  principle test within a real trauma trial. 
These are now described in detail in this chapter. This was complemented by 
end-user (surgeon) feedback and analysis of  the reactions and understanding 
from patients’ perspective as research subjects (4.3.1 and 4.3.2). The 
hypothesis for the Collective Uncertainty Project (CUP) is that clinical cases 
from a trial can be assessed online by a panel of  experts in order to provide 
the data necessary to quantify the level of  confidence or equipoise about 
treatment choice.
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4.1 Methods to elicit and quantify clinical equipoise
A web based tool was developed for collecting treatment outcome 
prognoses from clinicians for specific clinical cases.  A dedicated CUP 
webpage (http://www.warwick.ac.uk/go/heft/cup) was set up, using the 
University of  Warwick Sitebuilder software (IT services, University of  
Warwick, UK) for building webpages on the University virtual platform. 
It had a link to enable a member of  a trial research team to submit clinical 
data, including images such as Xrays and CT, to the CUP team. Data were 
published in an anonymised manner on a password protected voting page 
(Fig. 4.1). Participating clinicians were alerted to a new case by email or 
SMS via a secure Warwick University online forum. Emails contained 
web links to the published cases and an invitation extended to examine 
the available data and estimate outcome probabilities for contrasting 
interventions. Outcome probabilities provided estimates of  expert opinion 
on whether a patient would get better or worse by various degrees if  the 
procedure in question were applied.  
When selected, case web links opened relevant case voting pages. Clinicians 
were asked to enter their usernames and passwords in order to access the 
published clinical data. Each voting page was an ‘image gallery’, which 
allowed clinicians to see the thumbnails at a glance, and zoom into the detail 
with a single click as necessary. The right hand column presented relevant 
patient data, such as age, occupation and the circumstances leading to the 
injury.
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After assessing the clinical data available for a given patient, the clinician 
was able to scroll down to an interactive voting scale, featuring bars (initially 
set at zero) above each of  seven outcome categories indicating whether 
after surgical intervention the patient’s condition would get “much worse” 
(1), “significantly worse” (2), “a bit worse” (3), “no difference” (4), “a bit better” 
(5), “significantly better” (6) or “much better” (7). Each outcome prognosis bar 
could be dragged with a left-click of  the mouse to a desired percentage, 
which was then reported numerically over the bar. It was important and 
intentional that clinicians were asked to give an honest outcome prognosis, 
rather than simply to express their personal preference for one or another 
treatment. This was done specifically to reduce preference bias.  Once the 
assessment reached a total of  100% (reflected in a digital window in the 
upper left corner of  the scale) the submit button allowed the data to be sent 
to the trial lead for analysis (Fig. 4.2).
Once submitted, the votes were stored online within FormsBuilder. This 
is an add-on tool to Sitebuilder, that enables creation and maintenance 
of  different types of  online forms to facilitate interactive features, such 
as remote data submission by website users (Fig. 4.3). At any time the 
CUP team could download the submitted votes in Excel format for more 
detailed statistical analysis. 
Initially the system was tested in a pilot study by seven Orthopaedic 
surgeons from five UK hospitals. Ten retrospective calcaneal (heel bone) 
fracture cases were selected and adjusted to represent typical variability. 
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The surgeons followed the instructions on the website with online and 
telephone technical support available; no specific training was given. When 
voting on all ten cases was completed, surgeons were asked to fill in an 
evaluation questionnaire (Appendix K). The available clinical information 
was found sufficient and the whole process user friendly by all participating 
surgeons. Voting on a single case never took longer than 5 minutes. All 
surgeons responded and were willing to participate in further research on 
the subject.
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Borrowing from the concept of  subjective logic (Jøsang 1997; Jøsang 2001), 
a pooled expert opinion can be thought of  as comprising three distinctive 
aspects: belief, disbelief and uncertainty. Belief represents the tendency of  
experts to expect a particular treatment to perform better for a particular 
patient (case); this manifested itself  in the tendency for the experts to drag 
bars up in the higher (Right) end categories of  the voting scale (Fig. 4.4a). 
Conversely, the level of  disbelief is equated with the tendency for a particular 
patient to do worse with the given procedure; this manifested itself  in the 
tendency for the experts to score cases in the lower (Left) end categories 
of  the voting scale (Fig. 4.4b). The uncertainty associated with the belief and 
disbelief represents the spread of  the data across the opinion range (Fig. 
4.4c)
The pooled collective opinion as a combination of  belief, disbelief 
and uncertainty can be mapped on a ternary plot that displays these 
characteristics in a manner that allows them to be compared to decision 
rules that partition the opinion space. A ternary plot is a plot for displaying 
three variables which sum to a constant; in our case belief, disbelief and 
uncertainty. It graphically depicts the ratios of  the three variables for each 
case as positions in an equilateral triangle, thus allowing patient cases to 
be compared and contrasted simply in a two-dimensional diagram. This 
ability to visualise and compare collective expert opinions about different 
cases is at the heart of  the Patient Eligibility Assessment through Collective 
Equipoise (PEACE) described next (chapter 4.2). Once completed, the 
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(a) consensus about better outcome after operative treatment, (b) Consensus about no better or worse 
outcome after operative treatment and (c) Uncertainty (equipoise) about outcome after operative treatment.
Figure 4.4. Opinions about three cases expressed by surgeons in the pilot study. 
(a)
(b)
(c)
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feedback about the level of  uncertainty and advice about trial eligibility is 
emailed back to the submitting trial team. The assessment process from 
case submission by a trial team to a feedback email (Fig. 4.5) can be 
completed within a 48 hour time frame.
Figure 4.5. Web-based assessment of a clinical case by a virtual expert panel.
Trial Research Team Expert Panel
PEACE Website
case submitted case alert
case assessment
PEACE Team
case publishedcase data
collective expert
opinion feedback
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4.2 Patient Eligibility Assessment through Collective   
 Equipoise (PEACE) 
In the previous section, methodology was described that showed how to 
elicit and pool expert opinions concerning a clinical case in real time. The 
focus in this section is to explain the underlying conceptual framework 
for analysis and interpretation of  clinical equipoise levels based on pooled 
opinions. In particular, it will examine how decisions about trial eligibility 
can be made dependent on the level of  clinical equipoise. The process may 
superficially appear complex, but it is in reality rather simple and easy to 
explain to clinicians in lay terms. The remainder of  this section provides a 
more formal (technical) description of  the important components of  the 
Patient Eligibility Assessment through Clinical Equipoise (PEACE) process 
for those familiar with recruitment processes and decision making in this 
setting. The following sub-section (4.2.1) provides a lay summary that puts 
the process in a wider context and as such may appeal more to a clinical 
audience. 
The PEACE process is outlined schematically in Figure 4.6 using examples 
of  expert clinical assessments in three selected clinical cases. To express 
a pooled opinion mathematically, a distribution curve can be fitted to 
pooled data for each case marked i, ii and iii to estimate parameters that 
characterise the fit using concepts of  belief, disbelief  and uncertainty, 
according to the principles of  subjective logic (Jøsang 1997). Belief  
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represents the tendency of  a clinical expert to expect a trial intervention to 
work better, while disbelief  represents the tendency of  an expert to expect a 
trial intervention to do worse for a patient. The uncertainty associated with 
the belief  and disbelief  is expressed by the expert through the spread of  the 
data between belief  and disbelief. For example, in cases presented in Figure 
4.6, the scores of  some experts are concentrated around one category, while 
other experts spread out their prognosis between several categories. When 
a distribution curve is fitted to several expert opinions in the same case, it 
becomes a collective expert opinion for this clinical case. It is expressed in 
the same way as scores from individual experts through uncertainty spread in 
different categories between belief and disbelief. 
 
Values informing a distribution curve can then be mapped as a dot onto a 
ternary plot (opinion space) that represents belief, disbelief  and uncertainty 
as positions in an equilateral triangle, where each corner of  the triangle 
represents the highest level of  belief  (positive outcome), disbelief  (negative 
outcome) and the level of  uncertainty, that together constitute a pooled 
expert opinion. The pooled opinions representing greater levels of  belief  
and greater levels of  disbelief  are mapped towards the right-hand and left-
hand corners of  the triangle respectively, while a higher level of  uncertainty 
will move an opinion towards the uncertainty apex (Fig. 4.6). A detailed 
statistical methodology that allows this way of  quantifying the level of  
clinical equipoise from voting data for a panel of  experts for an individual 
clinical case has been published (Parsons, Kulikov et al. 2011) (Appendix I).
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Selected Cases
Decision Rules
Figure 4.6. Expert opinions analysis - schematic illustration for three real life calcaneal 
(heel bone) fracture cases (UK Heel Fracture Trial).
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When several cases are mapped on the opinion space, their level of  
equipoise can be compared and/or assessed against provisionally agreed 
decision rules. Decision rules represent the level of  clinical equipoise 
between clinicians that deems a clinical case eligible for a trial. They 
can then be imposed onto the opinion space, shown as interrupted and 
dotted curves in Fig. 4.6. Patient eligibility for a trial is then dependent 
on the opinion dot position in relation to a decision rule line or lines. 
The framework is designed as an open platform, so decision rules can be 
discussed and applied according to the needs of  a specific clinical trial. 
However, in this work a baseline 80:20/70:30 eligibility decision rule is 
proposed according to the work by Johnson et al. (1991), described in 
chapter 3.1. 
Feedback from the pilot study, described earlier in this chapter, indicated an 
agreement between surgeons that they would consider operative treatment 
only if  it is likely to make a patient better. Based on these findings it was 
determined that the point of  equipoise was located slightly to the right 
of  the centre point of  the assessment scale towards belief  between no 
difference and a bit better. The 70:30 and 80:20 equipoise distribution 
lines have been superimposed on the opinion space accordingly, shifted 
to the right from the no difference point between outcomes in the middle 
(Fig. 4.6). Collective opinion dots appearing inside the 70:30 zone, such 
as case (iii), are considered as cases ethically acceptable by the public for 
the trial, because collectively experts give less than a 70% chance of  either 
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improved or worse outcome if  one or another treatment is chosen. Cases 
mapped outside the 80:20 zone, such as case (i), indicate too high a level 
of  agreement between experts about likely outcome for a treatment to be 
ethically randomized into a trial and therefore were deemed not eligible. 
The limits of  equipoise obtained by opinion surveys are generally not 
precise, cannot be clearly translated into a probability and depend on 
various factors such as the level of  emotional attachment to the subject of  
the research and individual variations in approaching uncertainty. For these 
reasons, a zone between the 70:30 and 80:20 decision rules on the opinion 
space was viewed as a ‘buffer zone’ reflecting an “order of  magnitude, rather 
than a precise cut-off  limit” (Johnson, Lilford et al. 1991, p. 33). Exhaustive 
permutation resampling aided decision making for those cases in the buffer 
zone, such as case (ii); the statistical process outlined above was repeated 
for every possible combination of  experts in the panel, who expressed 
an opinion on that case. The results of  this process can be visualised as a 
cloud of  smaller dots on the opinion space, representing possible collective 
opinions based on real expert votes. In order to decide eligibility for cases 
mapped in the buffer zone, the number of  possible opinion dots in the 
eligible zone inside 70:30 and the not-eligible zone outside 80:20 can be 
compared. If  relatively more combinations of  expert opinions are mapped 
to inside the 70:30 rule, then the case is deemed eligible for a trial. If  on the 
other hand more opinions are mapped to outside the 80:20 rule, then the 
case for inclusion in a trial cannot be ethically justified.
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4.2.1 PEACE: a lay summary 
In summary, the PEACE framework allows one to collect opinions from a 
group of  experts about a clinical case in real time. Opinions for each case 
are pooled using simple rules and processed through the application of  
statistical methods (i.e. fitting a model distribution and estimating a number 
of  parameter attributes that characterise the expert opinions for the case), 
resulting in a collective opinion that can be mapped onto an opinion space. 
The results of  the pooling are estimates that represent the belief, disbelief 
and uncertainty that the intervention will be effective for each case. These 
three attributes are scaled so that they sum to one, in the same way that 
probabilities do; this ensures that for instance as our belief in the effectiveness 
of  a treatment increases, then our disbelief and/or uncertainty must decrease. 
The simplest graphical way to represent three quantities that vary in this 
way is what is known as a ternary plot (see Figure 4.6). A ternary plot 
allows one to plot three values in a natural manner for each case such that 
an increasing value for each attribute results in the plotted point moving 
towards the apex of  the triangle representing that attribute. The results of  
many cases for a single study can be plotted in such a way, showing the full 
range of  expert opinions on each case in the study (Fig. 4.7). Decisions 
about whether or not to include individual cases in a trial can be made based 
on the plotted position on the ternary plot, in this case called opinion space. 
A decision rule should be decided on before a study begins; these may be 
based on previously published work or be completely new ideas. Rules are 
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superimposed graphically on the opinion space, effectively dividing the space 
up into a number of  regions which guide the user as to the appropriate 
decision for the case; (i) recruit the case into the study and randomize, 
(ii) allocate to the test treatment or (iii) allocate to the control treatment. 
Application of  the Patient Eligibility Assessment through Clinical 
Equipoise (PEACE) process was tested in the context of  a real life trauma 
trial comparing operative and non-operative treatment after heel fracture. 
This is described in the following section.
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4.3 Modelling the PEACE framework in a challenging   
 trauma trial
The PEACE methodological framework was introduced as an independent 
research project within the UK Heel Fracture Trial (UK HeFT), which 
compared operative and non-operative treatment for displaced fractures 
of  the calcaneal (heel) bone across 22 hospitals in England and Wales 
(Chapter 3). The project had a separate ethical approval and a consent 
form, in addition to the main trial (Appendix C). This allowed inclusion of  
both those patients who took part in the UK Heel Fracture Trial and those 
who declined, as soon as the patient met the trial eligibility criteria. To avoid 
interference with the clinical course, patients were asked permission to use 
their data at the 6 weeks follow-up clinic or later. 
The instruction presented to surgeons was the same as in the pilot study: 
“Drag these bars upwards, to represent your judgement on whether surgical 
intervention will improve the patient’s condition” (Fig 4.1). The UK HeFT 
compared operative and non-operative treatment, where surgery was seen 
as potentially beneficial unless risks were overwhelming or the potential 
for improvement was small compared to the risks. Therefore ‘belief ’ that 
surgery can make a patient better implies intention to do surgery, while 
‘disbelief ’ implies the intention to avoid a surgical intervention, in other 
words to choose a conservative option.
Patients who met pre-set trial eligibility criteria and were initially approached 
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by a member of  the research team about the possibility of  participating in 
a trial were seen by a member of  the research team at the six week follow 
up clinic or later. They were then asked permission for their anonymised 
clinical details to be distributed among a panel of  expert clinicians for an 
opinion regarding the effectiveness of  the proposed treatment; they were 
assured that this was a separate matter and in no way influenced already 
initiated treatment. Clinical data including X-ray and CT scan images from 
consented patients were made available on a secure website managed by 
eLab at the University of  Warwick, and all panel members were alerted by 
email and optional text message to the posting of  a new patient and asked 
to offer their personal opinion about the likely prognosis of  the proposed 
treatments. The expert assessment panel included 12 surgeons from nine 
hospitals. All surgeons were foot and ankle specialists and acted as principal 
investigators in their individual trial centres.
Three trial centres agreed to submit their patients’ data to the Collective 
Uncertainty Project. Seventy-seven calcaneal fractures in 70 patients were 
assessed during three years of  the UK HeFT. On average six surgeons 
voted in each case (minimum three and maximum nine). Collective opinion 
dots for all cases mapped on the opinion space. Their position was assessed 
against the 80:20/70:30 eligibility decision rule superimposed on the 
opinion space, as described earlier in 4.2. Collective opinion dots for all 
seventy-seven fractures can be seen in Figure 4.7 and are explained below. 
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Cases located in the eligible zone inside the 70:30 rule are shown as 
black opinion dots. Their location suggests that sufficient uncertainty 
between experts has been demonstrated to justify their eligibility for trial 
participation. They make up 74% (57) of  all assessed cases. 
Collective opinion dots outside the 80:20 rule zone are shown in red. 
Their position indicates that the panel experts reached consensus about 
likely treatment outcomes for 7 (9.1%) cases : two in favour of  operative 
treatment (located towards the lower right corner of  the opinion space) 
, while five other cases were seen as certain to produce poor results with 
surgery (located towards the lower left corner of  the opinion space).
 Finally, for 13 cases located in the buffer zone between 70:30 and 80:20 
rule lines (yellow dots) exhaustive permutation resampling  had to be 
performed, as described earlier in 4.2. After the number of  dots inside 
the 70:30 and outside the 80:20 zones was compared out of  the cloud of  
possible collective opinions for each case, eight of  them were added to the 
eligible pool. This makes up 84.4% of  patients from the three UK HeFT 
centres invited to the trial participation according to pre-set fixed eligibility 
criteria, for whom clinical equipoise was confirmed.
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Figure 4.7. The PEACE opinion space for the Collective Uncertainty Project.
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4.3.1 Surgeon feedback
A feedback survey from surgeons collected data informally during the 
research project and then formally via questionnaires (Appendix G) when 
the patient recruitment and the voting on all cases had been completed. 
Eleven out of  our 12 panellists returned their feedback forms. Ten of  them 
indicated that this was a low research time methodology, meaning that little 
time and effort was required for case assessment. All eleven offered support 
for introducing the framework in surgical RCTs, even if  in challenging ones 
only. In cases where consensus about treatment outcomes was present 
between surgeons, five of  our  experts would still offer random treatment 
allocation within a clinical trial context, four would choose a treatment 
according to consensus, while two would leave the final decision to the 
treating surgeon.
Informal feedback revealed difference in interpretation of  the treatment 
prognosis by two surgeons who provided consistently ‘strong’ opinions 
for assessed cases. Opinions were viewed as ‘strong’ if  all 100% of  
possible votes were allocated to one or two neighbouring categories on the 
treatment outcome scale (Fig. 4.2). This highlighted the necessity of  clear 
explanation and instructions to experts about the scale usage.
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4.3.2 Patient feedback 
Patient feedback about the PEACE concept was collected formally 
during the final part of  patients’ interviews (chapter 3.3). All twenty two 
patients who agreed for an interview were from the Collective Uncertainty 
Project database. This means that at some point prior to the interview 
they all consented for their anonymous clinical data to be used for a study 
about comparing expert opinions. It seemed only fair and logical to give 
participants some form of  feedback. The aim was to learn about their 
understanding and views about possible introduction of  the framework in 
future similar trials.
Towards the end of  interviews, I suggested to participants that they should 
see the study results in the form of  bar charts with combined surgeons’ 
votes for their own calcaneal fracture. They were all interested to see these:
“if you had several surgeons looking at those X-Rays and then giving you 
that result, I think it would be better” (CH003, 46 year old male, manual 
worker)
For many, looking at the charts helped with understanding the need for a 
trial and presented a more balanced view of  surgeons:
“But it also shows you if these are surgeons that they’re not all pushing for 
‘Oh it would have been better if I’d have operated’.” (CH018, 76 year old 
male, retired)
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This was more in line with how many participants imagined that random 
allocation to a treatment during a trial would occur:
Respondent: “Yes and how does the computer decide?”
Interviewer: “Completely random.”
Respondent: “But with the computer you must put some information in to 
say ‘this is what the X-Ray is showing at the moment’ and then entering it 
and it makes the decision of the best, so self-healing or...?” (CH026, 42 year 
old female, manual labourer)
Seeing the chart settled doubts for those patients:
“when I looked at it then [during the trial] one of the questions I asked the 
next day was quite a simple question really, which is - there must be a ratio 
where an op is the only way forward and how would you get to that point, 
in a one to ten scenario where anything from seven and above is an op and 
anything below seven is a non-op.  That’s where I was struggling in my head to 
get to, because I couldn’t get that answer.” (CH020, 43 year old male, office 
worker)
The idea and the theory behind the charts were easily understood:
 Respondent 2:  “Yes, I find it very interesting.”
 Respondent 1:  “I understand that, yes.”
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 Respondent 2:  “It’s understandable and very interesting.”
 Respondent 1:  “It is, because it shows you there’s a mixture of opinions.” 
 (CH018, 76 year old male, retired, and his spouse)
This was the case even with those who usually struggle to understand 
charts:
 Respondent: “I don’t really understand charts anyway.”
 Interviewer:  “But you found you could understand this one?”
 Respondent:  “Yes.” (CH036, 25 year old male, skilled self-employed)
This young man found an interesting and correct way of  interpreting the 
chart he saw:
“Yes, it does look very clear now.  I mean like, you know, I mean to me like 
there’s a lot more surgeons who are really saying it makes it a bit better, but 
it swings in roundabouts really, doesn’t it?” (CH036, 25 year old male, 
skilled self-employed)
Yet more detailed interpretation of  charts was often misguided, for 
example, concerning strong votes:
Respondent 1:  “If this was presented to me now, I would say ‘I won’t 
have surgery.’  If that was presented to me now that’s what I’d say; ‘I’m not 
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having surgery because this man seems to know that I’ll probably get worse.’  
These are just...”
Respondent 2:  “...Sitting on the fence.”
Respondent 1:  “Yes, they’re just on the fence.  This man is quite confident 
that I’ll get worse.” (CH023, 47 year old male, skilled self-employed, and 
his spouse)
Although seeing opinions from different surgeons helped to explain 
uncertainty about a treatment choice and there was general support for it to 
be used in future trials, many patients felt that advice and guidance from the 
treating surgeon would be essential:
“I’d still have to discuss it and I’d take the lead from the surgeon that was 
dealing with me, or the consultant that was dealing with me at the time 
without a doubt, but it would have definitely helped yes” (46 year old male, 
skilled)
They felt that such results would be better interpreted and presented by a 
clinician, rather than given to them directly:
“I mean it is good information but reassurance and what-not doesn’t really, 
you know...to me like people who just think that this is basically a bit of 
paper and the results.  You know, you don’t really get reassurance from it 
do you?  To me, to look at that it looks fairly clear, but it’s just obviously 
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that it is like just mixed feelings isn’t it?.. I think talking about hearing it 
from a surgeon is more sort of reassurance than just seeing it on a graph, 
because obviously the surgeon is going to be doing the work with you isn’t 
he, whereas the graph isn’t?  So yes, I think to have the surgeon talking to 
you would be a lot better really.” (CH036, 25 year old male, skilled self-
employed)
The surgical panel reached a consensus about the treatment of  choice 
for six patients who were interviewed. Four of  them did not join the 
trial. Interestingly, all of  them were treated according to the panel 
recommendation and were very pleased about their decision:
“I’d have gone with them; it’s three against one isn’t it?” (CH027, 55 year 
old female, skilled) 
Does this mean that surgeons often would find a way to communicate 
their preference even in the context of  RCTs? As one of  those patients 
indicated:
“He explained to me that the fracture was this long, and had it been a bit 
longer they might have done surgery but he, you know, he thought well, 
I’d be alright and they ought to leave it, that’s fine.” (CH027, 55 year old 
female, skilled)
The other two were randomised and, again, had their treatment allocated 
in line with the panel recommendation. One of  them, a 76 year old retired 
110
lady, was still comfortable with random treatment allocation after seeing 
the surgeons’ opinions. Another patient in a similar situation, a 40 year old 
academic, was taken aback by the discrepancy between the information he 
was given when he joined the trial and the results of  the surgeons’ votes, 
where they agreed about the preferred treatment option unanimously:
“I would think, I would expect that [er] the part of it was that the doctor 
at least has some doubts about which [er] which treatment to choose ...  Of 
course, the doctor is very experienced and qualified to have his opinion, 
right, but ethically I think if you are in the trial and you are shown the 
video which says the doctors are not sure, then this means your doctor is not 
sure.”(CH015, 40 year old male, academic)
He asked a lot of  questions and concluded:
“I realise it’s not realistic to only take people in the trial where the doctor 
is completely putting his hands up and saying, [er] “I am, I have no clue.”  
Right? “But [er] it’s fifty-fifty.”  But at least we should discount the, those 
cases where the doctor is sure about that treatment.” (CH015, 40 year old 
male, academic)
His conclusion echoed the opinion of  most of  the other interviewed 
patients, that randomisation should not be offered when consensus about a 
choice of  procedure is present between experts.
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In the next, concluding, part, results of  all three stages of  the PEACE 
methodological framework development will be discussed.
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4.4 Discussion
The PEACE framework demonstrated a reliable correlation between 
the levels of  uncertainty and consensus about treatment choice for cases 
assessed during a real life multi-centre clinical trial. Most cases were mapped 
safely in the eligible zone in line with pre-set eligibility criteria (84.4% match 
in the UK HeFT population), while a small number were highlighted when 
consensus about a treatment choice was present between experts. The 
suggested approach to elicit, pool and quantify expert opinions in order 
to estimate the level of  clinical equipoise was based on a strong ethical 
background of  clinical research and seemed to work well in practice. It is 
visually simple to understand and easy to use, as evidenced by our expert 
feedback. The framework is designed as an open platform to be adaptable 
to a variety of  clinical research scenarios. Careful attention and thorough 
discussion of  the question posed to panellists and decision rules to be 
applied are required before the start of  recruitment. Ideally, this should be 
piloted prior to the commencement of  the main trial. It needs to be made 
clear to clinicians that they are being asked to provide an honest prognosis 
of  possible outcomes, if  treated in their own hands, rather than simply 
expressing a treatment preference.
Patients also had good understanding and a positive outlook on the 
PEACE concept. Charts with combined opinions from different surgeons 
about their own injury, which is the corner stone of  the Patient Eligibility 
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Assessment through the Clinical Equipoise, were in line with their own 
expectations about clinical research and helped with understanding why it 
was necessary for their kind of  injury. There was little doubt from a patient 
point of  view that it is unethical to offer a random treatment allocation 
in the presence of  consensus about a treatment choice between experts. 
Future use of  the PEACE concept in future trials was widely supported. 
Presentation of  assessment results by the treating clinician was favoured by 
patients in terms of  clinical quality assurance. It is also desirable because 
patients oversimplified and misinterpreted voting results when viewing and 
attempting to analyse themselves.
It is reassuring that the group of  eligible patients identified by the PEACE 
methodology largely overlaps with patients eligible according to standard 
fixed pre-set eligibility criteria. It is significant, however, that for a small 
number of  patients there is a clear consensus between experts about one or 
another treatment being likely to lead to a better outcome. This confirms a 
concern that most patients involved in the trial expressed in their interviews 
in Chapter 7 about random treatment allocation. Fixed pre-set eligibility 
criteria cannot replicate or replace expert judgement, and it is unethical 
to offer randomisation in the absence of  clinical equipoise. It follows that 
the PEACE framework offers protection for patients in cases when there 
is a consensus between experts about a treatment that is likely to lead to 
a better outcome, even when factors affecting this judgement are not yet 
known or not expressed in currently available evidence. It is still possible 
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to research these factors and investigate whether they indeed lead to an 
expected outcome if  patients are offered participation in a study as part of  
a comprehensive cohort design (Torgerson and Sibbald 1998).
At the same time, what the PEACE methodology can offer is simplified 
inclusion criteria for the trial eligibility assessment. In the case of  the UK 
HeFT it was clear that severely displaced and comminuted fractures could 
not be entered into the trial. What was far from clear was how to describe 
the extent of  injury that should not be included. After extensive debates 
between specialist surgeons involved in the trial design: “Calcaneal fracture 
with severe deformity, with the lateral wall of  calcaneus impinging on the 
fibula” was agreed as an exclusion criterion. Those who are involved in 
Orthopaedic Trauma management can readily recognise that this definition 
is open to interpretation. This came up again and again when Principal 
Investigators were briefed on patient recruitment: ‘what exactly do you 
mean by this..?’ On several occasions during the course of  a trial, surgeons 
called the head office asking about a particular case. If  simplified PEACE 
criteria were used in the UK HeFT, at least 57 more patients excluded 
with ‘fibula impingement’ as well as many from other excluded categories 
marked in the brown box in Figure 2.1 would have been assessed for trial 
eligibility. The additional number of  eligible patients under PEACE would 
have more than compensated for the small number of  patients for whom 
a consensus about treatment choice, expressed by the expert panel, would 
have resulted in their exclusion from the trial (Fig. 4.8).
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Figure 4.8.	Overlap	of	patient	cohorts	meeting	simplified	PEACE	criteria	for	trial	eligibility	
assessment	and	those	eligible	according	to	standard	fixed	pre-set	eligibility	criteria	in	a	clinical	
trial.
- font changed in flowchart
Eligible
both
ways
Blue box - total number of 
patients screened for trial
Pink disc - patients eligible 
according to the standard 
pre-set eligibility criteria
Green disc - patients meeting
simplified PEACE criteria for 
eligibility assessment
Green/yellow disc - possible 
increase in number of eligible 
patients if the PEACE principle 
is used
Having described the successful design and testing of  the PEACE 
framework, in the next chapter the new approach to trial patient 
recruitment is described  and researched.
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Chapter 5 Study B: Patient Trial    
   Information Video (PTIV)    
   recruitment approach
“I think it depends on how you word things sometimes doesn’t it?  It’s how 
you deliver the message, you know.” – a patient eligible for the UK HeFT 
(CH043).
This chapter describes a new approach to patient recruitment in a trial that 
combines a standardised audio-visual presentation of  the trial information 
with one-to-one personal support, in order to address the challenge posed 
in the second research question (chapter 1.6):
How to achieve clear, impartial and consistent delivery of trial information 
to patients in the context of a challenging surgical trial, when the compared 
interventions are obviously different? 
 Apart from identifying eligible patients, a treating clinician is not involved 
in the proposed trial recruitment process. In fact the clinician specifically 
avoids personal contact with possible trial participants in order to avoid 
disclosure of  their likely personal treatment preference while patients 
decide about trial involvement.  Feedback from both parties is explored 
(5.2), especially considering the question of  whether the surgeon’s initial 
absence is notable and significant.
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Delivery of  clear, comprehensive and impartial information during the 
recruitment process is a considerable challenge in a clinical trial involving 
obviously different procedures (Paramasivan, Huddart et al. 2011). It 
is difficult for recruiters to avoid constant use of  ‘loaded’ specialised 
terminology when talking to a patient. Often a recruitment pathway 
is complicated, involving not only different people, but even different 
specialties; so effective communication is of  paramount importance. Finally, 
expression of  treatment preferences, both by potential participants and by 
trial staff, is an issue. 
For the UK HeFT, a new method for approaching eligible patients to 
inform and invite them to participate was developed, combining a Patient 
Trial Information Video (PTIV) with availability of  a dedicated study team 
member to deal with any patients’ queries and concerns. This combination 
was designed to provide consistently high quality of  disclosed information, 
strengthened by an individual approach to improve understanding.  The 
aim was to exclude a treating surgeon from initial patient contact in order 
to avoid a possible treatment preference disclosure, as described  in the UK 
Heel Fracture Trial Manual v2.1May08 (p. 10):
“ 3.2 Role of the Principal Investigator
We have prepared a DVD in which the Chief Investigator explains the 
injury the patient has sustained and the possible treatment options, 
together with advantages and disadvantages of each method.  This is 
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intended to enable you to take a step back from the process of informing 
the patient about treatment options, so that you are not put in the 
position of having to remain neutral when you might have an opinion as 
to which treatment could be better for that patient.
Once the information process is completed, the research associate will 
obtain informed consent to join the trial, and you will only have to take 
consent for surgery in the normal way if that is the treatment to which 
the patient is randomised.  At this point, please make sure you do not 
re-visit the question of which treatment option might be best; simply 
obtain consent for the surgery.”
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5.1 The PTIV approach to recruitment in a trauma trial
The initial PTIV script was drafted according to the Information Sheets 
& Consent Forms Guidance for Researchers and Reviewers (version 3.2 
May 2007) published and regularly updated by the National Research 
Ethics Service. The script fully reflected the information disclosed in the 
UK HeFT Patient Information Sheet. This was reviewed and discussed 
with the Trial Steering Committee members, including those who had not 
received formal medical training., Principal Investigators and Research 
Physiotherapists involved in the trial set up were also involved in the 
discussion. The video was filmed with the Chief  Investigator explaining the 
trial with model and visual demonstrations of  relevant points. The aim of  
the process was to present an eligible patient with clear and comprehensive 
information about the trial, including a balanced, unbiased view about two 
treatment options. Special attention was paid to avoid confusion through 
potentially ‘scary’ specialised wording and phrasing (Donovan, Mills et 
al. 2002). Once the patient recruitment started, several eligible patients 
were approached by the Chief  Investigator and the Trial Co-ordinator and 
informal feedback about the video was collected. Final editing touches were 
applied at that point and the video content was not changed again through 
the rest of  the recruitment period. A CD with the final PTIV version is 
attached. Both initial and final copies of  the video were supplied to the 
Research Ethics Committee involved.
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A dedicated Trial Recruitment Research Associate was employed and 
trained for each trial centre. This Associate acted as a contact person 
to address any possible patient queries and/or concerns, including 
involvement of  a treating surgeon or other trial staff  as necessary during 
the recruitment period. The surgeon was excluded from direct interaction 
with a patient during the trial recruitment process, unless a patient 
specifically wanted to meet his/her surgeon before making a decision about 
trial participation. As the trial expanded, adding more centres across the 
UK, extra training sessions were organised where the recruitment pathway 
was discussed and ‘tips’ were provided by lead recruiters.
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5.2 Surgeon and patient feedback
All surgeons were very supportive of  the suggested recruitment pathway 
from the outset. It was seen by them as liberating from the trial routine 
and it defined them as decision makers about trial eligibility. Nobody raised 
objections or declined to take part because of  the PTIV approach, so no 
need was felt for formal feedback. 
On the other hand, patient feedback was collected formally as part of  
the qualitative study (Chapter 3.3 and 6) to explore effects of  the new 
methodology on its recipients. Patients were interviewed a considerable 
time (one to two years) after the trial participation was offered to them, in 
line with the intention that feedback should have minimal or zero impact 
on a clinical or trial course. On the one hand, this had the advantage that, 
on initial recollection, patients remembered what was most important 
and significant for them during the trial recruitment process. However, 
they often struggled to remember further details and impressions, so the 
PTIV was shown again during interviews after the initial recollection was 
prompted.
At the outset I expected to learn patient views about the clarity of   the 
information provided and the possible impact of  the surgeon’s absence 
during the trial recruitment process. Another important issue was whether 
the choice of  compared treatments was evenly balanced from the patients’ 
perspective and so whether the video could be used effectively as a decision 
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aid about trial participation. Two additional aspects about the approach 
emerged from the data. One was that the PTIV potentially could be an 
important information source in managing patient expectation during the 
recovery period. The other was a more general concern about appropriate 
timing and the environment for the clinical study invitation. All these issues 
are presented and discussed below.
5.2.1 Clarity and understanding of trial information
In this section, I am going to look at the reaction of  patients when asked 
whether the trial information was clear and easy to understand. I shall quote 
(in italics) from responses which patients provided.
Overall, patients’  reaction to the audio-visual presentation about the trial 
was positive: 
“That video is much better than reading about it.  With him talking to you 
and giving that explanation for everything – what happens and everything; 
it’s much better.  You can understand that much better. All the leaflets in the 
world don’t put things over as clearly as somebody on a video or talking to 
you” (CH018, 76 year old male, retired)
Some comments seemed to respond directly to guidelines and 
recommendations published by the National Research Ethics Committee 
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about giving impartial information and allowing patients time to decide 
without any pressure:
“it was good that was, because it wasn’t like you telling us and the way he 
did it – that DVD, you could watch it and you could listen to it and you 
could decide yourself without someone else there trying to influence you.” 
(CH019, 28 year old female, unemployed)
The clarity of  the presented trial information was universally recognised as 
one of  the main video features: 
“It’s clear, yes.  It’s as clear as day.” (CH035, 39 year old male, manual 
labourer)
“It’s short, it’s clear and it tells you about how you can leave it naturally 
to heal and how you can have the operation.  It gives the advantages and 
disadvantages.” (CH026, 42 year old female, manual labourer)
“It can’t be any clearer, can it? It can’t get any clearer. No, no. That’s quite 
good that, I thought.” (CH022, 75 year old male, retired)
“It’s very well done isn’t it? It’s very explanatory. It clearly defines the 
definition between op and non-op.” (CH020, 43 year old male, office 
worker)
For most patients the PTIV improved their injury understanding, as 
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explained by one interviewee: 
“The DVD was really helpful.  It made me understand more about the 
actual injury because up to that point, I didn’t understand what had actually 
happened.  I knew I’d fractured my heel and that’s as much as I knew, but 
when I watched the DVD, you know...the impact side of it and things like 
that, I understood then”. (CH020, 43 year old male, office worker)
The fact that the trial information and especially treatments were explained 
by a senior medical specialist did not go unnoticed: 
“He introduces himself even beforehand talking about the injury. That’s very 
helpful that he introduces himself as a medical professor.” (CH015, 40 year 
old male, academic)
Patients appreciated the effort and quality of  information provided: 
“He’s a good communicator for sure.  He’s had to say what he said.” (CH043, 
52 year old male, manual labourer)
“The presentation was good.  Obviously it was calm, reassuring, professional 
and the surgeon thing giving you a lot of information, which I suppose if you 
hadn’t have had that trial it would have just been a fact sheet I’d imagine 
that would have just been given over, or not even that.” (CH021, 46 year old 
male, skilled)
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The PTIV appeared to achieve the main purpose to explain why the study 
was set: 
“It was very useful yes, because it explained exactly what the dilemma is 
and the pros and cons of treatment and obviously the dilemma the surgeons 
and the doctors have got of what is the best treatment.” (CH032, 60 year 
old male, skilled self-employed)
The above quotes demonstrate that the PTIV provided clear, concise 
information about the trial, that was easily understood by patients.
5.2.2 Was the surgeon missed? 
One crucial and central question to be addressed was about the surgeon, 
and whether his/her presence was missed during the trial recruitment 
process.
Only two out of  22 patients specifically requested to see a treating surgeon 
before a decision about trial participation was made: 
“Well, I’m not gonna make my mind up instantly; I’d like professional 
advice from a surgeon or something like that.” (CH022, 75 year old male, 
retired)
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One of  those two was the only patient in the interviewed group who 
misunderstood the trial concept:
Interviewer:  “But have you been aware that actually, [Name: 0:47:02] 
or the specialist who didn’t know that at the time had actually seen your 
X-Rays and knew about you and that he actually made the decision that 
you were a suitable candidate for this study?”
Respondent:  “No.  I wasn’t aware, no.”
Interviewer:  “Because obviously it’s not the person who is showing you the 
DVD.  It’s the specialist who decides if the person is suitable for the study 
and then you’re approached about the study.”
Respondent:  “OK.  That makes sense.”
Interviewer:  “Would that make a difference if you knew?”
Respondent:  “Yes.” (CH026, 42 year old female, manual labourer)
From these patient quotes we can conclude that in at least some of  the 
cases, the patients needed a personal contact with the specialist in charge 
of  their care as soon as the question about possible treatment options  was 
raised. This issue is discussed further in chapter 7.2, when combined with 
selected statistical trial data.
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5.2.3 Operative vs non-operative treatment options balance
In this section, I shall look at patients’ reported views about the choice of  
operative and non-operative solutions presented to them.
It was reassuring to learn that all but three out of  22 interviewees agreed 
that a balanced view about compared treatments was presented, as intended 
by the trial team:
“he [Professor presenting in the video] wasn’t just sort of trying to push you 
for non-operation, or push you either way” (CH018, 76 year old male, 
retired)
“He gives the cons and the benefits of it” (CH026, 42 year old female, 
manual labourer)  
There was strong evidence that the other three patients were actively 
looking for and ‘picking out’ information that comforted and accorded with 
their treatment preference, despite the extra effort taken by the trial team to 
present a balanced view. It is interesting that these patients could describe 
the video as being both in favour and against operative treatment. That in 
itself  confirms that the factual information presented was evenly balanced: 
“If I didn’t know what I wanted to do before I watched that, I’d certainly 
pick an operation after watching it anyway.. It said it was a very fine 
balance to which you had... To us, it wasn’t a fine balance.  It was completely 
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the operation – no doubt about it.” (CH019, 28 year old female, 
unemployed)
With that, we can compare the following reaction: 
“Obviously they’re trying to veer you towards surgery because that’s his job.” 
(CH039, 42 year old male, skilled)
and likewise this:
“If he was a sales rep he would do well because I thought he was selling the 
operation side of it”. (CH038, 41 year old male, skilled)
Prior beliefs had a strong influence on interpretation: 
“Some people really do like to have the operation done; but for me, that was 
just confirming that I didn’t want to have it done’; ‘I think what puts a lot 
of people off is when he turns round and says ‘The skin might not marry up 
properly’, you know.  Women and men are vain like, you know.” (CH030, 
50 year old male, manual labourer)
Even in the situation when information about a procedure choice appeared 
evenly balanced to most patients, some of  them had a strong preference 
bias and would pick out information to support their view.
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5.2.4 PTIV as a decision aid   
In this section, I explore how good a decision aid the PTIV was when 
patients faced an invitation to become the subjects of  clinical research while 
under medical care. For many patients the PTIV was undoubtedly a good 
decision aid as they considered trial participation: 
Interviewer:  “And did it help you in your decision?”
Respondent:  “Oh, totally yes, immediately.  Immediately yes, there’s no 
doubt about it.” (CH043, 52 year old male, manual labourer)
For some patients the video presentation was sufficient for them to make a 
decision that they wished to join the trial: 
“You know, I understood exactly what he was saying.  That’s basically why 
we joined wasn’t it?” (CH018, 76 year old male, retired)
It was interesting to hear comments by a patient who for some reason was 
not shown the video during the recruitment process: 
“Yes, I would have liked to have seen that before, I must admit – yes, just... 
But no, it’s helped me clear up my own thinking, if you like, seeing that.” 
(CH007, 76 year old female, retired)
The video was certainly thought-provoking: 
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“The DVD would make you ask further questions of whoever you were 
dealing with.” (CH014, 68 year old female, retired)
Many patients having experienced the injury first hand agreed with the 
information retrospectively at the time of  interview: 
“He’s right about a few things.. when I saw it again and not so much today, 
well and today, it’s talked a lot of common sense.” (CH046, 49 year old 
male, professional)
The PTIV is seen as a valuable and reliable decision aid.
5.2.5 Possible additional value of the PTIV
In this section I present an interesting observation about the opportunity 
patients had of  seeing the PTIV much later, after their treatment had been 
concluded.
After seeing the video again long after the injury incident in the calm 
environment of  a research interview , three interviewees emphasised the 
value of  seeing the video again: 
“Maybe if I didn’t know what this was about I would want, I would want 
to watch this film twice or to read the transcript.” (CH015, 40 year old 
male, university academic)
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“You’re hurting, you’re injured, you watch the DVD and that was all in 
hospital. You’ve had a lot going on through your mind and you come home 
and you’ve forgotten all about that DVD.  I think if somebody could watch 
it again after sort of twelve months then that man has told you that it’s 
going to hurt, that your foot might be deformed and he’s probably forgotten 
that he’s told you it might be deformed.  I’d forgotten that.  I’d forgotten 
most of that DVD.  That’s why I asked, is it the same DVD that I was 
shown.  I couldn’t remember it and I can remember most films, or whatever 
I watch, but I think because of your injury you tend to blot a lot of stuff out 
and you’re shown it in hospital.  You’re in unfamiliar surroundings.  You 
do the trial.  You know what it’s about.  You’re not stupid.  You understand 
it, but I think to be shown it again eight or twelve months down the line 
you think ‘Oh crikey, he did say there would be some pain.  I forgot about 
that.  I forgot he told me I’d have a bit of pain.  I forgot he said that.’  Then 
probably after fifteen months I wouldn’t have gone down to the doctor and 
said ‘It’s still hurting.’  That man told me it would hurt.  It probably could 
still hurt and I’d suffer with arthritis.  I’d forgotten about that.” (CH023, 
47 year old male, skilled self-employed) 
The same 47 year old man quoted above expressed some preference to see 
a living person, rather than a video image: 
“The most important was somebody coming to talk to you – not the DVD 
but somebody actually physically standing there talking to you and saying 
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what it was about.. Literature I don’t read.  I’ll look at it and I’ll put it 
down.  I don’t.  That’s a good idea with the DVD because I do sit and watch 
it, although my mind can wander a little bit because it’s sort of a television, 
but if somebody is stood there talking to you then you’ve got to listen to what 
they say because they can ask you a question so you tend to listen to people 
a bit better and that was the best way for me”. (CH023, 47 year old male, 
skilled self-employed)
However, this same man  was quite happy with having a Research Assistant 
as a contact person and joined the trial.
5.2.6 Time and place
This section looks at some questions about when and where the approach 
to patients should take place and how they should be invited to take 
part in the trial. Commonly concerns were expressed about timing and 
environment when being approached by research team: 
“I was sat down in the waiting part – not the waiting part, the actual 
private part and shown a DVD.  I can always remember though thinking, 
‘This isn’t the time to see it.’.. I think that a copy of that should be given to 
the patient to look at in their own time, rather than immediately after.  Like 
I said before, there are a lot of things in your mind where you’ve injured 
yourself and not only about the injury but the repercussions of it and then 
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to be shown that as well, I think it’s a bit too much at the time for me.” 
(CH043, 52 year old male, manual labourer)
The timing issue however may not be directly related to the PTIV; this 
patient actually had a good impression of  the presentation overall: 
“It’s just that I find it a bit frightening to hear that sort of thing sometimes 
and particularly when I was shown it straight after having the injury in the 
first place, but otherwise it was very good, yes.” (CH043, 52 year old male, 
manual labourer)
This is discussed further in chapter 6.1.2. The PTIV aside, it was a 
common experience for patients to be given too much factual information 
in the context of  the clinical research, when patients were expecting more 
encouragement and/or reassurance from the medical profession at the time 
of  injury and hospital admission: 
“I understood what he meant by that, you know, so I suppose the language 
which is to the patient is important just to make them understand it a little 
bit better perhaps, or to make them feel more at ease because that didn’t 
make me feel at ease particularly.. Even now it doesn’t really with some of 
the words he uses.  I know he’s got to use them, because he’s actually stating 
the fact just a little bit too black and white for me.  You know, perhaps 
it could be smoothed off a bit for some people because some people are 
frightened of that aren’t they?  You know, like I say, you don’t only think 
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about what’s happened to your body, although that’s important, but you do 
think about the repercussions of it.” (CH043, 52 year old male, manual 
labourer)
To four interviewees, all male with different levels of  education, one of  
them retired, the video was seen as rather too direct:
Respondent: “...when I first saw it, it didn’t sort of give me any inspiration 
to sort of do the trial straightaway, so maybe you’d bring that in.  You know, 
you go into someone’s face.  You could say ‘Well, this is what possibly could 
have happened with the result of what you’ve done.”
Interviewer:  “It’s a bit straight on is it?”
Respondent:  “It’s straight on and you think, ‘Oh.’” (CH046, 49 year old 
male, professional)
For those four, both the images and the words were upsetting, discouraging 
them from participation in the trial: 
“You see what frightened me, when I saw that video that this young lady 
showed me of somebody else’s operation, there were screws all in it, all the 
way around it, to hold it in a shape. I thought ‘Blimey , with that all in, 
you never get that out if anything goes wrong.” (CH022, 75 year old male, 
retired)
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“There are a lot of words he uses, right?  They frighten you, really.  He says 
‘This is a serious injury’.  First of all you’re thinking, ‘Oh god,’ you know ‘Is 
it?’  Now he’s talking about deformities and all of that sort of thing and 
I think the language that he uses, although he’s obviously got to tell you 
what’s what, it’s a bit intimidating.” (CH043, 52 year old male, manual 
labourer)
One of  these men, and another retired lady, took the information very 
personally: 
“When I first saw that like, I thought, ‘Is that me?’.. the DVD says my heel 
bone is broken into several places, so straightaway you’ve got bloody hell fire, 
scared.  The biggest thing I wanted to do was see the CT scan to see how bad 
it was, so straightaway it put a bit of a fear into people.  You know, it could 
have say, compromised a broken heel bone, which could be like this or like 
this, yes?” (CH046, 49 year old male, professional)
So there was considerable concern not only about timing and place, but also 
about the volume and level of  detail of  research information provided.
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5.3 Discussion 
The PTIV recruitment approach possibly helped to recruit more trial 
centres for the UK HeFT, because surgeons told us they were attracted by 
the fact that they would not need to go through the explanation of  the trial 
and consent with a patient. 
The video provided consistently high quality trial information delivery 
that was fully compliant with current regulations and recommendations. 
Many, but not all (19 out of  22), patients thought that the treatment advice 
was impartial and balanced. However, emotional response varied greatly 
between participants. One of  them described it in this way: 
“For some people I think it’s a good thing and for some people I think it 
might frighten them a bit, make them a bit nervous.” (CH043, 52 year old 
male, manual labourer)
The PTIV approach succeeded in replacing a treating surgeon during 
the trial recruitment process. Very few patients (2 out of  22) specifically 
requested to see their surgeon and only one patient (and this was one of  
those two) misunderstood the trial concept. 
Even though carefully selected to provide a necessary minimum for 
sufficient understanding, the factual information was overwhelming, 
troubling and difficult to remember at the time of  injury. Watching 
the video again in different, calm and relaxed settings during research 
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interviews confirmed the value of  the information provided about the 
injury. This could have helped some of  the patients during the recovery 
period.
At the time of  injury, a combination of  a high quality information video 
and an independent research assistant perhaps failed to produce assurance 
about quality of  care, usually provided by a clinician. This was the case 
even though the research assistants were specifically selected to represent 
a particular healthcare profession (physiotherapy or nursing). It has been 
argued recently that it is of  paramount importance to place  the emphasis 
on the intention to provide the best possible care in a research context, in 
particular giving reassurance that random allocation to a treatment would 
not disadvantage a participant (Leighton, Lonsdale et al. 2012). This is 
based on emerging evidence that even with a pragmatic approach, the 
clinical research environment and governance tends to improve the overall 
level of  care provided for participants. 
I have demonstrated in this chapter that the patients in the HEFT trial 
reacted, on the whole, very positively to the new procedures adopted for 
the trial information presentation and delivery. In the following chapter, I 
shall go on to discuss the factors that influenced a patient’s decision about 
participation in the trial.
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Chapter 6 Study C: Deciding about trial  
   participation – what makes a  
	 	 	 difference?
This chapter looks at the content that emerged from the UK HeFT patient 
interview narratives in response to the third research question (chapter 
1.6):
What is the patient perspective of the recruitment process in a challenging 
surgical trial, when the best current advice as well as innovative approaches to 
the principles of patient participation are integrated?
Twenty-two patients from one trial centre (chapter 3.3) consented and 
were formally interviewed. In addition, one patient refused to come to 
the hospital for an interview, but was willing to provide information over 
the telephone immediately: the interview notes were therefore recorded 
impromptu in a research notebook. 
The sample of  patients appear to have similar demographic variation 
to the wider HeFT patient population (Table 6.1), including 15 patients 
who declined trial participation. The only obvious deficiency was under-
representation of  younger patients. It was particularly difficult to get them 
to attend an interview. Two young male patients initially agreed to be 
interviewed, but never arrived for an appointment, even after attempts were 
made to re-schedule.
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Table 6.1. Demographic variation of the interviewed cohort (n=23)
Social status
n
Age groups Sex
(M:F)
18-40 41-60 Over 60
Unemployed/Retired 5 (1) 2 (2) 2:3
Manual labour 5 (1) (4) 3:2
Single parent/ Housewife 2 1 (1) 1:1
Office work 1 (1) 1:0
Skilled 4 (4) 3:1
Self-employed 3 1 2 3:0
Professional/Academia 3 2 (1) 2:1
Patient numbers who refused to participate in the UK HeFT are in (brackets).
The patient sample (Table 6.1) was sufficient for a number of  themes to 
be described by different interviewees. This  helped to achieve a better 
understanding of  patients’ true inner feelings and beliefs. No new themes 
emerged in the last few interviews, so it was felt that the point of  data 
saturation was achieved.
Content-rich interview data allowed insight into the patient decision making 
process about trial participation and identified factors that had a significant 
influence on patients’ decisions about trial participation (6.1). Further, a 
typological analysis identified certain types of  patients whom trialists face in 
a challenging surgical trial, defined by their emotional response, attitude and 
which factors they consider in order to make a final decision (6.2).
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6.1	 Factors	influencing	patients’	decisions	about	trial			
 participation
Several attributes emerged as important for orthopaedic trauma patients 
when faced with an invitation to take part and when provided with 
information about the clinical trial and treatment choice: social and 
economic factors, environment and timing of  invitation, balancing pros 
and cons of  taking part, external sources of  decision support and prior 
treatment advice. Patients’ perception of  these factors is presented in this 
section.
6.1.1 Social and economic factors
Social and economic concerns were mostly reported as adding to general 
injury stress, rather than having a direct impact on trial participation 
decisions:
“Obviously at the time I was suffering from major trauma, so you’ve got a 
number of things going through your head and not just the injury.  How 
long am I going to be off work?  I’ve got to sort my mortgage out.  The wife’s 
two hours drive away.” (CH021, 46 year old male, skilled)
Only one interviewed patient, a 43 year old single father of  small children, 
was directly affected by his social responsibilities. He hurried home at the 
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first opportunity to attend to his childcare responsibilities and was happy to 
be interviewed, but only over the phone. Only taking impromptu summary 
notes was possible (chapter 3.3), so no direct quote is available from this 
interview.
6.1.2 Environment and timing of invitation to participate
Factors described below echo strongly experiences discussed already in 
chapter 5.2.6, when the PTIV approach experiences where discussed. Half  
of  the 23 interviewees felt that their ability to understand and process the 
trial information was affected, sometimes significantly, by pain, strong 
painkillers and injury stress: 
Interviewer: ..do you remember who actually spoke to you about the trial 
itself ? 
Respondent: “No, because they’d got me on morphine.”
Interviewer:  “Do you know what sort of information you’d been given?”
Respondent: “I don’t know because my mind was... It was elsewhere.”  
(CH003, 46 year old male, manual labourer)
This raised questions about appropriate timing of  the trial invitation: 
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Respondent: “You’re not really ready to listen at the time.  It doesn’t sink 
in quite when you’ve just had the accident.  It doesn’t really sink in does it?  
You know, because you’re not really ready to expect...”
Interviewer:  “...Why do you think it doesn’t quite sink in?”
Respondent:  “Because you’re still in a bit of pain and shock, you know, 
and you just don’t realise exactly what is what.” (CH007, 76 year old 
female, retired)
Information about the trial, even though generally well understood once it 
was  processed, seemed overwhelming on initial contact and introduction: 
“The only thing I thought that perhaps maybe puts people off doing the 
research is it seemed that as soon as it was confirmed that it was a heel 
fracture the people were there with the DVD and because you’re there 
getting drugs and you’re in shock that this has happened to you and then 
somebody is shoving a DVD in front of you and saying, ‘Come and be part 
of this.’ .. because if you’re having drugs and you’re a bit here and there, I 
don’t think you’re taking in what they’re saying to you anyway.” (CH033, 
43 year old female, professional)
Even those who do not have a fear of  hospitals found the hospital 
experience and environment rather distressing: 
“I’m out of my environment... And don’t forget this was a shock.. lying in 
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a bed, foot up, what’s going to happen? .. you don’t really need someone 
to come and say to you, ‘Would you be part of our trial as well?’ .. You go 
through a lot, don’t you, while you’re lying there.” (CH027, 55 year old 
female, skilled)
It appears that many patients look for psychological support and 
reassurance that they are in the right place and in safe hands to make them 
better, which the trial invitation fails to provide: 
“I suppose that doesn’t give you a confidence boost at the time when you’re 
lying there with a broken heel and they don’t know which way to go and 
which is the best way.  I can remember that quite clearly.” (CH021, 46 year 
old male, skilled)
Three patients felt uncomfortable about not having any guidance or advice 
in the process of  deciding on a preference for one treatment rather than 
another: 
“I know we’re a free society and with the freedom of information act you’ve 
got a lot more open now, but sometimes it could be a blessing not to tell them 
everything.  Is that good or bad?” (CH039, 43 year old male, skilled)
They and other patients refused to believe (quite rightly) that their treating 
surgeons do not have a treatment preference. Their spontaneously 
proposed solution was that more targeted treatment advice should be 
provided, even in the absence of  an obviously better choice. This seems 
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similar to the pre-randomisation concept (Zelen 1990): 
“You know, not bully them into it, but rather than giving them the choice 
when in the surgeons’ own minds they know that this operation needs 
doing.. So really they should say ‘Look, we are advising you’ and not saying 
‘you’ve got to have it,’ but ‘we are advising you to have this operation.’” 
(CH030, 50 year old male, manual labourer)
One patient was rather distressed by the absence of  a surgeon’s 
recommendation and this may have contributed to the trial concept 
misunderstanding:
“On my injury I had to make a personal decision of whether I was going to 
have a plaster or an operation and I still don’t understand up to this day 
now why.  I had the operation by having to make that decision.. I spent two 
days being really upset while the swelling was coming down and thinking it 
over in my mind.”(CH026, 42 year old female, manual labourer)
6.1.3	 ‘Trade	off’	process	–	balancing	pros	and	cons
Even though the trial information presented seemingly a balanced view 
about treatment options, there was strong evidence of  a ‘trade off ’ process 
according to a patient’s own perception of  risk and benefits for both 
treatments: 
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“I think having my foot set in a cast in my mind’s eye would be less 
restrictive, but with the surgery I thought that it would achieve more 
movement.” (CH038, 41 year old male, skilled)
Understandably, the prospect of  an invasive procedure with significant 
scarring raised a lot of  anxiety for many: 
Respondent: “...they haven’t given me much incentive to have the 
operation if they’re telling me about this skin thing.  It’s not so much for 
a bloke, but from a female’s point of view like I say, with swimming or 
anything.. if they would have said to me ‘Listen, we can operate on you 
today and you’re going to be out of here in two days time.  You’ll be on 
crutches for a week and then that’s you mended,’ I couldn’t see...  What was I 
going to say?”
Interviewer:  Clear benefit? 
Respondent:  “Yes.  I couldn’t see the benefit I would gain out of having the 
operation because I’m on crutches for the same amount of time, plus the fact 
of what does he say, a five percent chance of an infection?” (CH030, 50 year 
old male, manual labourer)
Some patients had a more positive attitude to surgery: 
“The way I looked at it is that if something is broke, it needs fixing.” 
(CH019, 28 year old female, unemployed)
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From the UK HeFT results we know that there were almost equal numbers 
of  patients who did not want (n=144) and who wanted (n=146) to have 
surgery among those who refused to take part in the trial (Chapter 2, Fig. 
2.1). Only two patients were completely passive about the trial participation: 
“I left it entirely up to them.  They’re the ones that sort of knew better really 
what they wanted me to do, so I was quite willing to do whatever they 
required me to do.” (CH007, 76 year old female, retired)
They were both female, one 76 year old retired lady and the other 28 year 
old young mother.  Their decision to take part in the trial was easy: 
“’We’re doing these trials.  Would you like to take part?’ and I just said 
‘Yes, okay that will be fine.  I don’t mind.’” (CH004, 28 year old female, 
unemployed)
However, the older lady achieved this effectively through denial of  the 
choice given to her whether to take part or not: 
“I didn’t have a choice as such.  I left it more or less to their discretion what 
they did with me.  I wouldn’t say I said, ‘I’ll choose this’, or ‘I’ll choose that.’  
I left it to their discretion.” (CH007, 76 year old female, retired)
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6.1.4 Sources of decision support
At least a third of  the patients interviewed found making a decision about 
the trial and/or treatment choice straightforward, once all the information 
was given to them. One in three stated that people they knew (family, 
friends, colleagues etc.) had a significant influence and effect on their final 
decision.
Four patients felt that it was necessary to obtain external third party 
information in addition to what was provided for them. None of  them 
were happy with the random treatment allocation, although they were 
positive towards clinical research. They  offered to take part, but with their 
own treatment choice: 
“You’re going to read up on it, Google it, Internet it, see what feedback 
people have had already if they’ve done it before, so it’s not like I haven’t 
just said, no I don’t want to do it.  I’ve like, researched it in a small sense.” 
(CH039, 42 year old male, skilled)
Apart from online searches, they would look and listen to any other 
available information sources and those are unlikely to be evidence-based:
“I watched this DVD and obviously I’d got Internet access there and I 
started doing a bit of my own research and my next door neighbour here; 
he’s a nurse and I spoke to [Name] and one or two other things.  The 
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boss did the same break funnily enough..’.. ‘by Wednesday I was almost 
getting an expert, you know.  I started to learn a lot about the foot all of a 
sudden, so I mean I’m glad I had access to it and I mean I started to learn.” 
(CH021, 46 year old male, skilled)
6.1.5 Prior treatment advice
Despite the best efforts in our trial recruitment centre to prevent any 
advice about a treatment choice until a potentially eligible patient had been 
assessed for trial eligibility, two patients reported being advised about the 
extent of  their injury and possible treatment in the Emergency Department:
“He [in A&E] said ‘No, you’ve got a fracture of the heel,’ and he said ‘We’ll 
probably operate on it tomorrow...’ I’m lying there on the Monday evening 
thinking that I’m going to be operated on the next day.” (CH021, 46 year 
old male, skilled)
“I can’t think of her name, some doctor.  She came to have a look and she 
said that it looked like I’d shattered my heel bone, explained to me that it 
was probably one of the worst breaks you can do.” (CH038, 41 year old 
male, skilled)
Both those patients declined random treatment allocation in preference for 
operative treatment. This is a well known factor, which is both important 
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and significant. I shall pick it up later when I discuss the findings of  my 
study and make recommendations for future practice.
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6.2 Patient attitudes
Thematic analysis revealed similar responses to the trial participation offer 
among some patients. Typological analysis was introduced (chapter 3.3) 
and resulting patient types according to their response and attitude towards 
the invitation to take part in a challenging trauma trial are presented in the 
diagram (Figure 6.2). 
Each patient type will now be discussed separately. 
mixed patient type
prior treatment advice
CH0XX   case codes from the CUP
               mixed patient type
CH004 
CH007
CH015
CH018
CH023
CH032
CH033
CH036  
CH027  
CH020
Happy, but not random
No surgery/No hospital
CH035
CH043  
Change of heart
CH003
CH014
CH018
CH022
CH030
CH031  
I need to decide
Not In My Back Yard (NIMBY)
HeFT Eligible Patient Types
Misunderstanding
RCT positive
That’s fine
Help others
CH019
       CH021
       CH022  
       CH038
CH039
CH046
  
CH026  
Figure 6.2. HeFT Eligible Patient Types diagram.
The expert must decide
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6.2.1 RCT positive
First of  all it was interesting to see what makes patients agree to the clinical 
trial in the RCT positive group (Fig. 6.2, Appendix H.1). This group 
included eight out of  23 interviewees.
6.2.1.1	 	In	equipoise	–	‘that’s	fine’
The interview data confirmed that individual equipoise about treatment 
options is rare even among trial participants. Only two patients who did 
not engage in the pros and cons “trade off ” process between two trial 
treatments were in equipoise. One was a 28 year old single mother, who 
summarised her feelings as follows: 
“It was explained to me that it was just trials.  I could opt out.  I wouldn’t 
be treated any differently and she had to make a phone call to see if it was 
operative or non-operative and it was just like a stab in the dark really to 
which one I got, so I was like ‘Okay then that’s fine’.” (CH004, 28 year old 
female, unemployed)
The other one of  those two patients, a 76 year old retired lady, did not even 
engage in trying to understand the trial concept and process: 
“I knew that they would keep an eye on what happened.  I realised that, 
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you know...but I didn’t know exactly what was going to happen and how it 
would proceed.” (CH007, 76 year old female, retired)
Her decision was based on complete trust in professionals who provided 
her medical care and a willingness to help others:
“They’re the ones that sort of knew better really what they wanted me to 
do, so I was quite willing to do whatever they required me to do.. the main 
reason was I thought if I could help anybody else in the same circumstances 
then I was willing.” (CH007, 76 year old female, retired)
One more patient, a 40 year old university academic, was completely 
comfortable with the concept of  the RCT, despite having some preference 
towards one of  the trial treatments: 
“Maybe because I am a scientist doing research myself, or maybe just 
because, [er] because everybody knows how important medical research is. 
.. I was having difficulty coming up with a reason why I shouldn’t do this.” 
(CH015, 40 year old, academic)
6.2.1.2			Social	responsibility	–	‘help	others’
For the other six interviewees in the RCT positive group it was 
overwhelmingly a sense of  social responsibility that made them join: 
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“If I can help you to help people then I’m doing my bit.. You have to, to help 
people out and to sort out the best procedures.” (CH023, 47 year old male, 
skilled self-employed)
One of  them, a 25 year old self-employed mechanic, linked this 
responsibility directly with NHS service: 
“Just take part and give something back to the NHS and help other people 
out for the future really” (CH036, 25 year old male, self-employed)
These five patients agreed to participate in the trial even though they were 
not comfortable with the trial concept of  random treatment allocation and 
had a degree of  preference for one treatment.  Some of  them hoped to 
avoid an operation:
“I think fortunately for me they decided not to operate” (CH032, 60 year 
old male, skilled self-employed)
At the same time others wanted an operative treatment to be allocated: 
“I was sort of inclined, on the basis of what I knew, that I am, that maybe I 
should have that operation.” (CH015, 40 year old male, academic)
When patients discussed or mentioned eventual treatment outcomes, it 
seems that their level of  satisfaction depended on their initial treatment 
preference. So patients allocated randomly to a treatment had second 
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thoughts if  the treatment was not in line with their wishes or feelings even 
though those may have been subconscious. On the other hand, patients 
who chose their treatment themselves (described in the next section 6.2.2) 
were all happy with the choice, even when the outcome did not sound very 
good. 
6.2.2 I need to decide
Another sizable (7/23) and heterogeneous group of  interviewed patients 
(Fig. 6.2, Appendix H.2) were not able to give up responsibility for a 
decision that would affect their future life: 
“I didn’t want them to make that decision for me, because if they made the 
wrong decision I couldn’t live with that, whereas if I’ve made that decision 
then it’s down to me.” (CH038, 41 year old male, skilled)
They were negative about the randomisation process: 
“I think that’s what maybe put some people off staying in the programme 
because it’s a bit like roulette isn’t it?” (CH039, 42 year old male, skilled)
Six out of  seven of  these patients, however, were positively proactive about 
taking part in research if  randomisation could be removed: 
“I was happy to do it, but I didn’t want the choice taken away from me.  
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I still wanted to have the final choice of surgery or...if it was offered.” 
(CH021, 46 year old male, skilled)
“I did ask if I could be part of the trial, but just be the operation side but 
they wouldn’t let me.” (CH019, 28 year old female, unemployed)
None of  them really appreciated or understood the value of  random 
treatment allocation. As the same young lady explained: 
“let me just make a choice and still be part of the trial, I don’t see how 
that made any difference whatsoever.” (CH019, 28 year old female, 
unemployed)
They were taken aback when confronted with the currently recommended 
explanation of  a trial that clinicians did not know which was the better 
treatment for them: 
“Somebody comes up and says ‘We’re doing a trial,’ and why they’re doing 
a trial and ‘We don’t know which is the best way to proceed with this,’ 
and you’re thinking ‘Well hold on a second’.” (CH021, 46 year old male, 
skilled)
In the situation when a clinician ‘did not know’ and could not provide some 
guidance or advice, they would seek additional information using a variety 
of  alternative sources before making any decision: 
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“You’re going to read up on it, Google it, Internet it, see what feedback 
people have had already if they’ve done it before, so it’s not like I haven’t 
just said, no I don’t want to do it.  I’ve like, researched it in a small sense.” 
(CH039, 42 year old male, skilled)
Despite the trial information delivering a message that two treatment 
options offered to trial participants were finely matched, when a patient’s 
own ‘research’ was applied, the balance was lost: 
“To us, it wasn’t a fine balance.  It was completely [one treatment option] – 
no doubt about it.” (CH019, 28 year old female, unemployed)
To some  extent, these patients felt that they would be disadvantaged by not 
being allocated their preferred treatment:
“If I had [another treatment option] I might have disadvantaged myself.” 
(CH046, 49 year old male, professional)
Their top priority was to make what seemed the best choice in their 
situation:
“To find out what the best way for me and to proceed with it if it was 
offered.” (CH021, 46 year old male, skilled)
Once they made their choice, these patients were committed to the best 
possible treatment outcome: 
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“I think it’s the nature of the animal, so if you want to sit on your arse and do 
nothing, or if you want to try and get back to how you were.”  (CH038, 41 
year old male, skilled)
It appeared that taking part in research as it was offered was not seen in this 
group as an option that assured the best quality of  care: 
“You just feel as though if you do enter the programme you might be 
railroaded towards going down what they want, rather than what you want, 
so once you enter these terms it’s all very well saying you can just opt out when 
you want, but there’s always a bit of pressure.” (CH039, 42 year old male, 
skilled)
It must be noted that two patients from this group had prior advice about 
a possible choice of  treatment from a health professional before they were 
approached by a specialist group about trial participation (marked with 
caution triangle in Fig. 6.2). They chose their treatment accordingly.
6.2.3 Negative attitudes to invasive treatment and/or   
 hospital
The third large (8/23) group of  patients (Fig. 6.2, Appendix H.3) shared a 
negative attitude and concern about invasive treatments: 
“I just don’t want an operation if I can avoid it.” (CH014, 68 year old 
female, retired)
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They also had a low opinion of  hospitals in general : 
“I just hate hospitals like, you know.  I just wanted to get out, as a lot of 
people do.” (CH030, 50 year old male, manual labourer)
This man, as indeed others in the group, still engaged in the ‘trade off ’ 
decision process, but it was heavily biased against operative treatment: 
“It didn’t give me much incentive to have the operation to be honest with 
you and maybe that’s because I wanted to get out of hospital as soon as I 
could.” (CH030, 50 year old male, manual labourer)
Interestingly, this was the most fluid group, with many of  them relying on 
advice from others to support their feelings: 
“I was offered plaster or an operation and he didn’t really go into the 
operation side much because he said he’d looked at my face and he could see 
the thought of an operation was no, horror.”  (CH014, 68 year old female, 
retired)
These patients were most susceptible to change their opinion under 
external influence: 
“It was an easy decision not to have it but my wife talked me into it and my 
family saying it would be for the best, so I got it done.” (CH018, 76 year old 
male, retired)
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This 76 year old man (marked in two categories with a blue flag in Fig. 6.2) 
joined the trial after discussion with his family. Another 75 year old man 
(marked in two categories with a yellow flag in Fig. 6.2) really wanted to 
help and would be happy to: 
“Get in your trial, if you can just tell, not have an operation, just tell...” 
(CH022, 75 year old male, retired)
Two patients, had a ‘change of  heart’ (Fig. 6.2) during the interview. Both 
were manual workers (39 and 52 year old men) for whom the heel fracture 
was potentially a career changing event. When questioned what their advice 
would be to others towards the end they gave an encouraging message 
about joining the trials and would have joined themselves: 
“From what you’ve told me this evening and from what I’ve seen on there, 
it’s very interesting because it’s personal to me.  I’ve had this injury and it’s 
not a common injury, so I think that anyone that’s been offered the chance 
to take part in a study – not necessarily to have surgery, because that’s a very 
personal thing, but anyone that wants to take part in helping to find out 
more information, or definitive information even about this should do it.  
Why not?” (CH043, 52 year old male, manual labour)
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6.2.4	 ‘Don’t	give	me	choices’	:	the	expert	must	decide
One patient (a 55 year old female hairdresser) could not face responsibility 
for a decision about her treatment or trial participation (Fig. 6.2): 
“I couldn’t afford to make the wrong decision. I wasn’t prepared to make 
that decision.” (CH027, 55 year old female, skilled)
She was determined to get the best option and expected experts to provide 
it for her: 
“I would rather somebody who’s a consultant or is, you know, knows this 
field [um] to make the decision for me.” (CH027, 55 year old female, 
skilled)
She felt strongly that the trial was an experiment rather than provision of  
the best possible care: ‘Not on me’, she said, and was extremely concerned 
about the possibility of  making the wrong choice:
“Don’t give me choices because I might make the wrong one.” (CH027, 55 
year old female, skilled)
She responded to this dilemma by ignoring the research team’s plea for 
participation: 
“If I broke my arm next week and you came to me again I’d probably say, 
‘No, I don’t want to’.” (CH027, 55 year old female, skilled)
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6.2.5 Misunderstanding of the clinical trial concept
Only one patient, a 42 year old female manual labourer, completely 
misunderstood the concept of  a clinical trial (Fig.6.2): 
“On my injury I had to make a personal decision of whether I was going to 
have a plaster or an operation and I still don’t understand up to this day 
now why.  I had the operation by having to make that decision.” (CH026, 
42 year old female, manual labour)
This misunderstanding brought her to the position where she had to 
make an important, but inappropriately difficult, decision that she was not 
qualified or prepared for. This led to a significant distress: 
“I had a decision to make of whether to have it put in plaster and wait 
and see how quickly it healed itself; the bones, or to have an operation and 
I spent two days being really upset while the swelling was coming down 
and thinking it over in my mind.” (CH026, 42 year old female, manual 
labour)
Consequently, she was desperately looking for the sort of  specialist advice 
and support that she had come to the hospital to receive in the first place.  
She did not see this offered in the context of  the HeFT recruitment 
procedure: 
“I wanted to see my specialist first about the injuries and talk about that 
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first and then afterwards you don’t mind, because you know you’ve seen 
someone.  You feel at ease don’t you?  You’re focused and then you’re willing 
to listen about what this survey is and how you can help other people as 
well.” (CH026, 42 year old female, manual labour)
163
6.3 Discussion 
The interviewed patient cohort matches the UK HeFT patient population 
closely. Not only does it have good demographic variation (Chapter 
4, Table 4.1), there is also a similar proportion (around one third) of  
patients who agreed to take part in the trial. The remaining two thirds of  
patients are split evenly into groups who chose operative or non-operative 
treatment. These were the same proportions as in the actual trial. In 
addition, no new themes (codes) were created when analysing the last few 
interviews. This data saturation suggests that the patient sample was at least 
close to the maximum variation of  the UK HeFT patient population.
It is reassuring that only one of  23 interviewees completely misunderstood 
the trial concept, because the literature review (Chapter 1.5) suggests 
that a significant proportion of  patients is at risk of  making an incorrect 
interpretation of  trial information in surgery. This reflects positively on the 
chosen method of  trial information delivery to patients, which included the 
Patient Trial Information Video. However, the timing of  the trial invitation 
together with the apparent failure of  the research team to provide assurance 
about the quality of  care provided for the patients appear to be major 
themes, even for patients who agreed to take part in the trial. The conscious 
decision in the trial design to avoid initial contact with a treating surgeon, 
replacing it with the PTIV approach, may have contributed to this.
The study confirms that most patients apply a ‘trade off ’ process to their 
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decision making about clinical research participation to the extent that some 
needed additional independent sources of  information. They ‘researched 
it in a small sense’ before making a final decision. Moreover, the majority 
of  patients quite correctly assume that surgeons themselves are likely to 
have a treatment preference to some extent when they assess a patient 
and his or her injury. It is difficult not to notice that, as a result,  for most 
people a choice between two very different treatments is not equal. Only 
two out of  23 interviewed patients confirmed individual equipoise about 
treatment options and did not use the ‘trade off ’ approach.  This means 
that many who agreed to the trial compromised under the weight of  social 
responsibility they felt, rather than being in equipoise. It is not surprising 
then to learn that the majority felt disadvantaged if  they had been randomly 
allocated a treatment choice which in their eyes was second best, and were 
unable to compromise. This majority of  patients form two large typological 
groups.
One group is characterised by a more emotional, negative response 
to interventional forms of  treatment and hospitals in general. Their 
views range from dislike to fear. This is a more fluid group of  subjects, 
susceptible to different forms of  external influence and often willing to take 
advice or accept an explanation. This is demonstrated by two patients. They 
both start being concerned about and willing to avoid an operation, yet one 
of  them eventually decides to join the trial after discussion with his family, 
while the other is willing to join if  his choice to avoid surgery is respected. 
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Hence the two patients eventually ended up in two different typological 
groups. The other two patients from the same initial group converted to the 
randomised trial participation  group during the course of  the interview, as 
they realised the importance and better understood the background of  the 
clinical research.
Patients in the other group take a more rational and pro-active approach 
in finding the difference between the two proposed treatments, as applied 
to their individual circumstances. They are committed to the best possible 
treatment outcome and are positive about participation in research, but 
without the desire to have random treatment allocation. This is because 
they want to take responsibility for a decision that may affect their life, 
rather than give it up to random allocation by chance, which has negative 
social associations reminiscent of  playing roulette. Sometimes there is a 
direct association with previous experience or knowledge, as demonstrated 
in two cases who had received  prior medical advice before being 
approached by the trial team. Another patient made a decision based on his 
previous experience of  a serious leg injury that needed surgical treatment.
There is a small number of  patients who are initially negative to 
invasive treatments, but can potentially be converted to randomised 
trial participation. But there is a much larger number of  patients willing 
to take part, but refusing random treatment allocation on grounds of  
rationality. Only one patient was directly negative about the trial or research 
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participation in general. Taking into account one other patient who 
misunderstood the trial information, and those who did not actively express 
willingness to take part without randomisation, there are still at least 70% 
(16/23) patients who could provide valuable research data as described 
above, as opposed to the 35% (8/23) who actually took part from this 
group. This is a significant amount of  potential clinical data that is ignored 
with a ‘randomised only’ Clinical Trials design.
Demand for more targeted treatment information supports the argument 
in favour of  the pre-randomisation approach (Zelen 1990) to patient 
recruitment in a challenging surgical trial. One of  the patients suggested 
this spontaneously:
“Well maybe if they said ‘We want to track your progress and we believe 
this will be an option, a better option,’ then it might be you’d get more people 
being guided or advised to go down the operation route and you’d probably 
get a better feedback...” (CH039, 42 year old male, skilled)
Better understanding of  the factors that influence patients’ decisions about 
trial participation may indicate areas of  the trial recruitment process to be 
researched further and optimised. In particular, this may inform optimal 
usage of  the novel trial methodology proposed in this study. This is 
attempted in the next chapter.
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Chapter 7 Conclusions
This chapter summarises the study results which answer the research 
questions set out in chapter 1.6. Each research question is stated prior to 
providing a summary outlining the results described in earlier chapters.  The 
questions cover the whole process of  patient recruitment in a challenging 
surgical RCT, looking at ethical issues, effectiveness and integrity. 
Perspectives of  stakeholders and currently available methodological 
advice are taken into account. Combination of  proposed methodological 
developments tested in the context of  the real life surgical RCT and 
the patient feedback leads to better understanding of  trial recruitment 
components and their effects on patient decision about trial participation. 
As the outcomes of  each study presented in this thesis are analysed, 
concerns and areas for further development and research are identified.
In the final part of  this chapter, the results of  the quantitative and 
qualitative studies are combined in order to suggest a possible model for 
future usage of  the methodological framework. The model adds to the 
methodological portfolio available to researchers when considering options 
for designing an appropriate  recruitment process for a specific trial. This 
new model is a suggestion only at this stage; clearly the practicality and 
usefulness will only really be tested by implementation in a real-life setting, 
which should be the subject of  future research.
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7.1 Study A: PEACE methodological framework
Is it possible to develop a methodology that integrates/transfers the principle of 
Clinical Equipoise into a clinical trial recruitment process?
A new methodology was developed to determine levels of  clinical equipoise 
for patients in a clinical trial, allowing identification of  patients eligible for 
randomisation (Chapter 4). The Patient Eligibility Assessment through 
Clinical Equipoise (PEACE) framework can be implemented in real time 
during a trial. It uses modern technology to distribute clinical data for 
expert assessments on line and state-of-the-art statistical tools to pool and 
compare collective data. This approach allows one to integrate the core 
principles of  clinical research, such as clinical equipoise and randomisation, 
in a clinical trial recruitment process.
The PEACE framework adds to the methodological portfolio of  trial 
designs that are available to researchers undertaking challenging surgical 
trials, particularly those comparing contrasting procedures, where 
patient recruitment is expected to be difficult.  Often the comparison is 
between higher risk operative interventions and safer, but arguably less 
effective, conservative measures. There are examples of  trials when a 
traditional fixed eligibility criteria approach simply fails; up until now no 
methodological alternative has been available in these settings. Examples 
of  such failures include the endoscopic anti-reflux procedures (EARPs) 
trial (Eckardt, Pinnow et al. 2009), where 134 patients were interviewed, 
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but only 13 (10%) were successfully recruited. In addition, there were 
virtually no patient referrals from 50 collaborating private practices and 23 
hospitals. The authors blamed the scepticism of  the referring physicians 
and strict selection criteria for this failure. The situation was even worse 
for MIMOSA, the mixed urinary incontinence (MUI) medical or surgical 
approach trial (Brubaker, Moalli et al. 2009), where 1198 subjects were 
screened and approached for study enrolment, but only 27 consented to 
randomisation. The Early Randomized Surgical Epilepsy Trial (ERSET) 
(Engel, McDermott et al. 2012) was also stopped prematurely due to much 
slower than expected patient accrual.
There are two main reasons why the PEACE framework has the potential 
to improve recruitment in such challenging surgical trials. First, it allows for 
simpler initial entrance criteria, so more patients would be considered for 
a trial than with conventional fixed entry criteria (Chapter 4.4). Secondly, 
every potential trial participant is assessed by an expert panel. This is in line 
with patient expectations from a clinical consultation; that is, to get the best 
possible advice on the appropriate treatment (Chapter 1.4). Expert panel 
assessment with the option of  personal involvement in such an assessment 
will also likely encourage more sceptical clinicians to take part or refer 
patients.
As outlined in Chapter 1.4, the theoretical basis of  the PEACE framework 
is a recognition that randomised clinical trials are ethical and necessary in 
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the presence of  clinical equipoise. When clinical equipoise exists, it should 
be difficult to decide on the best treatment or procedure for a patient in 
most cases. It is accepted as good clinical practice to discuss such cases with 
several experts before a final decision is made. The PEACE framework 
aims to identify cases where experts agree about a better outcome for 
one or another treatment for a patient; in these cases it follows that 
randomisation becomes unethical and the patient cannot be recruited into 
the study. It is significant that for some cases recognised as eligible by the 
fixed eligibility criteria used in the UK HeFT, experts agreed that one or 
another treatment option was likely to produce a better outcome.  It can 
be argued that these instances indicate that the framework would give 
patients reassurance that their cases are individually assessed in order to 
provide the best treatment choice. Conversely, when no consensus about 
likely treatment outcome has been demonstrated, a clinician would have 
more confidence that random treatment allocation would not disadvantage 
their patient even when they may have an individual preference. Similarly, 
patients offered randomisation would be reassured that opinion across 
a panel of  experts was such that there was no agreement on the best 
treatment in their particular case. The panel assessment results were easy to 
interpret and simple enough to be explained to both patients and clinicians 
(Chapter 4.3). Both groups were positive about introducing the new 
concept in future trials.
The current methodological framework is flexible and open source, so 
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that it can be adjusted to the needs and specifics of  a given trial. Most 
importantly, for consensus about an intervention choice to be considered, 
the following factors need to be discussed before implementation and 
decided by the trial team: a) the questions posed to experts (Chapter 4.3); 
b) the clinical information to be submitted; c) the decision rules for case 
eligibility or otherwise. Once agreed, the rules need to be accepted by all 
Principal Investigators and trial centres involved in a study prior to the 
commencement. I think that the work by Johnson et al. (1991), as used in 
this study (Chapter 4.2), is a good starting point. It is strongly advisable to 
test the chosen rules in a pilot study, using hypothetical cases and a putative 
panel of  experts if  necessary (Chapter 4.1).
The expert panel choice is crucial and needs to involve well known and 
respected specialists in a given area, although votes in all cases must be 
anonymous. Experts need to be clear how patient trial eligibility is decided 
and understand that a treatment choice in each case depends on them, in 
order to increase the level of  expert involvement. Experience from the 
Collective Uncertainty Project (Chapter 4.3) suggests that at least four 
experts need to express their opinion in order to make a case valid for 
eligibility assessment; however it is clear that a higher number of  experts 
make an analysis more powerful. From the UK HeFT experience, a panel 
of  somewhere between 10 and 20 experts should provide a sustainable 
number of  votes per case over what is often a considerable period of  
time required for trial recruitment. Expert votes need to be monitored 
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by the research team and may be questioned, for example concerning the 
use of  overwhelmingly strong votes (e.g. 100% in favour of  one or other 
treatment) or possible bias. It is important for a treating clinician to be 
able to express their opinion as part of  the panel, so that they are directly 
involved in the clinical decision for their patient and able to compare their 
vote with the other panellists. PEACE is designed to be ‘time light’ for the 
expert clinicians involved; this is achieved, however, through extra work and 
effort required from the research team.
7.1.1 Concerns and areas for future research/development.
Although tested in the context of  a real-life RCT, the PEACE framework 
was not actually used in the trial recruitment process. Rather, it provided 
valuable data to guide further developments, so that it can be used in future 
trials. The web based tool for expert opinion elicitation was constructed 
from several freely available software blocks (Chapter 3.1). This 
demonstrated that it is feasible, even on a limited budget. It worked well, 
but had occasional glitches due to factors out of  the control of  the research 
team, such as software or system updates. It is imperative and a legal 
necessity due to data protection issues that the software and patient data 
should be secure, stable and under the full control of  the study research 
team. If  the system developed for UK HeFT were to be used elsewhere, the 
clinical data input and assessment could be simplified, for example through 
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compatibility with hospital digital imaging systems, such as picture archiving 
and communication systems (PACS), and the development of  dedicated 
applications compatible with portable digital devices, such as Tablet PCs.
Currently, statistical modelling is implemented in a high level statistical 
software package (R Developmental Core Team 2013), but for widespread 
use by clinicians and clinical trialists a more user friendly point-and-click 
Graphical User Interface (GUI) would be preferable. It would require a 
considerable amount of  initial (one-off) additional work by programmers to 
develop such a system.  
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7.2 Study B: PTIV trial recruitment approach.
How to achieve clear, impartial and consistent delivery of trial information 
to patients in the context of a challenging surgical trial, when the compared 
interventions are obviously different? 
A new approach to patient recruitment was successfully introduced in a 
challenging trauma trial (Chapter 5): a Patient Trial Information Video 
(PTIV) supported by a dedicated specially trained study team member to 
assist with any patient’s queries and concerns. The information video and 
introduction of  the trial information moderated by a third party are the 
two powerful tools known to improve the informed consent process in 
RCTs (Chapter 1.4). They were combined in order to exclude a treating 
surgeon from initial patient contact, so that a possible disclosure of  a 
likely treatment preference by the surgeon was prevented. This allowed a 
consistently high standard of  trial information delivery to eligible patients 
and minimised involvement of  the clinical team in the research process. 
The latter proved to be attractive to clinicians involved as Principal 
Investigators (Chapter 5.2) and may have a positive effect on increasing 
the number of  clinicians and centres willing to take part in future trials. 
Dedicated Research Assistants are now routinely used to approach eligible 
patients about trial participation in all RCTs set up by the Trauma and 
Orthopaedics Department in Warwick Medical School.
However, an attempt to exclude the treating clinician from the recruitment 
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process until a decision about trial participation was made sometimes 
led to failure to provide sufficient psychological support and assurance, 
which should be a part of  the clinical care provided for a patient in pain 
and distress. A small proportion of  patients were rather upset about not 
being able to see a treating surgeon early on admission (Chapter 5.2.2). In 
addition, it appears that neither surgeon exclusion nor impartial delivery 
of  clear and high quality trial information managed to improve the 
level of  patient acceptance of  randomisation, and consequently of  trial 
participation, as had been hoped. This is in agreement with the previously 
stated opinion that it is the patient’s ‘effective equipoise’ that is pivotal to 
any decision about trial participation (Chard and Lilford 1998). Therefore, 
it is not effective or advisable to limit the surgeon-patient interaction either 
with the PTIV or possibly with any other trial recruitment approach. 
Most previous efforts to improve patient recruitment were concentrated 
around improvement of  quality and understanding of  the trial information. 
Yet reviews of  the most effective ways to increase understanding disagreed 
about their effect on patients’ willingness to participate in the actual RCTs 
(Chapter 1.4). This conclusion has been confirmed in the current research. 
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7.2.1 Concerns and areas for future research/development
The patient feedback (Chapter 5.2) should be considered when developing 
trial video material in the future. Although it is evident that there is 
significant individual variation in the interpretation of  the video, potential 
participants/lay persons can be involved at earlier stages of  production. 
Different formats could also be considered, for example, including patients 
with the same condition or from similar clinical trials in the presentation.
Finally, an interesting feature of  the Patient Trial Information Video was 
expressed in the patient interviews. This is the value of  being able to watch 
the video during the lengthy recovery period after the injury (Chapter 
5.2.5). This could be exploited and researched further, in order to improve 
retention of  trial information and manage patient expectations.
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7.3 Study C: Decision process about trial participation.
What is the patient perspective of the recruitment process in a challenging 
surgical trial, when the best current advice as well as innovative approaches to the 
principles of patient participation are integrated?
A qualitative study was designed (Chapter 3.3) and analysis was performed 
of  significant and emerging themes concerning patients invited to participate 
in a national multicentre trauma RCT comparing operative versus non-
operative treatment (Chapter 6.1). Emerging data indicated similar patterns 
of  response to the invitation to take part in the trial, which prompted 
typological analysis of  patients’ attitudes in the decision making process 
about trial participation (Chapter 6.2).
The feedback obtained from patients during the three years of  the UK HeFT 
was illuminating. It provided evidence that could be valuable for the design 
of  similar trials in the future.
At the present time, clinical research is not usually expected by patients to 
be an integral part of  clinical care (Robinson, Kerr et al. 2005). Yet trialists 
assume an informed rational approach from subjects to the decision about 
committing to a research process, in particular random allocation to an 
intervention group. Possibly, this stems from the ethical responsibility to 
provide all important information about the compared interventions and 
the research process, in order to ensure informed consent or refusal to 
participate (Chapter 1.4).
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This study confirms previous reports that most patients struggle 
to understand and retain trial information, especially in the hospital 
environment, where they may be affected by medication and have difficulty 
coping with change in their condition (Chapter 6.1). Although some of  
them are happy to consider all possible information about a treatment 
choice, most found the sheer volume and type of  information provided 
overwhelming. In particular, patients are very uncomfortable with 
uncertainty about a treatment choice, as presented in current RCT designs. 
In a pragmatic clinical consultation scenario, a clinician is expected to 
provide an individual assessment and expert advice, which needs to balance 
carefully the advantages, risks and availability of  alternative treatments. 
Patients with newly diagnosed conditions or injuries, often in pain and 
distress, request some psychological support and reassurance of  the best 
clinical care as part of  good standard clinical practice. It appears that the 
current trial recruitment process interferes with, and may even exclude, 
this clinical decision making process, by the application of  fixed eligibility 
criteria. Even patients who agreed to take part in the UK HeFT mostly did 
it due to a sense of  social responsibility, rather than being comfortably in 
equipoise about a treatment choice. 
A surprising alternative suggestion to reduce research process interference 
in the clinical care process was uncovered. This came up spontaneously 
from several interviewees from the UK HeFT (Chapter 6.1.2). Patients 
were rather uncomfortable with the idea of  accepting two very different 
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interventions as being equally good, yet not knowing which one they 
were going to have. They were desperate for some form of  guidance and 
reassurance from their surgeon that one or another treatment was a good 
choice for them, even where there was no evidence to support which one 
was better.
This is suggestive of  pre-randomisation (Chapter 1.4), where an eligible 
patient is randomly allocated to one of  the compared treatments before 
being approached for potential recruitment (Zelen 1990). This technique 
was used successfully (83% recruitment rate) in a previous significant large 
trial of  calcaneal fractures in Canada (Buckley, Tough et al. 2002). Pre-
randomisation was considered for the UK HeFT, but later dropped because 
a patient is randomised without a consent, which is difficult to justify 
ethically.
The typological analysis (Chapter 6.2) highlighted the different approaches 
patients adopted to deal with this additional stress. While some were passive 
or even intimidated by the clinical and research data provided, others 
pro-actively took charge of  the clinical decision making process. Using 
available external sources of  information and their own judgement, they 
usually preferred and chose one treatment or the other. The treatment 
preference was the main reason for non-participation in the UK HeFT, 
despite most of  the participants being positive towards clinical research. 
However, this undoubtedly subjective and biased approach produced evenly 
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split and similar patient groups (146 preferred operative and 144 non-
operative care, Fig. 3.1), closely resembling those obtained from random 
treatment allocation. These groups represent a significant number of  
patients (83% of  351 who refused to take part in the UK HeFT) who are 
committed to the best treatment outcome, yet are ignored by researchers, 
unless an inclusive trial design is used (Torgerson and Sibbald 1998). 
In addition, most of  those excluded from the research analysis due to 
treatment preference appear to have a specific psychological profile. They 
are pro-active about the decisions leading to their treatment choice and 
committed to the best possible outcome for the chosen treatment. These 
subgroups of  patients (Fig. 6.2) can be seen in the light of  a new theory 
of  patient attitudes in the surgical trial. This highlights that certain types 
of  patients are not and cannot be included within the current recruitment 
approach, affecting the generalizability of  the results. This may be viewed 
as a selection bias secondary to, or even caused by, current methodological 
approaches to patient recruitment. In turn, this may contribute to failure to 
spot a difference between treatment outcomes, or indeed even to erroneous 
inferences for the whole trial.
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7.3.1 Concerns and areas for future research/development
A major limitation of  this work is that the above results concern a single 
trial centre in a single orthopaedic trauma RCT, albeit a multi-centre study. 
This was my first experience of  qualitative research, although I had support 
and guidance from senior qualitative researchers. In order to make stronger 
and wider inferences, the results would need to be replicated in the setting 
of  other challenging surgical RCTs.
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7.4 Mixed methods – research success story
Arguably the most significant outcome of  this research project is the 
development of  the novel methodological framework for Patient Eligibility 
Assessment through Clinical Equipoise (PEACE), that was successfully 
tested during a real clinical trial (Chapter 4). It is, however, the qualitative 
study of  patient experiences in this trial (Chapter 6) that can guide the 
future use of  the new framework. This is because it is the patient’s ‘effective 
equipoise’ that matters in the trial recruitment process (Chard and Lilford 
1998). 
7.4.1 Model for future use 
The UK Heel Fracture Trial (UK HeFT), that provided a setting and 
platform for the current research, is a typical example of  a challenging 
surgical RCT that is the subject of  this research (Chapter 2). Contrasting 
operative and non-operative treatments have been compared, so patient 
recruitment was expected to be difficult. The trial recruitment process was 
set up according to the latest methodological advice, including introduction 
of  a novel combination of  two powerful tools known to improve the 
informed consent process in RCTs: a trial information video and availability 
of  a dedicated research team member to address patient’s concerns 
(Chapter 3). These measures, however, failed to improve the level of  trial 
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recruitment. It was low, but comparable to other similar trials (Chapter 2).
As highlighted earlier (7.3), patients found the suggestion of  random 
allocation to a treatment group disruptive to the expected pattern of  
normal clinical care. What they expect is expert advice, discussion with 
the treating clinician and support to make the best possible choice of  
treatment. This expectation helps to explain the success of  the pre-
randomisation approach used in previous similar trials (Chang, Falconer et 
al. 1990; Buckley, Tough et al. 2002); in this methodology an eligible patient 
is allocated to one of  the interventions to be compared prior to being 
approached about trial participation. The consultation process that follows 
then resembles a standard clinical situation, when a pre-allocated (proposed 
in standard practice) intervention is offered, although in the context 
of  research participation. The control (alternative in standard practice) 
intervention is described as an equal and available alternative, should the 
patient have a strong preference and decide to decline the pre-allocated 
treatment. Indeed, such an approach was spontaneously suggested by some 
patient interviewees from the UK HeFT. 
The major obstacle that prevents a wider use of  pre-randomisation is 
the ethical concern about the lack of  consent when the research process 
(i.e. pre-randomisation) has been initiated (Chapter 1.4). However, if  the 
PEACE framework was introduced, this ethical issue would be eliminated. 
This is because pre-randomisation at the point of  trial eligibility assessment 
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can happen after a prospective patient is approached by a clinical team 
initially and alerted about an ongoing study. Permission for their clinical 
data to be assessed by an expert panel would be sought in the context of  
a consultation process to identify an optimal intervention, if  sufficient 
agreement between experts is present. A treating clinician can engage 
in the panel assessment of  a case. In this way, the initial decision by a 
patient to engage in the research process (expert panel assessment) is not 
associated directly with the dilemma of  random allocation to the compared 
interventions, which is often viewed negatively by patients. Rather, they 
allow the expert panel to determine a more appropriate intervention when 
possible or random allocation, if  no consensus is reached. Pending the 
panel’s decision, a period of  time is available for a patient to consider and 
prepare to face uncertainty and a possibility of  different outcomes. 
It is my aim to set up a follow up study that would involve the PEACE 
framework linked to the pre-randomisation approach in the trial 
recruitment process, according to the model described above. Close 
collaboration with specialists and/or researchers in statistics and 
information technology would be essential for success of  the future 
projects. I hope to overcome justifiable scepticism from the research 
community, funding bodies and ethical committees through a series of  
engaging publications, arising from data acquired already. Positive and 
encouraging feedback from both experts and patients in the UK HeFT is a 
powerful driving force for this task.
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A larger pool of  patients approached about possible trial participation 
(Fig.4.8, Chapter 4.4) and improved patients’ experience of  research 
involvement may appeal to the wider concept of  larger, simpler trial 
designs, so that they become integral, rather than disruptive, to normal 
clinical practice. The data acquired then guides the trial until the research 
objective is achieved or shown to be not worth pursuing  (Weijer, Shapiro et 
al. 2000).  
A weakness of  this study is that the main conclusions and 
recommendations are based on evidence collected from a single, albeit 
multi-centre, RCT. Potentially, due to some unknown or unforeseen reasons, 
these data may have misled us and provided a poor evidence base on which 
to make recommendations. The effectiveness of  the PEACE framework 
in identifying eligible patients and eventually improving trial recruitment 
rates is yet to be proven. In particular, it has not yet been proven whether 
the process of  Patient Eligibility Assessment through Clinical Equipoise 
will meet patients’ primary expectation and demand for the best possible 
care and interventions applicable to their case. So it may be that until the 
methods developed here can be shown to be useful in at least one other 
study, it is likely that there will be scepticism within the research community 
and limited take-up or buy-in. 
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Appendix A
UK HeFT collaborating hospitals
Addenbrooke’s University Hospital, Cambridge
Arrowe Park Hospital, Wirral
Aintree University Hospital, Liverpool
Birmingham Heartlands Hospital
University Hospital Wales, Cardiff
Cheltenham General Hospital
Gloucester Royal Hospital
James Cook University Hospital, Middlesbrough
King’s College Hospital, London
Leeds General Infirmary
Leicester Royal Infirmary
Musgrove Park Hospital, Taunton
Northern General Hospital, Sheffield
Norfolk & Norwich University Hospital
Royal Bolton Hospital
Royal Devon & Exeter Hospital
Royal Liverpool Hospital
Royal Victoria Hospital, Belfast
Selly Oak Hospital, Birmingham
Ulster Hospital, Belfast
University Hospital Coventry & Warwickshire
Wrexham Maelor Hospital
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Appendix B
Statistical analysis of the UK HeFT patient demographic data
UK Heel Fracture Trial: Statistical Summary (25–Feb–2011)
Data Screening
The Centre Patient Log at the end of recruitment has background data on 1325 individuals.
All the background information is available for the 152 enrolled individuals. Of the 1173 non-enrolled
individuals, four have invalid Gender and have been omitted for simplicity, leaving 1321 individuals in the
following analysis. Also, nineteen non-enrolled individuals had unknown dates of birth (DoB); given the
distribution of the known ages (see for example Figure 1) it seems very likely that these individuals were
elderly. The previous statistical summary (31–Aug–2010) omitted these nineteen subjects; the current
analysis includes them with a conventional DoB 22–Dec–1922, possibly giving a more accurate picture of
the overall age distribution of the non-enrolled subjects, though not of the speciﬁc ages of some of the
oldest individuals.
The 1321 individuals may be classiﬁed according to enrollment status, deﬁned as
1. Enrolled (152 patients)
2. Eligible but refused (331 patients)
3. Ineligible with bilateral fractures (60 patients):
32 during 2007 when bilateral fractures automatically implied ineligibility,
28 from January 2008.
4. Ineligible without bilateral fractures (778 patients).
Apart from the speciﬁc issues raised above concerning DoB and occasional missing Gender, which only
aﬀect non-enrolled individuals, the data quality appears excellent—for example, gender is compatible with
name (when given).
Drop-out Rate
A total of 132 out of 152 enrolled individuals (87%) completed the 6-month form. For individuals enrolled
in 2007, 2008 and 2009 the proportions were 26/33 (79%), 50/61 (82%) and 56/58 (96%) respectively. Note
that early in the trial, some subjects withdrew shortly after randomization, or were found to be ineligible
(e.g. by being outside the 3 week limit since injury).
The ﬁnal 24-month form has so far been completed by 92 individuals enrolled on the trial. Of these, 76
(83%) have completed all four forms (6-, 12-, 18- and 24-month), and 10 (11%) had not completed the
6-month form.
Everyone recruited by the end of January 2009 should have completed the 24-month form by now; 89/99
(90%) have done so. Of the 10 who have not completed the 24-month form, 5 did not complete any of the
forms.
Everyone (53/53) recruited after January 2009 has completed at least the 12-month form, compared to
82/99 = 83% of those recruited up to the end of January 2009. If the current pattern continues, then we
can expect at least 90% (137) of the 152 enrolled individuals to complete the 24-month form, and about
85% to have completed all four forms.
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Data Summary
The following tables summarise number of patients by gender, age on admission, and status.
Age (decade)
Status < 20 20– 30– 40– 50– 60– 70– 80– 90– 100– Total
Female Enrolled 1 3 5 3 4 4 4 0 0 0 24
Refused 2 11 11 11 14 7 3 2 0 0 61
Bilateral 1 5 5 1 0 0 0 0 0 0 12
Ineligible 14 24 27 27 26 32 31 23 3 0 207
Total 18 43 48 42 44 43 38 25 3 0 304
Age (decade)
Status < 20 20– 30– 40– 50– 60– 70– 80– 90– 100– Total
Male Enrolled 2 17 29 28 19 24 8 1 0 0 128
Refused 6 47 47 69 48 37 10 5 0 1 270
Bilateral 2 14 13 8 4 3 3 1 0 0 48
Ineligible 41 160 131 93 59 54 17 12 2 2 571
Total 51 238 220 198 130 118 48 19 2 3 1017
Thus out of 304 women, 85 (28%) were eligible for entry to the trial, and 24 (8%) were enrolled; whereas out
of 1017 men, 398 (39%) were eligible, and 127 (13%) were enrolled. The proportion of eligible individuals
refusing to be entered into the trial is similar at 61/85 (72%) for women and 270/398 (68%) for men.
Representativeness of Data
An important feature of the current data in the Centre Patient Log is that the injury tends to occur in
younger men and in older rather than younger women, yet younger men and older women are more likely
to be ineligible, and possibly less likely to be enrolled, as shown in the following tables.
Status
Age Enrolled Refused Bilateral Ineligible
Female 50+ 12 26 0 115
< 50 12 35 12 92
Status
Age Enrolled Refused Bilateral Ineligible
Male 50+ 52 101 11 146
< 50 76 169 37 425
Thus women and younger men in particular may be underrepresented in the trial; any such patterns will
of course be considered when interpreting the trial results.
More detail on these patterns can be seen in Figures 1 & 2 (on the next two pages).
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Male Enrollment
Figure 1: Age by enrollment status (Males)
Figure 1 suggests that younger men are rather more likely than older men to be ineligible for entry to
the trial (in many cases because of alcohol, drug or psychological problems). Other than that, the age
distribution for men is broadly similar across all four categories.
Note that all but one of the ages around 86 correspond to males given the conventional DoB 22–Dec–1922,
however the ﬁve ages around 100 look unusual but seem to be genuine.
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Female Enrollment
Figure 2: Age by enrollment status (Females)
Figure 2 shows considerable diﬀerences in the age distributions. Compared to the men, older women are
less likely to be eligible for the trial, and middle-aged women are perhaps more likely to refuse to be entered
even if eligible. Also, of ineligible females, bilateral fractures are more common in younger women.
4
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Eﬀect of Including Bilateral Fractures
Figure 3: Enrollment split at January 2008
Figure 3 plots enrollment status for males up to the end of 2007, and from January 2008 onwards (when
patients with bilateral fractures were no longer automatically excluded). The plots show that the age
distributions are similar, but that many patients with bilateral fractures became eligible for the trial.
Corresponding plots for females have been omitted, as the data are too sparse.
J. E. H. Shaw (Statistician)
5
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Appendix C
Collective Uncertainty Project ethics amendment
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Appendix D
Collective Uncertainty Project patient interview schedule
Preamble:          
 I’m interested to know about how and why you were invited to take 
part in the UK Heel Fracture Trial, what sort of  trial it was, what kind of  
information you were given, what you decided and why, what it was like 
taking part, and how you feel about it now looking back. I’d like you to tell 
me your story/what happened in your case with as much detail as possible. 
Then I may have some extra questions if  you haven’t already covered them 
in what you say. 
Prompts:          
Recruitment, information and consent
How did you first hear about the trial (i.e. A&E, nurse on ward, admitting 
doctor…?)
Who approached you? What did they say/how did they communicate? Why 
do you think they approached you?
What information were you given? How well written was it? What did you 
think of  DVD? Was it what you needed?
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What did you understand about the trial? What was it testing for? 
Did you feel that you understood about the trial and the treatments 
involved?
Do you think the Research Associate who talked to you understood it?
What did the Research Associate /doctor say about the treatments being 
compared? 
Did they talk about uncertainty? 
Did you feel that you were able to ask all the questions that occurred to you 
and were they answered fully?
Why did you decide to take part/not take part? Probe for main and 
subsidiary reasons. If  not, could your decision be different if  it was a drug 
trial?
How easy did you find it to make up your mind? 
Did members of  your family or your friends influence your decision about 
whether to participate? How?
Did you feel put under any pressure either way? Gratefulness / social 
desirability / attention - Did you feel that the Research Associate /doctor 
was hoping that you would agree to participate? 
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Were you hoping that you’d be allocated to one group rather than the 
other(s)? If  so, did you discuss this with the Research Associate / doctor?
Do you have any sense that there is a moral duty to take part in research? 
(Role of  faith?)
Did you know much about trials and research beforehand? Media reports?
In trials people may use a lot of  technical terms – words like randomisation, 
control groups, placebo, intervention, blind or double-blind. Did you feel 
you were given enough explanation of  terms like this? Are there things now 
you feel you didn’t understand or wish you’d known more about?
What’s your understanding of  what randomisation is and why it’s needed?
Taking part
How did you feel when you learnt which group you had been allocated to?
What was it like taking part in the trial? What did it involve for you?
Did you ever think about dropping out (or why did you drop out?)
Do you think you got ‘better’ treatment as a result of  being in the trial? 
What kind of  extra or better things?
Did you have someone you could contact if  you were uncertain about 
anything?
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Were you ever unsure about what to do, e.g. on holiday?
Were there any side effects for you?
Any implications for personal/family relationships?
Afterwards
Are you having any long-term follow-up? How is this organised?
Are you glad you took part or do you have any regrets?
Do you know who funded the trial? Does it matter to you where the money 
for a trial comes from?
What are your feelings about the way trials are organised?
Is there anything you’d want to say to NHS professionals about the conduct 
of  trials?
And to policy-makers? Do you think that more should be done to raise 
public awareness about taking part in clinical research as a treatment 
process?
What would you say to anyone else thinking about whether to take part in a 
trial?
PTIV - Show the DVD with pause for any comments along the way. Then 
210
give time to reflect.
Uncertainty - You may remember that we did a study about uncertainty. 
Your injury was assessed by several surgeons specialising in foot and ankle 
trauma across the UK. This is a diagram demonstrating their opinions 
(explain a diagram). Is it easy to understand?
Do you think it could be helpful to you at this stage? In what way? Would 
uncertainty diagram help in your decision at the time?
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Appendix E
Ethical Approval for the CUP patient interviews
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Appendix F
Patient information/invitation to the interview with reply slip
Corporate Uncertainty Study (Patient Interview)
Hello
My name is Yuri Kulikov. I am a researcher from Warwick Orthopaedics, 
Warwick Medical School. I would like to invite you to an interview about 
your experience of  the UK Heel Fracture Trial. It does not matter if  you 
agreed to take part in the trial or not. Before you decide if  you want to be 
interviewed or not, I want to tell you why the interview is being held, and 
what you can expect if  you do take part. Please read what I have to say 
carefully, talk about it with friends or relatives if  you wish and feel free to 
ask me any questions you may have. Please take as much time as you like to 
decide. 
Thanks for reading this.
What is the purpose of  the study?
Randomised controlled trial (RCT) is the most reliable method to compare 
different treatments. However, they are particularly difficult to do when 
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surgical treatments are studied. The UK Heel Fracture Trial was set up 
to the best standards for modern clinical trials and also used some new 
methods which we hope provide better understanding and experience for 
patients who are invited to take part in the trial. 
We hope that information from interviews will help researchers and health 
professionals to understand what it is like for people to receive an invitation 
to and/or to take part in a surgical clinical trial . We would like to know 
if  we provided sufficient support and information for you to make an 
informed decision about taking part in the trial. 
Why have I been chosen?
Everybody who agreed to provide their data for our Corporate Uncertainty 
Study will be invited for an interview. This is partly because it is very 
important that we hear views of  different patients - those who either 
agreed or not to take part in the trial, those who had an operation or not, 
those who are happy or not with their experiences etc. Also we have very 
interesting results from the Corporate Uncertainty Study which we want to 
share with you during the interview. We want to hear your opinion before 
we consider using this assessment tool in future.
Do I have to take part?
No. It is entirely up to you to decide whether or not you want to take part. 
If  you decide to take part you will be asked to sign a ‘consent form’. You 
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are still free to withdraw at any time without giving a reason. No questions 
will be asked if  you stop. If  you do not take part, or stop taking part, the 
care you get from your doctors and nurses will not be affected in any way.
What will happen if  I take part?
If  you complete and send back the enclosed ‘reply slip’, I will contact you 
to arrange an interview at a time and place that suits you. We suggest for 
the interview to take place in your local hospital. You will be paid for the 
cost of  your travel. However, you may choose to be interviewed at home. 
I will try to answer any questions you may have about the interview or the 
Corporate Uncertainty Study.
What would the interview be like?
If  you agree to take part in the interview you will be given the ‘consent 
form’ to sign. You will keep a copy of  the consent form. The interview will 
be audio recorded.
The interview will be a little like a conversation, but I will help you talk 
about yourself  in your own words. I will ask you to talk about your 
experiences of  the UK Heel Fracture Trial.  I will ask questions about what 
happened to you, what your thoughts and feelings have been at different 
stages, how you have got information, what you have done, and what have 
been the good and bad parts of  the experience.
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While people sometimes find it helpful to talk about their story to 
researchers this research is not the same thing as counselling. However, I 
can provide you with contacts which can be used to get more help if  you 
want.
How long would the interview take?
The time it takes for an interview varies, depending on how much you have 
to say, but most interviews last at least an hour.  If  you would prefer, I can 
interview you on two different occasions.  Remember, if  you want to stop 
the interview at any time, you can do so without giving any reason at all.
What would happen after the interview?
I will label the interview tape with a code number and give it to a typist 
who will type out everything you said in the interview.  The typist signs an 
agreement to keep everything you say in the interview secret. The tape and 
the typed up record (transcript), identified only by the code number, would 
be kept in a secure place at Warwick Orthopaedics.
What you said will be analysed and compared with issues raised by other 
interviewees. Results will be presented in medical and scientific meetings 
and published in medical and scientific literature. Your name will not 
be disclosed in any way. The interviews will not be used for profit or 
commercial gain.
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What if  I decide to withdraw after the interview has taken place?
You are free to leave the study at any time. If  you decide to leave after an 
interview has taken place, all tapes, transcripts and typing of  your interview 
will be destroyed.
Who is organising and funding the research?
Warwick Orthopaedics is a research body of  the Department of  Trauma 
and Orthopaedics, Warwick Medical School, University of  Warwick and 
sponsors this research.
Contact for further information
I hope that this information sheet has told you what you need to know 
before deciding whether or not to take part.  If  you have any queries at all 
about the project or wish to make a complaint please email Y.I.Kulikov@
warwick.ac.uk or telephone Yuri Kulikov on 07725666023 or Professor 
Damian Griffin on 024 7696 8616.
Notes:
- I am a professional researcher and am paid for my work.  
- The study has been approved by Multi Centre Research Ethics Committee 
for health research (Ref. 06/Q1604/58)
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- The Warwick Medical School has a specific insurance policy to protect 
patients who take part in research. The insurance provides for ‘no fault 
compensation’ consistent with that provided through the Association of  
British Pharmaceutical Industries (ABPI), as well as for legal liability.
Many thanks for reading this information sheet.
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Corporate Uncertainty Study – interview reply slip
Please, fill in the relevant options, sign and post back in the pre-paid 
envelope provided:
☐ Yes, I am happy to be interviewed as part of the above study 
☐ I am considering being interviewed, but would like you to address 
following questions/concerns: (alternatively, email Y.I.Kulikov@warwick.
ac.uk or call 07725666023)
☐ I do not want to be interviewed (please, consider contacting Yuri 
Kulikov, Principal Investigator, or leave your contacts below for him to get in 
touch before you make a final decision)
Name:      Signature:     
Date
To arrange the interview you can contact me by:
Email      Mobile   
Telephone
Thank you!
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Collective Uncertainty Project: Final Analysis
Expert questionnaire
Dear Mr. X
Thank you very much again for continuous support of  the Uncertainty 
Project. To complete the data analysis we need to ask you to complete this 
final questionnaire. All the data provided will be treated as confidential and 
reported anonymously.
Background information.
1. Specialist register / certificate / FRCS(Orth) year 
2. Time  in research/academic  post  years  months
3. Research degree (if any)
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Appendix G
Surgeon questionnaire about the CUP expert panel 
participation
Collective Uncertainty Project: Final Analysis
Expert questionnaire
Dear Mr. X
Thank you very much again for continuous support of  the Uncertainty 
Project. To complete the data analysis we need to ask you to complete this 
final questionnaire. All the data provided will be treated as confidential and 
reported anonymously.
Background information.
1. Specialist register / certificate / FRCS(Orth) year 
2. Time  in research/academic  post  years  months
3. Research degree (if any)
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Your vote counts.
4. You have been one of the more frequent voters in the project. In your 
opinion, what are the factors that influenced this?
5. Would you agree that this is a “low research time burden” 
methodology, i.e. little time and effort is necessary to take part?
 Yes   No   Other  (please, explain)
6. Would you support this methodology to be adopted in a real life 
clinical trial?
 Yes  No  Other  (please, explain)
Typical example of  your vote with the panel in a case:
7. Having seen that surgeons approached voting process differently 
(meaning percentage distribution rather than expressing different 
opinions), would you like to comment about this? 
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Below is a rare example when a patient was eligible for the UK HeFT, but 
surgeons from the Uncertainty panel recommended operative treatment:
 
8. On the basis of votes in this or similar case, would it be more 
appropriate
  to randomise as usual 
  to offer treatment according to surgeons’ consensus   
  other (please, explain)
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t o
f h
os
pi
ta
l, 
yo
u’
d 
se
en
 th
at
, y
ou
’d
 
sp
ok
en
 to
 th
e 
co
ns
ult
an
t 
an
d 
th
en
 a
t t
he
 e
nd
 o
f t
he
 
da
y t
he
 b
all
 w
as
 p
ut
 in
 yo
ur
 
co
ur
t. 
 It
’s 
yo
ur
 d
ec
isi
on
, 
so
 yo
u’
re
 g
oi
ng
 lik
e,
 ‘W
ell
 
ar
en
’t 
yo
u 
gu
ys
 th
e 
ex
pe
rts
 
he
re
?’
- N
o 
on
e 
co
uld
 a
ct
ua
lly
 
de
fin
e	
w
ha
t	w
as
	ri
gh
t	a
nd
	
wh
at
 w
as
 w
ro
ng
, w
he
th
er
 
op
er
at
ive
 o
r n
on
-o
pe
ra
tiv
e 
an
d 
jus
t h
av
ing
 a
 b
it 
of
 
ind
ep
en
de
nt
 re
se
ar
ch
 o
n 
it 
he
lp
ed
 m
e.
  I
t p
ro
ba
bl
y p
ut
 
m
e	
off
	a
	lo
t	o
f	t
hi
ng
s.
- 6
0 
pe
rc
en
t I
 w
ou
ld
n’
t 
be
 p
ar
t o
f t
he
 tr
ial
 a
nd
 4
0 
pe
rc
en
t I
 m
ay
 b
e 
pa
rt 
of
 
th
e 
tri
al 
un
til 
I’d
 se
en
 th
e 
CT
 sc
an
, s
o 
I b
as
ed
 it
 o
n 
so
m
e	
of
	th
e	
st
uff
	I’
d	
se
en
	
on
lin
e 
to
 se
e 
ho
w 
ba
d 
or
 
ho
w 
sh
at
te
re
d 
th
e 
he
el 
wa
s 
an
d 
wh
en
 I 
sa
w 
th
e 
sc
an
, 
it 
wa
s y
es
, t
he
re
 w
er
e 
fra
c-
tu
re
s t
he
re
 b
ut
 I 
pe
rs
on
all
y 
di
dn
’t 
th
ink
 it
 w
as
 a
s b
ad
 
as
 w
ha
t I
’d
 a
ct
ua
lly
 se
en
 
on
 w
eb
sit
es
- T
he
y t
oo
k 
int
o 
ac
co
un
t 
th
e 
ris
k 
of
 in
fe
ct
io
n,
 th
e 
ris
k 
of
 fu
rth
er
 o
pe
ra
tio
ns
, s
o 
I 
ac
tu
all
y m
ad
e 
th
at
 d
ec
isi
on
 
th
er
e 
an
d 
th
en
.
- p
ar
t o
f t
he
 tr
ial
 is
 to
 
en
ha
nc
e 
an
d 
m
ak
e 
be
t-
te
r t
he
 se
rv
ice
s a
nd
 th
e 
re
ha
bi
lita
tio
n
- h
en
ce
 w
hy
 I’
m
 m
or
e 
th
an
 
ha
pp
y t
o 
su
pp
or
t t
his
 a
nd
 
if 
I c
an
 h
elp
 in
 a
ny
 w
ay
, I
’m
 
de
fin
ite
ly
	m
or
e	
th
an
	h
ap
py
	
to
 d
o 
th
at
.
- n
o 
tri
al
- n
o 
su
rg
er
y
- Y
es
, I
 th
ink
 I 
m
ad
e 
th
e 
rig
ht
 d
ec
isi
on
.  
Ye
s, 
I m
ea
n 
yo
u 
ne
ve
r k
no
w 
wh
at
’s 
go
ing
 to
 h
ap
pe
n.
- I
 d
on
’t 
th
ink
 it
 w
ill 
ev
er
 b
e 
a 
hu
nd
re
d 
pe
rc
en
t. 
 I 
us
ed
 
to
 d
o 
a 
lo
t o
f w
alk
ing
, h
ill 
wa
lki
ng
.  
I h
av
en
’t 
ac
tu
-
all
y t
rie
d 
th
at
, b
ut
 I 
ha
ve
 
wa
lke
d 
fo
r a
bo
ut
 fo
ur
 o
r 
fiv
e	
m
ile
s	
so
	I	
ca
n	
st
ar
t	t
he
	
wa
lki
ng
 a
ga
in 
an
d 
ge
tti
ng
 
ba
ck
 in
to
 d
oi
ng
 a
 lo
t m
or
e 
sw
im
m
in
g	
ag
ai
n	
an
d	
st
uff
	
lik
e 
th
at
 n
ow
.  
Ye
s, 
so
 it
’s 
no
t r
ea
lly
 g
et
tin
g 
in 
th
e 
wa
y. 
 It
’s 
jus
t s
om
et
hin
g 
I’m
 liv
ing
 w
ith
, w
ith
 a
 b
it 
of
 
pa
in 
ev
er
y s
o 
of
te
n.
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N
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 s
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o
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o
sp
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iv
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at
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de
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va
si
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at
m
en
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an
d/
o
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h
o
sp
it
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Pa
tie
nt
 a
nd
 c
on
te
xt
 a
t-
tri
bu
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s
Cu
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se
lec
tio
n
Re
lev
an
t c
ue
s
Ps
yc
ho
lo
gi
ca
l r
ep
re
se
nt
a-
tio
n 
of
 c
ue
s
Cu
e 
int
eg
ra
tio
n
Po
te
nt
ial
 o
ut
co
m
es
 (r
isk
 
as
se
ss
m
en
t) 
Ce
rta
int
ies
Ou
tc
om
es
 H
ap
py
?
CH
03
0 
– M
ale
, 4
1-
60
, 
m
an
ua
l la
bo
ur
- I
t d
id
n’
t g
ive
 m
e 
m
uc
h 
inc
en
tiv
e 
to
 h
av
e 
th
e 
op
er
at
io
n 
to
 b
e 
ho
ne
st
 
wi
th
 yo
u 
an
d 
m
ay
be
 th
at
’s 
be
ca
us
e 
I w
an
te
d 
to
 g
et
 
ou
t o
f h
os
pi
ta
l a
s s
oo
n 
as
 
I c
ou
ld
- I
’ve
 n
ev
er
 o
nc
e 
th
ou
gh
t, 
I 
wi
sh
 I 
wo
uld
 h
av
e 
ha
d 
th
e 
op
er
at
io
n
- I
 ju
st
 h
at
e 
ho
sp
ita
ls 
lik
e,
 
yo
u 
kn
ow
.  
I ju
st
 w
an
te
d 
to
 g
et
 o
ut
, a
s a
 lo
t o
f 
pe
op
le 
do
.
- ‘
W
ell
 w
ha
t h
ap
pe
ns
 if
 I 
do
n’
t h
av
e 
th
e 
op
er
at
io
n?
’ 
an
d 
th
ey
 sa
id
 ‘W
ell
 yo
u’
re
 
ou
t o
f h
os
pi
ta
l t
od
ay
 a
nd
 
yo
u’
ll b
e 
on
 c
ru
tc
he
s f
or
 si
x 
we
ek
s a
nd
 yo
u 
m
ig
ht
 h
av
e 
a 
lim
p.
’  
So
 I 
op
te
d 
no
t t
o 
ha
ve
 th
e 
op
er
at
io
n
- t
he
y k
ep
t t
ell
ing
 m
e 
ho
w 
m
ine
 w
ou
ld
 m
en
d 
its
elf
 
wi
th
ou
t p
ins
, I
 m
ea
n 
th
ey
 
sa
id
 th
e 
ch
an
ce
s a
re
 I’
d 
ge
t 
ar
th
rit
is.
- s
he
 b
as
ica
lly
 sa
id
, ‘
It’s
 
en
tir
ely
 u
p 
to
 yo
u.
’  
Sh
e 
sa
id
 ‘I
 c
an
’t 
te
ll y
ou
 to
 h
av
e 
an
 o
pe
ra
tio
n 
or
 n
ot
 to
.’ 
 
Sh
e 
go
es
, ‘
Al
l I 
ca
n 
sa
y i
s 
yo
u 
ca
n 
ha
ve
 th
e 
op
er
at
io
n 
if 
yo
u 
wi
sh
.’ 
 Y
ou
 k
no
w,
 so
 
I’m
 n
ot
 sa
yin
g 
th
at
 I 
di
dn
’t 
ge
t a
 g
re
at
 d
ea
l o
f i
nf
or
m
a-
tio
n 
be
ca
us
e 
I p
ro
ba
bl
y 
di
d 
an
d 
I p
ro
ba
bl
y w
as
n’
t 
ta
kin
g 
m
uc
h 
no
tic
e 
to
 b
e 
ho
ne
st
.
- I
 d
on
’t 
th
ink
 a
 c
om
pu
te
r 
sh
ou
ld
 te
ll m
e 
if 
I’m
 g
oi
ng
 
to
 h
av
e 
an
 o
pe
ra
tio
n 
or
 
no
t. 
 Y
ou
 k
no
w,
 I 
th
ink
 th
at
 
is 
do
wn
 to
 th
e 
ind
ivi
du
al
- I
 ju
st
 c
an
’t 
he
lp
 th
ink
ing
 
th
at
 if
 so
m
eo
ne
 sa
ys
 to
 
so
m
eo
ne
 ‘L
oo
k,
 yo
u 
ca
n 
ha
ve
 th
e 
op
er
at
io
n 
or
 yo
u 
ca
n’
t,’
 th
at
 yo
u 
ca
n 
or
 
yo
u 
ha
ve
 a
 c
ho
ice
, s
o 
yo
u 
eit
he
r h
av
e 
th
e 
op
er
at
io
n 
or
 yo
u 
do
n’
t, 
rig
ht
? 
 G
oi
ng
 
ba
ck
 to
 w
ha
t I
 sa
id
, if
 
so
m
eo
ne
 is
 sc
ar
ed
 th
en
 
th
ey
’re
 g
oi
ng
 to
 sa
y n
o 
ev
er
y t
im
e.
- j
us
t t
ur
nin
g 
ro
un
d 
an
d 
sa
yi
ng
	‘I
t	w
ill
	b
en
efi
t	y
ou
	a
	
lo
t t
o 
ha
ve
 th
is 
op
er
at
io
n’
 
an
d 
th
en
 it
 e
as
es
 e
ve
ry
-
th
ing
 d
oe
sn
’t 
it?
- s
om
et
im
es
 p
eo
pl
e,
 if
 
th
ey
’re
 g
ive
n 
a 
ch
oi
ce
 o
f 
an
 o
pe
ra
tio
n 
th
ey
 m
ig
ht
 b
e 
sc
ar
ed
.  
Yo
u 
kn
ow
, t
he
y’r
e 
sa
yin
g 
‘W
ell
 yo
u 
ca
n 
ha
ve
 
th
is 
op
er
at
io
n 
or
 yo
u 
ca
n’
t, 
bu
t w
e 
ad
vis
e 
yo
u 
to
 h
av
e 
it.
’  
Bu
t i
f p
eo
pl
e 
ar
e 
sc
ar
ed
 
th
ey
’ll 
sa
y ‘
W
ell
, h
e’s
 n
ot
 
te
llin
g 
m
e 
I’v
e 
go
t t
o 
ha
ve
 
it,
’ s
o 
th
ey
’ll 
sa
y ‘
I w
on
’t 
ha
ve
 it
.’
- i
f I
’m
 tr
ut
hf
ul 
wi
th
 yo
u,
 it
 
di
dn
’t 
m
ak
e 
se
ns
e 
ab
ou
t 
th
e 
op
er
at
io
n
- I
 d
id
n’
t t
hin
k 
th
er
e 
wa
s 
an
y p
oi
nt
 o
f h
av
ing
 th
e 
op
er
at
io
n 
`w
he
n 
th
e 
ou
t-
co
m
e 
th
ey
 sa
id
 w
ou
ld
 b
e 
th
e 
sa
m
e,
 a
pa
rt 
fro
m
 I’
d 
be
 
in 
ho
sp
ita
l lo
ng
er.
  I
 k
no
w 
wi
th
 so
m
e 
pe
op
le,
 if
 it
’s 
ba
d 
th
ey
 h
av
e 
to
 h
av
e 
th
e 
op
er
at
io
n,
 b
ut
 I 
th
ink
 I 
wa
s 
gi
ve
n 
th
e 
ch
oi
ce
 b
ec
au
se
 
it 
wa
s a
 st
ra
ig
ht
 sp
lit,
 yo
u 
kn
ow
.
- I
’d
 h
av
e 
a 
sc
ar.
  T
he
 sc
ar
 
m
ig
ht
 n
ot
 m
ar
ry
 u
p 
pr
op
-
er
ly 
an
d 
th
er
e’s
 a
 c
ha
nc
e 
of
 in
fe
ct
io
n 
an
d 
I’d
 b
e 
on
 
cr
ut
ch
es
 fo
r s
ix 
we
ek
s
- T
he
n 
yo
u’
ve
 g
ot
 th
e 
inf
ec
-
tio
n 
th
ing
 w
he
re
 h
e 
sa
ys
 
th
en
 yo
u 
m
ig
ht
 h
av
e 
to
 
ha
ve
 a
no
th
er
 o
pe
ra
tio
n
- t
he
re
 is
 a
 g
irl 
I k
no
w.
  
W
ell
, s
he
 u
se
d 
to
 w
or
k 
wh
er
e 
I w
or
k 
an
d 
sh
e 
br
ok
e 
he
r h
ee
l a
nd
 yo
u 
ca
n 
se
e 
th
e 
sc
ar.
  S
he
 d
id
n’
t g
et
 a
n 
inf
ec
tio
n 
bu
t y
ou
 c
an
 se
e 
th
e 
sc
ar,
 b
ut
 sh
e 
ha
s g
ot
 
a 
lim
p.
  I
t’s
 n
ot
 a
 b
ad
 lim
p,
 
yo
u 
kn
ow
, a
nd
 I 
ha
ve
n’
t g
ot
 
a 
ba
d 
lim
p 
wh
at
so
ev
er
 b
ut
 
m
ay
be
 th
at
’s 
jus
t l
uc
k.
- W
he
n 
th
ey
 tu
rn
 ro
un
d 
an
d 
sa
y y
ou
 k
no
w,
 ‘T
he
 o
ut
-
co
m
e 
m
ig
ht
 b
e 
th
e 
sa
m
e,
’ 
th
en
 p
eo
pl
e 
lik
e 
m
e 
ar
e 
jus
t 
go
ing
 to
 tu
rn
 ro
un
d 
an
d 
sa
y ‘
I’m
 o
ut
 o
f h
er
e 
no
w!
’
- T
he
y s
aid
 it
 h
ad
 m
en
de
d 
pe
rfe
ct
ly 
be
ca
us
e 
th
ey
 to
ld
 
m
e 
it 
wa
s a
 st
ra
ig
ht
 c
ra
ck
 
an
d 
to
 b
e 
fa
ir, 
I a
int
 h
ad
 
no
 p
ro
bl
em
s w
ith
 it
 si
nc
e.
  
Th
ey
 sa
id
 I 
m
ig
ht
 g
et
 a
 lim
p 
bu
t I
 h
av
en
’t 
go
t a
 lim
p,
 
so
 I 
op
te
d 
no
t t
o 
ha
ve
 th
e 
op
er
at
io
n 
an
d 
th
at
’s 
wh
y.
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A statistical framework for quantifying clinical
equipoise for individual cases during randomized
controlled surgical trials
Nicholas R Parsons1*, Yuri Kulikov1, Alan Girling2 and Damian Griffin1
Abstract
Background: Randomised controlled trials are being increasingly used to evaluate new surgical interventions.
There are a number of problematic methodological issues specific to surgical trials, the most important being
identifying whether patients are eligible for recruitment into the trial. This is in part due to the diversity in practice
patterns across institutions and the enormous range of available interventions that often leads to a low level of
agreement between clinicians about both the value and the appropriate choice of intervention. We argue that a
clinician should offer patients the option of recruitment into a trial, even if the clinician is not individually in a
position of equipoise, if there is collective (clinical) equipoise amongst the wider clinical community about the
effectiveness of a proposed intervention (the clinical equipoise principle). We show how this process can work
using data collected from an ongoing trial of a surgical intervention.
Results: We describe a statistical framework for the assessment of uncertainty prior to patient recruitment to a
clinical trial using a panel of expert clinical assessors and techniques for eliciting, pooling and modelling of expert
opinions. The methodology is illustrated using example data from the UK Heel Fracture Trial. The statistical
modelling provided results that were clear and simple to present to clinicians and showed how decisions
regarding recruitment were influenced by both the collective opinion of the expert panel and the type of decision
rule selected.
Conclusions: The statistical framework presented has potential to identify eligible patients and assist in the
simplification of eligibility criteria which might encourage greater participation in clinical trials evaluating surgical
interventions.
Keywords: Equipoise, Randomised controlled trial, Surgery, Statistical model
1 Background
There is an increasing demand for randomised con-
trolled trials (RCTs) in surgery to provide high quality
evaluation of new interventions; we use the word inter-
vention synonymously with treatment, procedure or sur-
gical procedure. In a background of ever evolving and
improving healthcare, differences between interventions
for the same condition are often small, substantially
increasing the risk of biased estimation of treatment
effects in simple (uncontrolled) observational studies of
the interventions [1]. The need for the kind of high
level evidence provided by RCTs for surgical interven-
tions is clear [2], although a number of methodological
issues have been raised for surgical trials [1,3]. One of
the most important issues being recruitment, and speci-
fically identifying whether patients are eligible for entry
into a trial.
The existing tremendous diversity in practice patterns
across institutions coupled with an ever increasing range
of available interventions suggests a low level of agree-
ment between clinicians about both the value of many
interventions and the appropriate choice of intervention
[4]. A present or imminent controversy in the expert
medical community about a choice between interven-
tions is called clinical (or collective) equipoise. Equipoise
* Correspondence: nick.parsons@warwick.ac.uk
1Warwick Medical School, University of Warwick, Coventry, CV4 7AL, UK
Full list of author information is available at the end of the article
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is the point where we are equally poised in our beliefs
about the potential benefits of a particular intervention
[5]; i.e. is intervention A better than intervention B.
Clinical equipoise is present “if there is genuine uncer-
tainty within the expert medical community - not neces-
sarily on the part of the individual investigator - about
the preferred treatment” [5]. In many cases the only way
to resolve collective uncertainty about the optimum
intervention choice is to undertake a clinical trial. Indi-
vidual equipoise relates to a single clinician, i.e. the posi-
tion where he or she has no preference amongst a range
of available treatments. It is subject to change for a host
of reasons, including peer pressure, the results of poten-
tially imperfect studies and the influence of advertising.
Freedman [5] argues that global clinical equipoise
should override the individual clinician’s lack of equi-
poise. Clinicians should subsume their personal views
and recruit patients into a trial, even if not individually
in a position of equipoise themselves. This view is impli-
citly accepted by society in the form of ethics commit-
tees, which must ensure that the treatments being
compared are reasonable options before trial partici-
pants are sought. Often, for a treatment that is not com-
pletely novel, this is demonstrated by the presence of
clinical equipoise in an expert and/or wider medical
community. Once ethics committee permission has been
granted, it then becomes an individual clinician’s deci-
sion whether the offer of entry into the trial is appropri-
ate for an individual patient [6]. Unfortunately, the
varied preferences expressed (which may be rational,
anecdotal or irrational) between individual institutions
and between individual surgeons within and between
institutions often make patient recruitment to trials very
challenging.
Statistically the level of individual uncertainty about
the effectiveness of an intervention can be quantified by
a (subjective) probability, which is assigned to a specific
hypothesis and is personal and varies with an indivi-
dual’s knowledge and expertise. “A measure of a state of
knowledge” [7] is provided by the Bayesian concept of
subjective probability. The process of expert evaluation
about the effectiveness of a proposed intervention in an
RCT is synonymous with elicitation of a Bayesian prior;
i.e. a statement of knowledge prior to performing an
experiment or trial usually stated in the form of a prob-
ability density. There are a number of approaches to
turning informally expressed ideas into a mathematical
prior distribution, with no consensus as to the optimal
method of determination for a process that is usually
problem specific [8]. We choose to elicit the subjective
opinion of a panel of experts as a basis for decision
making regarding the eligibility of a patient for recruit-
ment to an RCT [9]. This has the advantage of being
dynamic and flexible, in the sense that it is quite feasible
that opinions will change during the course of a trial, for
example with the publication of related research [8], or
as experience accumulates amongst clinicians as to how
best to undertake a surgical procedure.
Methods for formal measurement of clinical uncer-
tainty, as a prelude to a clinical trial have been sug-
gested previously [10] and measures of surgeon’s
equipoise in the setting of surgical trials have also been
reported [11]. However, we develop these ideas further,
using techniques for eliciting subjective judgements
before a trial [12-14] and introduce a novel framework
for decision making regarding recruitment to an RCT
that we hope will be easily understood by clinicians and
implemented in real time during the course of a trial. It
is particularly challenging recruiting patients to trials
comparing operative to non-operative treatments or a
standard against a new but popular well-marketed treat-
ment. Therefore we develop a statistical framework to
model clinical equipoise (Section 3), using a parametric
and a nonparametric approach, for data collected from a
clinical trial comparing conservative and operative treat-
ment for displaced fractures of the calcaneus. The
results of applying the models are reported in Sections
3.7-10 and we draw conclusions in Section 4.
2 Methods
Using available web design tools a method was devel-
oped to capture the opinions of clinicians in real time
for individual patients (cases) in an ongoing RCT. It
comprised of a virtual expert panel giving their opinion
about the effectiveness of a proposed treatment for indi-
vidual patients based on online clinical details; the indi-
vidual assessments were then synthesized and fed back
electronically to the lead clinical investigator. This pro-
cess is described in greater detail below.
Patients who met the initial trial inclusion criteria
were identified and approached by a member of the
research team to alert them to the possibility of partici-
pating in a trial. They were then asked permission for
their anonymized clinical details to be distributed
among a panel of experts/clinicians for an opinion
regarding the effectiveness of the proposed treatment.
Clinical data from consented patients were made avail-
able on a secure website managed by eLab at the Uni-
versity of Warwick, and all panel experts/clinicians were
alerted by email and text message (if requested) to the
posting of a new patient and asked to offer their perso-
nal opinion on the likely success of the proposed treat-
ments. The assessment scale is described in more detail
for the specific example of the UK Heel Fracture Trial.
Initially the system was tested in a pilot study with
seven surgeons from five UK hospitals. Ten retrospec-
tive calcaneal fracture cases were selected to represent
typical variability. The surgeons followed the
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instructions on the website with online and telephone
technical support available; no specific training was
given. When voting on all ten cases was completed, sur-
geons were asked to fill in an evaluation questionnaire.
Voting on a single case never took longer than 5 min-
utes and the available clinical information was found
sufficient and the whole process user friendly by all par-
ticipating surgeons.
After the successful pilot study the system was intro-
duced as an independent component of the UK Heel
Fracture Trial, which compared conservative and opera-
tive treatment for displaced fractures of the calcaneus.
The study had separate ethical approval and a consent
form, in addition to the main trial. This allowed inclu-
sion both of those patients who took part in the UK
Heel Fracture Trial and those who declined, as soon as
the patient met the trial eligibility criteria. To avoid
interference with the clinical course, patients were asked
permission to use their data at the 6 weeks follow-up
clinic or later. Their anonymous clinical data including
X-rays and CT images were posted to a secure website.
The expert assessment panel included 12 surgeons from
9 hospitals. All surgeons were foot and ankle specialists
and acted as principal investigators in their individual
trial centres.
After assessing the clinical data available for a given
patient, the surgeon was able to scroll down to an inter-
active scale, featuring bars (initially set at zero) above
each of seven outcome categories indicating whether
after surgical intervention the patient would get “much
worse“ (1), “significantly worse“ (2), “a bit worse“ (3), “no
difference“ (4), “a bit better“ (5), “significantly better“ (6)
or “much better“ (7). A left-click of the mouse and a
drag allowed each outcome prognosis bar to be set to a
desired percentage, which was reported numerically over
the bar. Once the assessment summed to 100%
(reflected in a digital window in the upper left corner of
the scale) the submit button allowed the data to be sent
to the trial lead for analysis. The UK Heel Fracture Trial
compared operative (surgical) and non-operative (con-
servative) treatment. Surgical techniques are becoming
widespread for calcaneal fracture, but do have associated
risks, therefore it was important for the clinician to
assess the improvement potential relative to the risks for
this procedure. Belief, in the context we describe here,
that surgery can make a patient better implies intention
to do surgery, while disbelief implies intention to avoid
surgical intervention, hence to choose the conservative
option. The question posed to the expert panel can and
should be tailored to the specific trial. For the UK Heel
Fracture Trial the experts were asked to compare opera-
tive (surgical) and non-operative (conservative) treat-
ment, which although strongly contrasting treatment
options may vary in the exact detail of the constituent
components. For studies with less contrasting treatment
options (e.g. two types of surgery) the question to
experts may simply be whether the test intervention
would be better or worse for a patient, compared to a
control (standard) intervention.
Table 1 shows four examples of data elicited from
between 4 and 6 clinical experts, not necessarily the
same individuals labelled as 1 to 6, who provided their
opinions on the effectiveness of surgical compared to
non-surgical intervention after fracture of the calcaneus.
As expected there are clear differences in the both the
locations and shapes of the individual distributions for a
number of these cases and indeed a number of clear
similarities for other cases. For instance, the opinions of
the clinicians vary widely for case 1; clinical expert 3 is
reasonably confident that the patient will improve signif-
icantly after treatment whereas for expert 4 the most
likely outcome of treatment is that the condition of the
patient will be unchanged. There is much clearer
Table 1 Assessment of the likely effectiveness of surgical
intervention after fracture of the calcaneus for four
example cases and up to six clinical experts
Case Assessment Clinical Expert
1 2 3 4 5 6
Case 1 Much Worse 5 5 0 0 0 0
Significantly Worse 5 5 0 0 5 9
A Bit Worse 10 25 5 15 10 21
No Difference 20 50 5 59 30 36
A Bit Better 30 15 15 25 45 23
Significantly Better 20 0 70 1 10 11
Much Better 10 0 5 0 0 0
Case 2 Much Worse 0 0 0 0 0 -
Significantly Worse 0 0 2 0 0 -
A Bit Worse 10 0 4 10 5 -
No Difference 15 10 12 13 20 -
A Bit Better 40 40 32 35 45 -
Significantly Better 30 50 48 40 30 -
Much Better 5 0 2 2 0 -
Case 3 Much Worse 10 10 5 5 - -
Significantly Worse 10 20 10 15 - -
A Bit Worse 15 30 10 20 - -
No Difference 20 20 15 20 - -
A Bit Better 20 10 30 20 - -
Significantly Better 15 10 20 15 - -
Much Better 10 0 10 5 - -
Case 4 Much Worse 20 5 40 10 20 -
Significantly Worse 60 85 50 80 70 -
A Bit Worse 15 10 10 5 5 -
No Difference 5 0 0 5 5 -
A Bit Better 0 0 0 0 0 -
Significantly Better 0 0 0 0 0 -
Much Better 0 0 0 0 0 -
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agreement for case 4 where all the experts expect the
patient to worsen significantly after treatment. How do
we use these data to decide whether a patient (case) is
eligible for recruitment to a clinical trial? We propose
two approaches here to model the opinions obtained
from each expert clinician, a parametric model based on
a Beta distribution (Section 3.2) and a nonparametric
model based on estimated means and standard devia-
tions (Section 3.3) that characterise expert opinions
using concepts of belief, disbelief and uncertainty. The
belief, disbelief and uncertainty are visualized using a
ternary plot that displays these characteristics in a man-
ner that allows them to be compared to decision rules
that partition the opinion space. Finally, resampling
methods are used to draw inferences concerning the
sufficiency of evidence from the clinical experts to
patient eligibility for recruitment
3 Results and Discussion
3.1 Expert opinion
An opinion regarding the effectiveness of a procedure
can be thought of as comprising of three distinctive
aspects; belief, disbelief and uncertainty. Belief represents
the tendency of an expert to expect a particular treat-
ment to perform better than an alternative (control
intervention) for a particular patient (case); i.e. the ten-
dency for the experts to score cases in the higher end
categories of the rating scale of Table 1. Conversely, the
level of disbelief is equated with the tendency for an
intervention to have a worse outcome as compared to a
control intervention; i.e. the tendency for the experts to
score cases in the lower end categories of the rating
scale. The uncertainty associated with the belief and dis-
belief represents the spread of the data across the opi-
nion range; i.e. all the scores might be concentrated in
the central category (no difference) or be spread equally
between all categories in Table 1 - we would have equal
belief in these two scenarios but a maximum difference
in uncertainty.
Borrowing from the notation of subjective logic
[15,16], we label the belief, disbelief and uncertainty
associated with an opinion for expert i as bi, di and ui,
and apply the constraint that
bi + di + ui = 1 and {bi, di, ui} ∈ [0, 1]3 (1)
where the triplet πi = {bi, di, ui} is described as the
opinion of expert i. Intuitively it makes sense that there
should be a constraint on these characteristics, as
expressed in (1), as clearly when we have a maximum
level of belief in a procedure we must necessarily have
zero disbelief and uncertainty. Similarly, when there is a
maximum level of uncertainty there clearly must be
zero levels of belief and disbelief. The constraint that
our levels of belief, disbelief and uncertainty must sum
to unity is of course a matter of convenience, in an ana-
logous manner to that in conventional probability where
the same constraint is used. It seems reasonable, using
statistical arguments, that we should scale our levels of
belief and disbelief about the effectiveness of a proce-
dure by the associated uncertainty. That is we are inter-
ested in the quantities b/u and d/u, in the same way we
might want to normalize a treatment difference in an
RCT by the associated standard deviation measuring the
spread or uncertainty in the estimated difference to give
an effect size. In order to estimate b, d and u, we need
to develop a model for the clinical expert assessment
data.
3.2 Parametric model
3.2.1 Assessment pooling
The assessment of the likely effectiveness of the inter-
vention x was scored on a discrete valued symmetric
scale with descriptive terms selected to imply an even
spacing between categories. For our selected example,
the seven-category ordinal scale, described in Section 2,
was transformed onto the interval [0,1] as follows;
2→ 314 , 2→ 314 , 3→ 514 , 4→ 714 , 5→ 914 , 6→ 1114
and 7→ 1314 . This retains the implicit spacing of the
ordinal scale and centres the new scale at the same
point as the original scale. Equivalent arguments can be
constructed for ordinal scales with different numbers of
categories.
Let xi, where 0 ≤ xi ≤1, quantify the likely effectiveness
of a procedure for individual expert i as part of a panel
of n experts. The distribution of xi is assumed to follow
an approximate Beta distribution (Figure 1), a continu-
ous probability distribution defined on the interval (0,1)
and parameterized by two positive parameters, denoted
by a and b, that modify the shape of the distribution.
The Beta distribution is widely used for modelling ran-
dom probabilities, particularly in the context of Bayesian
analysis [17] and has been used to describe not only
variability within a population as in a conventional sta-
tistical model, but also to describe the subjective degree
of belief in a Bayesian sense [8]. Expressed mathemati-
cally, the probability density function for xi is
fi(xi;αi,βi) = �(αi + βi)�(αi)�(βi)xi
αi−1(1− xi)βi−1, ,
where Γ(.) is the gamma function and parameters ai ≥
1 and bi ≥ 1, requiring that the distribution be unimodal
or at the extreme case, when ai = bI = 1, uniform. In
the surgical trial setting described here, it seems unlikely
that for instance a u-shaped distribution for xi (e.g. a =
0.5 and b = 0.5) would be plausible.
The multiplicative pooled assessment [18,19] of the
expert panel is obtained as
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f0(x) = {
�n
i=1
fi(xi;αi,βi)}1/n
where f0(x) follows a Beta distribution with parameters
α¯ = 1n
�n
i=1
αi and β¯ = 1n
�n
i=1
βi . This provides a
pooled assessment that represents the intersection of
the beliefs of the expert panel [19].
3.2.2 Opinion model
In order to translate the assessments from the panel of
n experts to a collective expert opinion, the measures
b¯
�
u¯ and d¯
�
u¯ (Section 3.1), that characterise the
pooled opinion, are related to the pooled assessment
parameters α¯ and β¯ . Equating the level of belief
expressed by an expert to the pooled assessments, it is
clear that α¯ must be proportional to b¯
�
u¯ , that is a lar-
ger value of α¯ represents a greater degree of belief; at
the extreme as α¯→∞ , then b¯→ 1 and u¯→ 0 , when
we have maximum belief we must have minimum uncer-
tainty. Similarly arguments lead to β¯ being
proportional to d¯
�
u¯ ; a larger value of β¯ represents a
greater degree of disbelief. Although, clearly from exam-
ple (a) in Figure 1, when the pooled Beta distribution
parameter estimates are at their minimum and α¯ = 1
and β¯ = 1 then there is maximum uncertainty ( u¯ = 1)
and minimum belief and disbelief, b¯ = d¯ = 0 . Formalizing
these arguments leads to the following expressions that
satisfy all these conditions
b¯
u¯
= α¯ − 1 and d¯
u¯
= β¯ − 1. (2 3)
Solving equations (2) and (3), along with the condition
that b¯ + d¯ + u¯ = 1 (equation 1), yields the following
expressions that characterize the relationship between
the triplet {b¯, d¯, u¯} and the parameters α¯ and β¯ ,
b¯ =
α¯ − 1
α¯ + β¯ − 1 , d¯ =
β¯ − 1
α¯ + β¯ − 1 , and u¯ =
1
α¯ + β¯ − 1 ; (4 6)
Figure 1 Beta distributions B(a, b) for various values of parameters a and b.
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where the triplet {b¯, d¯, u¯} clearly satisfies b¯ + d¯ + u¯ = 1 ;
a more detailed derivation of equations (4)-(6) is pro-
vided elsewhere [15,16]. Thus, when α¯ = β¯ = 1 ,
π¯ = {0, 0, 1} and the pooled opinion is total uncertainty
(ignorance); see example (a) in Figure 1. If parameters
α¯ and β¯ are greater than unity but equal, we have
equal belief and disbelief; for example (b) in Figure 1
where α¯ = β¯ = 2 and π¯ = { 13 , 13 , 13 } . As α¯ increases rela-
tive to β¯ the belief increases and the uncertainty
decreases and conversely as β¯ increases relative to α¯
the disbelief increases and the uncertainty decreases;
these two scenarios are illustrated in examples (d) and
(c) in Figure 1, where α¯ = 5 , β¯ = 2 and π¯ = { 46 , 16 , 16 }
and α¯ = 2 , β¯ = 5 and π¯ = { 16 , 46 , 16 } .
3.3 Nonparametric model
An alternative nonparametric formulation for belief, dis-
belief and uncertainty allows a more general approach
to that described in Section 3.2. Defining μi and si as
the mean and standard deviation of the assessment of
the effectiveness of the intervention xi for expert i,
where xi is in the range [0,1]. Then the uncertainty (ui),
belief (bi) and disbelief (di) associated with an opinion
for expert i can be expressed as ui = σ 2i
�μi(1− μi) , bi
= μi(1-ui) and bi = di =(1-μi)(1-ui); as 0 ≤ xi ≤ 1, then 0
≤ ui ≤ 1 and the measures satisfy equation (1). For
example using the data from Table 1 for expert 4 from
case 3, the weighted mean and standard deviation, based
on the transformed seven-category ordinal scale
described in Section 3.2.1
(1/14, 3/14, 5/14, 7/14, 9/14, 11/14, 13/14) with weights given by
(5,15,20,20,20,15,5), are μ = 0.5 and s = 0.226, and so u
= 0.204 and b = d = 0.398. Multiplicative pooling leads
directly to estimates for the opinion triplet {b¯, d¯, u¯} ,
with weights given by the nth root of the product of the
individual expert weights, in an analogous manner to
that described in Section 3.2.1 for the parametric model.
In fact the expressions for uncertainty, belief and dis-
belief for the Beta model in equations (4)-(6) follow
directly from the above expressions for u, b and d,
based on μ and s, after some rescaling, by noting that
the mean and variance of the Beta distribution are a/(a
+b) and ab/{(a+b)2 (a+b+1)} respectively.
3.4 Opinion space
As proposed by Jøsang [15], a ternary plot provides a
convenient method of representing the triplet of belief,
disbelief and uncertainty that constitute a pooled expert
opinion. A ternary plot represents the ratios of the three
variables as positions in an equilateral triangle, where
each base, or side, of the triangle represents a propor-
tion, with the point of the triangle opposite that base
representing a proportion equal to one. As a proportion
increases in any one sample, the point representing that
sample moves from the base to the opposite point of
the triangle. For instance, when α¯ = β¯ = 1 (maximum
uncertainty) the opinion is mapped to the apex of the
equilateral triangle, whereas when α¯ = β¯ = 2 there is
equal belief, disbelief and uncertainty and the pooled
opinion is mapped to the centre of the triangle. The
cases representing greater levels of belief and greater
levels of disbelief are mapped towards the right-hand
and left-hand vertices of the triangle respectively.
3.5 Decision rules
In order to determine the level of equipoise that should
be satisfied for a clinical trial to be considered ethical
Johnson et al. [20] conducted an ethometric study to
investigate how much clinical equipoise can be dis-
turbed before potential trial subjects deem it to be
unethical. A series of hypothetical clinical trial scenarios
were presented to people from a broad range of societal
and geographical groups within the UK. They were
asked to specify the level of collective doubt between
two treatment modalities that they would accept if cast-
ing a vote on an ethics committee. Johnson et al. [20]
defined the 80:20 rule, that represented the split in equi-
poise that should be allowed for a trial to be judged to
be ethical and recommended its use as an appropriate
tool for deciding whether recruitment is ethically justifi-
able; based on their empirical evidence that less than 3%
of subjects questioned thought that a trial should
morally be undertaken if equipoise was beyond this
point. By way of comparison, an alternative mean
threshold rule might consider it ethical to recruit
patients if the mean clinical effectiveness (μ), estimated
as a/(a+b) for the Beta distribution, were within pre-
determined limits. For instance, it might be considered
ethical to recruit patients into a trial if the mean clinical
effectiveness were in the range 0.4 ≤ μ ≤ 0.7.
The 80:20 and mean threshold equipoise decision rules
can be mapped onto the opinion space and visualized
on a ternary plot. For the Beta model (Section 3.2), the
former rule can be mapped on to the ternary plot by
iteratively finding solutions for Beta distribution para-
meters, a and b, that give estimates for the probability
density function equal to 0.2 and 0.8 to the left and
right of the central point on the expert rating scale, and
for the latter rule by simply solving equations (4)-(6)
using the constraint that μ(a+b)=a.
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3.6 Hypothesis testing
The significance of the estimated pooled opinion ( π¯ ) is
assessed using resampling. For the Beta model for Sec-
tion 3.2, pooled assessment parameters
α¯∗m = 1n
�
i∗∈Sm
αi∗ and β¯∗m = 1n
�
i∗∈Sm
βi∗ are estimated
for Sm, a set of size n constructed by sampling with
replacement from {1,2...n}; for example for the pooled
assessment of 5 experts Sm might be {1,2,2,4,1} or
{5,3,3,1,1}. This process is repeated many times by ran-
dom construction of Sm to give empirical bootstrap [21]
distributions α¯∗1, α¯∗2, . . . , α¯∗M and β¯∗1, β¯∗2, . . . , β¯∗M , and
thereby π¯∗1 , π¯∗2 , . . . , π¯∗M . From this empirical distribu-
tion, a bootstrap confidence interval for π¯ is derived for
the purpose of hypothesis testing. A similar resampling
scheme can also be developed simply for the nonpara-
metric model of Section 3.3.
This resampling methodology represents the variability
in opinion that might be obtained for any combination
of experts in the panel, including in principle a panel
composed entirely of a single expert, and as such repre-
sents the full range of possible opinions for the selected
population of experts. For the relative small panel of
experts in our example, exhaustive permutation resam-
pling [21] is the preferred option, but this may be com-
putational unrealistic for large n where bootstrapping
with M = 1000 would be sufficient.
3.7 Beta distribution fitting
The outlined statistical framework is illustrated using
the example data introduced in Section 2 (Table 1). We
focus here on the Beta model (Section 3.2) as an exem-
plar, as this fits our data well and is computational
slightly more complex to implement than the nonpara-
metric method. Statistical analysis was undertaken in
the statistical software package R [22]. Code to replicate
the analysis presented here is available on request from
the corresponding author.
The parameters of the Beta distribution were esti-
mated for each clinical expert for the four cases shown
in Table 1 using the fitdistr function available in
the MASS [23] library in the statistical software pack-
age R [22]. This function estimates parameters for a
range of univariate distributions, including the Beta
distribution, using maximum-likelihood methods. For
the four example cases introduced in Section 2 the
pooled parameter estimates were α¯1 = 7.11 , α¯2 = 9.57,
α¯4 = 5.14, α¯4 = 5.14 and β¯1 = 5.67, β¯2 = 4.71 ,
β¯4 = 19.01 , β¯4 = 19.01 . The fitted distributions for
each clinical expert and pooled estimates are shown in
Figure 2.
3.8 Opinions
The pooled parameter estimates from the Beta distribu-
tion fitting for the four example cases were used to esti-
mates the belief, disbelief and uncertainty using
equations (4)-(6); this gave the following estimates,
b¯2 = 0.645, b¯2 = 0.645, b¯3 = 0.307, b¯4 = 0.179,
d¯2 = 0.279 , d¯2 = 0.279 , d¯3 = 0.341 , d¯4 = 0.778 and
u¯2 = 0.075, u¯2 = 0.075, u¯3 = 0.351 , u¯4 = 0.043 . Inspec-
tion of Figure 2, indicates that there appears to be sig-
nificant belief for case 2 that the patient will improve
after treatment (surgery) and conversely significant dis-
belief in the effectiveness of the treatment for case for
case 4; this is reflected in the large (> 0.6) estimates of b
and d for cases 2 and 4 respectively. Also, there is sig-
nificant uncertainty, seen by the flatness of the curves in
Figure 2(c), in the collective opinions of the experts for
case 3; this is apparent in the large level of uncertainty
for this case, relative to the other cases.
3.9 Decision rules
In order to determine whether an opinion provides suf-
ficient evidence for eligibility for recruitment to a clini-
cal trial, we must first define a decision rule. Here we
focus on two rules, the 80:20 [20] and the mean thresh-
old rules; although the procedures described here are
equally applicable to many more rules that could poten-
tially be defined. The 80:20 and mean threshold rules
partition the opinion space, visualized by the ternary
plot, into regions that determine whether the patient
can or cannot ethically be recruited to a trial.
The division lines between the regions for the 80:20
rule were determined iteratively (using an interval
search method) by finding estimates of the Beta distri-
bution parameters a and b that exactly divided the
probability density 80% and 20% around equipoise, and
projecting these estimates into the opinion space using
equations (4)-(6). This process was achieved using an
implementation of the uniroot function in R [22].
After discussion with the clinical experts it became clear
that the point of equipoise for the assessment scale
described in Section 2 for the 80:20 rule was not located
centrally but was in fact located at the division between
the ‘No difference’ and the ‘A bit better’ categories. That
is, because surgery was seen to be an active intervention
for a condition that required treatment, the point of
equipoise was located slightly to the right of the centre
point of the assessment scale; which for our definition
of the assessment scale is at 8/14 rather than at 1/2 on
the interval (0, 1). The asymmetry that this implies for
the 80:20 decision rule is clear in Figure 3. The mean
threshold rule divided the opinion space into three
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distinct regions μ < 0.4, 0.4 ≤ μ ≤ 0.7 and μ < 0.7 char-
acterised by the thresholds 0.4 and 0.7 for the mean,
that determined whether the intervention was likely to
be effective. The divisions between regions were mapped
onto the opinion space by solving equations (4)-(6)
using the constraint that μ(a+b) = a. For instance for μ
= 0.7 and u = 0, then b = 0.7 and d = 0.3 and when d =
0 then u = 3/7 and u = 4/7 ; these points define the
intersections between the upper division boundary with
the lower and right edges of the ternary plot in Figure 3.
3.10 Hypothesis testing
The exhaustive permutation test described in Section 3.6
was applied to each of the test cases. This gave 462, 126,
35 and 126 combinations of opinions for the four cases
that used respectively 6, 5, 4 and 5 expert clinical asses-
sors. The belief, disbelief and uncertainty for all the
Figure 2 Fitted Beta distributions for each clinical expert (—) and pooled estimates (-) for each case.
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combinations of opinion were estimated for each of the
four cases and plotted along with the decision rules in
Figure 3.
The ‘cloud’ of points for each case represents the
variability due to the range of opinions expressed by the
expert assessors. Where there were considerable differ-
ences of opinion, for instance for case 1, there was a
much wider spread of points than where there was over-
all agreement amongst the experts about the likelihood
of success of the intervention, for instance for case 2 or
4. It is instructive to look at one particular opinion tri-
plet to more fully understand the meaning of the tern-
ary plots.
For case 1, the opinion triplet π = {0.712,0.211,0.077}
located towards the lower right hand vertex of the tern-
ary plot has very high belief and low uncertainty. This is
the opinion associated with six replicates of the assess-
ment of clinical expert 3 for case 1 (see Table 1), who
had a strong belief that the patient would get signifi-
cantly better after treatment. If this expert assessor were
Figure 3 Estimated triplets for all permutations of opinions with the 80:20 (—) and mean (–) decision rules. The best estimate of
collective opinion is given by the large symbol (•).
Parsons et al. Trials 2011, 12:258
http://www.trialsjournal.com/content/12/1/258
Page 9 of 11
236
indeed representative of the wider population of experts,
then it would certainly be unethical for the patient to be
recruited to the trial and consequentially the opinion for
this potential scenario is located to the right of the
80:20 and mean threshold decision rules.
Labelling the regions to the lower right and lower left
of the plots to the right and left of the 80:20 and mean
threshold decision rule partition curves as the ‘belief’
and ‘disbelief’ regions, allows us to count the number of
opinions falling within these regions for each case and
rule; see Table 2. Defining the null hypothesis to be that
a case should not be recruited to the trial, Table 2 pro-
vides evidence for this hypothesis and suggests appropri-
ate p-values based on the 80:20 rule for the four cases to
be 0.026 (i.e. 12/462), 0.333, 0.000 and 1.000 and based
on the mean threshold rule to be 0.011 (i.e. 5/462),
0.000, 0.029 and 1.000. Testing at the 5% level (two-
sided) indicates that for the 80:20 rule cases 1 and 3
would be eligible for recruitment and for the mean
threshold rule cases 1, 2 and 3 would be eligible for
recruitment. For this decision making process to have
some validity, the decision rule and the significance
level would clearly need to be stated before data collec-
tion was undertaken.
4 Conclusions
We describe a statistical framework for the assessment
of clinical uncertainty, as a prelude to a clinical trial and
demonstrate, using data from the UK Heel Fracture
Trial, how expert opinions can be pooled, modelled and
presented on a ternary plot that represents an opinion
space. Individual cases can then be assessed in relation
to decision rules mapped onto the opinion space, pro-
viding clear and rapid decisions regarding trial eligibility.
The methodology has potential to identify eligible
patients and assist in the simplification of eligibility cri-
teria which might encourage greater participation in
clinical trials.
Methods for the assessment of clinical uncertainty, as
a prelude to a clinical trial, have been suggested pre-
viously [10,11]. However, the methodology described
here is the first attempt at a structured statistical frame-
work to undertake this type of analysis. Beta
distributions were fitted to assessments of the likely
effectiveness of an intervention elicited from a virtual
panel of experts and pooled using methods familiar to
exponents of determining expert probabilities [19]. Opi-
nions were expressed using previously suggested [15]
definitions of belief, disbelief and uncertainty that we
believe fully characterised the clinical expert assess-
ments. Our analysis restricted the choice of Beta distri-
butions for modelling to unimodal forms (a ≥ 1 and b ≥
1). This was not a concern for the examples described
here or indeed more widely for other data we have
explored in the setting of surgical trials. However, it is
in principle possible in other applications that the most
likely assessment of clinical effectiveness of an interven-
tion is that a patient would either get much better or
much worse with any other outcome being extremely
unlikely. In this setting belief, disbelief and uncertainty
as expressed in equations (4)-(6) would not be defined.
For the data presented here the Beta model proved to
be the most informative, however where this is not the
case the nonparametric methods described, based on
estimated means and standard deviations, provide useful
alternatives for any distribution on the interval [0,1].
Although the examples described here all use seven
point likert type scales for elicitation, the statistical fra-
mework introduced would work equally well with any
type of ordered categorical assessment scale.
Expert opinions are pooled here using multiplicative
methods [19], as we felt that this best represented clini-
cal equipoise [24] and the views of the experts consulted
for the example data; i.e. that all experts opinions were
‘correct’ and the pooling should represent the consensus
based on the intersection of beliefs. However, our view
is pragmatic and we see no reason why additive pooling
could not be used in preference to multiplicative pool-
ing, particularly if it was felt that the latter method was
giving too much weight to the assessment of one or
more ‘over-confident’ individual experts.
We have presented significance tests at the 5% level to
assess whether a patient might ethically be recruited to
a trial. Our selection of this level for the tests was some-
what arbitrary and clearly this could be set, prior to ana-
lysis, at a higher or lower level for a different application
or a less formal procedure adopted if necessary. The
80:20 rule [20], which is based on some empirical evi-
dence, was selected as a standard for decision making
regarding recruitment. The alternative mean threshold
rule, as well as being intuitively reasonable, was sug-
gested in part to encourage some debate as to what
form the decision rule should take for different cases
and in various settings. This is clearly an area that
requires additional research.
The focus of this paper has been on developing tools
for improving recruitment to trials. For those patients
Table 2 Opinion counts by case, decision region and rule,
and the total number of opinion combinations available
for the exhaustive permutation test
Rule Region Case 1 Case 2 Case 3 Case 4
80:20 Belief 12 42 0 0
Disbelief 0 0 0 126
Mean threshold Belief 5 0 0 0
Disbelief 0 0 1 126
Opinion Combinations 462 126 35 126
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deemed eligible for recruitment who decide to enter an
RCT, it would seem natural to use the expert evidence
elicited through this process as a clinical prior, based on
subjective opinion, in a formal Bayesian analysis [14].
The methodological framework discussed here has
provided additional insight that would otherwise have
not been available for the heel fracture trial. Although,
clearly this methodology will need to be assessed in
future studies to identify whether it can actually deliver
improvement in trial recruitment rates. The methodolo-
gical framework we describe is currently limited to two-
arm trials, although we see no reason why this could
not be extended to more than two treatment groups.
The opinion pooling we describe is appropriate for
situations where individual expert opinions may differ to
a moderate or large extent, but it is not at all clear that
pooling opinions where for instance experts have totally
opposing views (100% belief or disbelief in treatment
effectiveness) would be appropriate, as the pooled opi-
nion would in reality represent no individual expert’s
opinion. Therefore we would recommend the methodol-
ogy be limited to only those scenarios of the former
rather than the latter type. Although we have focussed
on surgical trials, we would expect the methodology
described here to be applicable to any RCT where
recruitment was problematic. The methodology also has
clear application in pilot studies where feasibility is
being assessed and also potentially as a support tool for
inclusive trials where patients are allowed to select an
intervention as well as being randomised in a conven-
tional manner [25].
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Appendix J
Not used
239
Appendix K
Evaluated Questionnaire for the Collective Uncertainty Pilot 
Study
 CORPORATE UNCERTAINTY TRIAL (CUT) Feedback Form"
"
Please, delete or cross out as appropriate"""
- Overall online voting system was: easy/difﬁcult to use.""
Comments:""""
- On average it took … mins to vote on a case.""
- Clinical information was sufﬁcient/inadequate.""
Comments:""""
- Extra images were essential/unnecessary.""
" Movie (MPEG) format – great/not better/could not open""
Comments:""""
- Technical support was ""
easy/difﬁcult to reach""
sufﬁcient/inadequate""
Comments:""""
- Best points:""""
- Could be improved:""""
- Did not like:"""
240
Appendix L
Example of literature search
241
242
243

